{
  "meta": {
    "title": "Biochemistry_Test",
    "url": "https://brainandscalpel.vercel.app/biochemistry-test-d28ed827.html",
    "scrapedAt": "2025-11-30T12:49:00.559Z"
  },
  "questions": [
    {
      "text": "A young non-smoker with chronic cough and wheezing was diagnosed with α1 antitrypsin deficiency. The following image shows the normal electrophoresis of serum proteins. Which of the following bands (A, B, C, D) becomes thin in this patient?",
      "choices": [
        {
          "id": 1,
          "text": "D"
        },
        {
          "id": 2,
          "text": "C"
        },
        {
          "id": 3,
          "text": "B"
        },
        {
          "id": 4,
          "text": "A"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>In&nbsp;<strong>&alpha;1 antitrypsin</strong> deficiency,<strong>&nbsp;t</strong>he band that is marked as <strong>B,</strong> representing&nbsp;<strong>&alpha;1 globulin,</strong>&nbsp;<strong>becomes thin</strong>.</p>\n<p><strong>Serum protein electrophoresis</strong> is a method of separation and identification of proteins based on their net charge, size, and shape.&nbsp;The largest peak that lies closest to the positive electrode (left corner) is that of <strong>albumin</strong> since it is present in the largest proportion in plasma. <strong>Globulins</strong> make up a much smaller fraction of the total serum protein and are represented by smaller peaks to the right. Five globulin categories are represented: alpha-1, alpha-2, beta-1, beta-2, and gamma, with the gamma fraction being closest to the negative electrode (right corner).</p>\n<p>Certain common diseases and their electrophoretic pattern:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Condition </strong></td>\n<td><strong>&nbsp;Electrophoretic pattern</strong></td>\n</tr>\n<tr>\n<td>Chronic infections</td>\n<td>Smooth increase in gamma globulins</td>\n</tr>\n<tr>\n<td>Multiple myeloma</td>\n<td>Gamma globulin part is increased as a single narrow peak (<strong>M BAND</strong>)</td>\n</tr>\n<tr>\n<td>Malnutrition, cachexia, liver cirrhosis, nephrotic syndrome, severe burns</td>\n<td>Albumin is reduced</td>\n</tr>\n<tr>\n<td><strong>&alpha;1 antitrypsin deficiency</strong></td>\n<td>&alpha;1 band is thin and even lost sometimes</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>The following image shows the bands with their corresponding proteins in normal serum electrophoresis.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/fbd0983139604b11ad59a24ebd1bfdefx1280x606.JPEG\" alt=\"Explanation Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/b81001842fb14c4087d08b6afc00c708.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD2953",
      "difficulty": "hard"
    },
    {
      "text": "A 5-year old child presents to the OPD with excessive dryness in the eyes and difficulty in seeing at night. On examination, cutaneous lesions are seen over the elbows, as shown in the image below. Which of the following deficiencies can cause this cutaneous lesion?<div class='question-desc-html'><ol>\n<li>Vitamin A</li>\n<li>Vitamin B complex</li>\n<li>Vitamin C</li>\n<li>Vitamin D</li>\n<li>Vitamin E</li>\n<li>Vitamin K</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "1, 3, 4, 6"
        },
        {
          "id": 2,
          "text": "2, 3, 4, 5"
        },
        {
          "id": 3,
          "text": "1, 2, 3, 5"
        },
        {
          "id": 4,
          "text": "2, 3, 4, 6"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The given clinical scenario is suggestive of <strong>vitamin A deficiency</strong>. The cutaneous lesion in the image is <strong>phrynoderma</strong>, and it can caused by deficiency of <strong>vitamins A</strong>,<strong> B complex</strong>, <strong>C</strong>, and<strong> E</strong> and<strong> essential fatty acids</strong>.</p>\n<p>Phrynoderma are <strong>keratotic follicular papules</strong> commonly present over the elbows and knees. They can also extend to the shoulders, neck, back, thighs, buttocks, and abdomen. It is also known as <strong>toad skin</strong>. </p>\n<p>When it occurs due to <strong>vitamin A deficiency</strong>, it is associated with ophthalmic symptoms like <strong>xerophthalmia</strong>, <strong>night blindness</strong>, and <strong>Bitot's spots </strong>and cutaneous symptoms like <strong>xerosis</strong>, <strong>scaling</strong>, and <strong>acne</strong>.</p>\n<p>Management includes nutritional improvement through diet, multivitamin supplementation, and treatment of the underlying cause.</p><hr><h3>Related Pearl: Fat-soluble vitamins</h3><table>\n<tbody>\n<tr>\n<td rowspan=\"2\"><strong>Vitamin</strong></td>\n<td rowspan=\"2\"><strong>Active form</strong></td>\n<td rowspan=\"2\"><strong>Deficiency</strong></td>\n<td rowspan=\"2\"><strong>Toxicity</strong></td>\n<td colspan=\"3\"><strong>Required dietary allowance</strong></td>\n</tr>\n<tr>\n<td>Children</td>\n<td>Male</td>\n<td>Female</td>\n</tr>\n<tr>\n<td>Vitamin A</td>\n<td>\n<p>Retinol</p>\n<p>Retinal</p>\n<p>Retinoic acid</p>\n</td>\n<td>\n<p>Night blindness, xerophthalmia,</p>\n<p>Acne, psoriasis,</p>\n<p>Impaired immunity</p>\n</td>\n<td>\n<p>Affects lysosomes</p>\n<p>Acute- pseudotumor cerebrii, exfoliative dermatitis</p>\n<p>Chronic-fractures</p>\n</td>\n<td>\n<p>390-630mcg (1-9 years)</p>\n<p>770-1000mcg (10-18 years)</p>\n</td>\n<td>1000mcg&nbsp;</td>\n<td>&nbsp;\n<p>Adult - 840mcg</p>\n<p>Pregnancy - 900mcg</p>\n<p>Lactation - 950 mcg</p>\n</td>\n</tr>\n<tr>\n<td>Vitamin D</td>\n<td>1,25-Dihydro-cholecalciferol</td>\n<td>\n<p>Children- Rickets</p>\n<p>Adults-osteomalacia</p>\n</td>\n<td>Calcinosis</td>\n<td>&nbsp;\n<p>400 IU (&lt;1 year)</p>\n<p>600 IU (&gt;1 year)</p>\n</td>\n<td>&nbsp;600 IU</td>\n<td>\n<p>Adult - 600 IU</p>\n<p>Pregnancy - 600 IU</p>\n<p>Lactation - 600 IU</p>\n</td>\n</tr>\n<tr>\n<td>Vitamin E</td>\n<td>&alpha;-tocopherol</td>\n<td>\n<p>Hemolytic anemia,</p>\n<p>axonal degeneration,</p>\n<p>spinocerebellar ataxia</p>\n</td>\n<td>\n<p>Reduced platelet aggregation,&nbsp;</p>\n<p>Interferes with vitamin K</p>\n</td>\n<td>&nbsp;5-8 mg</td>\n<td>&nbsp;10 mg</td>\n<td>\n<p>Adult - 8 mg</p>\n<p>Pregnancy - 10 mg</p>\n<p>Lactation - 12 mg</p>\n</td>\n</tr>\n<tr>\n<td>Vitamin K</td>\n<td>\n<p>Menedione</p>\n<p>Menoquinone</p>\n<p>Phyloquinone</p>\n</td>\n<td>\n<p>Elevated prothrombin time and bleeding</p>\n<p>Haemorrhagic disease of newborn</p>\n</td>\n<td>\n<p>Hemolysis</p>\n<p>Hyperbilirubinemia</p>\n<p>Kernicterus</p>\n</td>\n<td>\n<p>&lt;1 year - 2-3&nbsp;&micro;g</p>\n<p>Children - 30-50&nbsp;&micro;g</p>\n&nbsp;</td>\n<td>55 &micro;g&nbsp;</td>\n<td>55 &micro;g&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Note:The <strong>RDA</strong> for <strong>Vitamin D</strong> in the <strong>elderly</strong> (&gt;60 years) is <strong>800 IU</strong>.</p><hr><h3>Related Pearl: Vitamin-A supplementation & treatment of Vitamin-A deficiency</h3><table>\n<tbody>\n<tr>\n<td colspan=\"3\">\n<div><strong>Vitamin A supplementation</strong></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><strong>Target group</strong></div>\n</td>\n<td>\n<div>6 to 11 months age</div>\n</td>\n<td>\n<div>12 to 59 month of age (1yr to 5yr)</div>\n</td>\n</tr>\n<tr>\n<td>\n<div><strong>Dose</strong></div>\n</td>\n<td>\n<div>100,000 IU (oral)</div>\n</td>\n<td>\n<div>200,000 IU (oral)</div>\n</td>\n</tr>\n<tr>\n<td>\n<div><strong>Frequency</strong></div>\n</td>\n<td>\n<div>Once</div>\n</td>\n<td>\n<div>Every 4&ndash;6 months</div>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<p><strong>Note</strong>: A total dose of&nbsp;<strong>17 lakh IU</strong> given as per the following schedule:</p>\n<ul>\n<li>100,000 IU is given with measles vaccine at 9 months</li>\n<li>200,000 IU is given with DPT booster at 15&ndash;18 months</li>\n<li>200,000 IU is given every 6 months (till 5years of age)</li>\n</ul>\n<p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td colspan=\"4\"><strong>Treatment </strong>of vitamin A<strong> deficiency</strong></td>\n</tr>\n<tr>\n<td><strong>Age</strong></td>\n<td>&lt; 6 months</td>\n<td>6-12 months</td>\n<td>&gt; 1 year</td>\n</tr>\n<tr>\n<td><strong>Dose</strong></td>\n<td>50,000 IU</td>\n<td>100,000 IU</td>\n<td>200,000 IU</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<p><strong>Note:</strong> Route of administration is <strong>oral</strong>, in the form of retinyl palmitate.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/4a63e0f73bfa48b8afbf055a90d7a9ae.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA2236",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following statements are true regarding the regulation of cholesterol synthesis?<div class='question-desc-html'><ol>\n<li>Insulin and thyroxine decrease HMG CoA reductase activity.</li>\n<li>Cortisol and glucagon decrease HMG CoA reductase activity.</li>\n<li>Statins inhibit HMG CoA reductase.</li>\n<li>Cholesterol increases HMG CoA reductase activity.</li>\n<li>Cholesterol represses transcription of HMG CoA reductase mRNA.</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "1, 3, and 5"
        },
        {
          "id": 2,
          "text": "2, 3, and 4"
        },
        {
          "id": 3,
          "text": "1, 2, and 4"
        },
        {
          "id": 4,
          "text": "2, 3, and 5"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Statements <strong>2</strong>,<strong> 3</strong>, and<strong> 5</strong> are true regarding the regulation of cholesterol synthesis.</p>\n<p><strong>HMG CoA reductase</strong> is the principal enzyme involved in the <strong>regulation</strong> of <strong>cholesterol synthesis</strong>. Cholesterol is synthesized from <strong>acetyl-CoA</strong> mainly in the liver and intestine. This process occurs in the endoplasmic reticulum and cytosol.</p>\n<div class=\"page\" title=\"Page 261\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>HMG-CoA reductase reduces<strong> HMG-CoA</strong> to <strong>mevalonate</strong> by NADPH in the pathway of cholesterol synthesis. This principal regulatory step is targeted by <strong>statins</strong>, which are drugs that efficiently lower cholesterol by <strong>inhibiting HMG-CoA reductase</strong>.</p>\n<p>Activity of HMG-CoA reductase is influenced by the following factors:</p>\n<ul>\n<li>By-products of the cholesterol synthesis pathway: <strong>Mevalonate</strong>, the immediate product of the reaction, and <strong>cholesterol</strong>, the main product of the pathway, <strong>inhibit</strong> enzyme activity. These metabolites also repress transcription of HMG-CoA reductase mRNA by inhibiting sterol regulatory element-binding protein (SREBP) transcription factor.</li>\n<li>Hormones:<strong> Insulin</strong> and <strong>thyroid hormones</strong> <strong>increase</strong> enzyme activity, whereas <strong>glucagon</strong> or <strong>glucocorticoids</strong> decrease it.</li>\n<li>Posttranslational modifications: Phosphorylation–dephosphorylation reactions affect enzyme activity. <strong>AMP-activated protein kinase (AMPK)</strong> phosphorylates and <strong>inactivates</strong> the enzyme.</li>\n<li>Diurnal variation</li>\n</ul>\n</div>\n</div>\n</div>\n</div><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/affadf70f6e14d269ed81f681a304e06x600x566.JPEG\" alt=\"Explanation Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/7087eb4a999a413da1c7e7c4a3566407x510x692.PNG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Rate determining enzymes and their key regulators</h3><table>\n<tbody>\n<tr>\n<td>Pathway</td>\n<td>Enzyme&nbsp;</td>\n<td>Regulating factors</td>\n</tr>\n<tr>\n<td>Glycolysis</td>\n<td>Phosphofructokinase (PFK-1)</td>\n<td>\n<p>AMP+, Fructose 2,6 bi-phosphate+</p>\n<p>ATP-, Citrate-</p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;gluconeogenesis</td>\n<td>Fructose-1,6-bisphosphatase</td>\n<td>\n<p>ATP+, Acetyl CoA+</p>\n<p>AMP-, Fructose 2,6 bi-phosphate-</p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;Krebs cycle</td>\n<td>Isocitrate dehydrogenase</td>\n<td>\n<p>ADP+,</p>\n<p>ATP-, NADH-</p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;glycogenesis</td>\n<td>Glycogen synthase</td>\n<td>\n<p>Glucose-6-phosphate+, insulin+, cortisol+,</p>\n<p>Epinephrine-, glucagon-</p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;glycogenolysis</td>\n<td>Glycogen phosphorylase</td>\n<td>\n<p>Epinephrine+, glucagon+, AMP+</p>\n<p>Glucose-6-phosphate-, insulin-, ATP-</p>\n</td>\n</tr>\n<tr>\n<td>HMP shunt&nbsp;</td>\n<td>Glucose-6-phosphate dehydrogenase (G6PD)</td>\n<td>\n<p>NADP+</p>\n<p>NADPH-</p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;Denovo pyrimidine synthesis</td>\n<td>Carbamoyl phosphate synthetase II</td>\n<td>\n<p>ATP+</p>\n<p>UTP-</p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;Denovo purine synthesis</td>\n<td>Glutamine-phosphoribosylpyrophosphate (PRPP) amidotransferase</td>\n<td>AMP-, IMP-, GMP-</td>\n</tr>\n<tr>\n<td>&nbsp;Urea cycle</td>\n<td>Carbamoyl phosphate synthetase I</td>\n<td>N-acetyl glutamate (NAG)+</td>\n</tr>\n<tr>\n<td>&nbsp;Fatty acid synthesis</td>\n<td>Acetyl-CoA carboxylase (ACC)</td>\n<td>\n<p>Insulin+, citrate+</p>\n<p>Glucagon-, palmitoyl-CoA-</p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;Fatty acid oxidation</td>\n<td>Carnitine acyltransferase I</td>\n<td>Malonyl-CoA-</td>\n</tr>\n<tr>\n<td>&nbsp;Cholesterol synthesis</td>\n<td>HMG-CoA reductase</td>\n<td>\n<p>Insulin+, thyroxine+</p>\n<p>Glucagon-, cholesterol-</p>\n</td>\n</tr>\n<tr>\n<td>Ketogenesis</td>\n<td>HMG-CoA synthase</td>\n<td>&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>+ Positive effect on the pathway.</p>\n<p>- Negative effect on the pathway.</p><hr><h3>Related Pearl: Sites of various pathways in cell</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Sites of metabolism</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Mitochondria</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Fatty acid oxidation (&beta;oxidation)</p>\n<p>Acetyl CoA production</p>\n<p>TCA Cycle</p>\n<p>Oxidative phosphorylation</p>\n<p>Ketogenesis</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Cytoplasm</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Glycolysis</p>\n<p>HMP Shunt</p>\n<p>Synthesis of steroids(SER)</p>\n<p>Proteins (RER and Ribosomes)</p>\n<p>Fatty acids</p>\n<p>Cholesterol</p>\n<p>Nucleotides</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Both</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Heme synthesis</p>\n<p>Urea cycle</p>\n<p>Gluconeogenesis</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Enzymes active in phosphorylated and dephosphorylated state</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Phosphorylated state</strong></p>\n<p>(Low insulin)</p>\n</td>\n<td>\n<p><strong>Dephosphorylated state</strong></p>\n<p>(High insulin)</p>\n</td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>Fructose 2,6 bisphosphatase</li>\n<li>PEP carboxykinase</li>\n<li>Pyruvate carboxylase</li>\n<li>Glycogen phosphorylase</li>\n<li>Hormone-sensitive lipase</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>Phosphofructokinase</li>\n<li>Pyruvate dehydrogenase</li>\n<li>Glycogen synthase</li>\n<li>Acetyl CoA carboxylase</li>\n<li>HMG CoA reductase</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF1639",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following phospholipids is found only in the mitochondria and helps in the mitochondrial function?",
      "choices": [
        {
          "id": 1,
          "text": "Cephalin"
        },
        {
          "id": 2,
          "text": "Cardiolipin"
        },
        {
          "id": 3,
          "text": "Lecithin"
        },
        {
          "id": 4,
          "text": "Plasmalogen"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Cardiolipin</strong> is the phospholipid found <strong>only</strong> in the <strong>mitochondria. </strong></p>\n<p>Cardiolipin is an important component of the <strong>inner mitochondrial membrane. </strong>It is essential for the <strong>optimal function</strong> of numerous mitochondrial <strong>enzymes</strong> involved in mitochondrial <strong>energy metabolism</strong> and for the <strong>maintenance </strong>of the<strong> </strong>mitochondrial membrane <strong>structure. </strong></p>\n<p><strong>Decreased cardiolipin</strong> or alteration in its metabolism results in<strong> </strong>mitochondrial dysfunction. This is<strong> </strong>seen in<strong> Barth syndrome </strong>(cardioskeletal myopathy) which is <span class=\"ILfuVd\"><span class=\"hgKElc\">characterized by an enlarged and weakened heart (<strong>dilated cardiomyopathy</strong>), weakness in muscles used for movement (<strong>skeletal myopathy</strong>), recurrent infections due to small numbers of white blood cells (<strong>neutropenia</strong>), and <strong>short stature</strong>.</span></span></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0042",
      "difficulty": "medium"
    },
    {
      "text": "You are studying the visual pigment cycle in the physiology lab. Identify the substance that converts cis-retinal to trans-retinal.",
      "choices": [
        {
          "id": 1,
          "text": "Rhodopsin"
        },
        {
          "id": 2,
          "text": "Scotopsin"
        },
        {
          "id": 3,
          "text": "Metarhodopsin II"
        },
        {
          "id": 4,
          "text": "Lumirhodopsin"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The substance that converts <strong>cis-retinal to trans-retinal</strong> is<strong> rhodopsin. </strong></p>\n<p>Rhodopsin is the visual pigment in the outer segment of rods responsible for scotopic vision (night/ dark vision). It is a light-sensitive pigment and consists of opsin and 11-cis retinal.</p>\n<div class=\"page\" title=\"Page 607\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>When <strong>light</strong> is absorbed by <strong>rhodopsin</strong>, it decomposes very quickly. This leads to an instantaneous change of the <strong>cis form of retinal</strong> <strong>into an all-trans form. </strong>This all-trans-retinal separates from scotopsin to produce bathorhodopsin. Bathorhodopsin is very unstable and decays to form lumirhodopsin, which then decays and forms metarhodopsin I, metarhodopsin II, and finally, into the completely split products scotopsin and all-trans-retinal. </p>\n<div class=\"page\" title=\"Page 608\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<div class=\"page\" title=\"Page 608\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Metarhodopsin II</strong> is also called <strong>activated rhodopsin, </strong>and it produces excitatory changes in the rods, which transmits optic nerve action potentials. to the central nervous system.</p>\n<div class=\"page\" title=\"Page 608\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Re-formation of rhodopsin involves the conversion of the all-trans-retinal back into 11-cis retinal. This requires metabolic energy and is catalyzed by retinal isomerase. 11-cis retinal then recombines with scotopsin to form rhodopsin. Rhodopsin now remains stable until it is triggered by light energy to start decomposing again.</p>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/2e43ca34c9164192b171fa70fed6dc9dx1280x1623.JPEG\" alt=\"Explanation Image\"><div class=\"page\" title=\"Page 608\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Role of vitamin A: The second route of re-formation of rhodopsin involves the conversion of the <strong>all-trans-retinal</strong> into <strong>all-trans-retinol, </strong>which is a form of <strong>vitamin A</strong>. All-trans-retinol is converted into 11- cis retinol by isomerase. 11-cis retinol is then converted into 11-cis retinal, combines with scotopsin, and forms new rhodopsin.</p>\n</div>\n</div>\n</div>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD3974",
      "difficulty": "easy"
    },
    {
      "text": "An exclusively breastfed newborn was brought with vomiting and diarrhea that developed since birth. On examination, the baby is jaundiced and has hepatomegaly. Blood glucose level was low and erythrocyte galactose-1-phosphate level was elevated. What is the diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Fructosuria"
        },
        {
          "id": 2,
          "text": "Von Gierke's disease"
        },
        {
          "id": 3,
          "text": "Classical galactosemia"
        },
        {
          "id": 4,
          "text": "Hereditary fructose intolerance"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The clinical scenario of an exclusively breastfed infant with vomiting, diarrhea, jaundice, hypotonia, and hepatomegaly with elevated erythrocyte galactose-1-phosphate level is suggestive of <strong>classical galactosemia.</strong></p>\n<p><strong>Classical galactosemia </strong>is an autosomal recessive disorder.<strong> </strong>The enzyme deficient here is <strong>galactose-1-phosphate uridyl transferase </strong>(GALT).<strong> </strong>Normally, newborns receive up to 40% of their calorie intake as lactose (glucose + galactose). Without GALT, the infant cannot metabolize <strong>galactose 1-phosphate, </strong>which accumulates and causes injury to the kidney, liver, and brain.</p>\n<p>Clinical features include <strong>vomiting, hypoglycemia,</strong> hepatomegaly, jaundice, congenital cataracts, aminoaciduria, and <strong>failure to thrive</strong>. There is an increased incidence of <em>Escherichia coli</em> neonatal <strong>sepsis</strong>. Long-term <strong>complications</strong> include speech delays, learning impairment, motor dysfunction, and hypogonadotropic hypogonadism (in females).</p>\n<div class=\"page\" title=\"Page 136\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>The presence of galactose in urine (positive Benedict's test), elevated blood galactose level, and elevated erythrocyte galactose-1-phosphate level help in confirming the diagnosis.</p>\n</div>\n</div>\n</div>\n<p>Treatment is a <strong>galactose-free diet</strong>. Supportive therapy and the prevention of complications are important.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/273ae933e27941edbdbe9e4f99d5dbe6x1280x1129.JPEG\" alt=\"Explanation Image\"><p>Other options:</p>\n<p>Option A: <strong>Fructosuria</strong> is due to the deficiency of <strong>fructokinase</strong>. There are no symptoms except for the benign excretion of fructose in urine.</p>\n<p>Option B: <strong>von Gierke's disease</strong> is due to <span data-preserver-spaces=\"true\"><strong>glucose-6-phosphatase</strong> or <strong>translocase</strong> deficiency. It is a <strong>glycogen storage disorder (Type I).  </strong>They may<strong> </strong></span><span data-preserver-spaces=\"true\">develop hypoglycemia and lactic acidosis in the neonatal period, but hepatomegaly usually develops at 3–4 months. They may</span> have doll-like facies, short stature, and a protuberant abdomen. Hyperuricemia, the elevation of triglycerides, low-density lipoproteins, and phospholipids are seen.</p>\n<p>Option D:<strong> Hereditary fructose intolerance</strong> is due to a deficiency of<strong> fructose 1, 6-bisphosphate aldolase (aldolase B)</strong>. Patients are healthy and symptom-free until fructose or sucrose is ingested. Clinical manifestations may include jaundice, hepatomegaly, vomiting, lethargy, irritability, and convulsions. It will not be seen in newborns who are exclusively on breast milk.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF0828",
      "difficulty": "easy"
    },
    {
      "text": "A 7-year-old girl presents with sudden onset of severe breathlessness with wheezing. Her peak expiratory flow rate is reduced significantly. Which of the following enzymes is important for the pathogenesis of the most likely diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "7-Lipoxygenase"
        },
        {
          "id": 2,
          "text": "12-Lipoxygenase"
        },
        {
          "id": 3,
          "text": "15-Lipoxygenase"
        },
        {
          "id": 4,
          "text": "5-Lipoxygenase"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p class=\"p1\">Sudden onset of severe breathlessness and wheezing with a reduced peak expiratory flow rate is suggestive of <strong>acute exacerbation </strong>of <strong>asthma.</strong> <strong>5-lipoxygenase</strong> enzyme is important for the pathogenesis of this condition. </p>\n<p class=\"p1\">Acute exacerbation of asthma is characterized by <strong>bronchoconstriction</strong> due to chemicals mediators like <strong>leukotrienes</strong> (LTB<sub>4</sub>, LTC<sub>4</sub>, LTD<sub>4</sub> etc.). Leukotrienes are produced from the breakdown of <strong>arachidonic acid</strong> by 5-lipoxygenase<strong> </strong>via the<strong> lipoxygenase pathway. </strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/5c4613d9ee8b4913a9a571ac5929e453x1280x2588.JPEG\" alt=\"Explanation Image\"><p class=\"p1\">Leukotrienes<span class=\"Apple-converted-space\"> </span>are <strong>eicosanoic acid </strong>derivatives formed in leukocytes, mast cells, platelets, and macrophages. They are<strong> potent constrictors</strong> of the<strong> bronchial airway. </strong>Leukotrienes<span class=\"s1\"> </span>also cause increased <strong>vascular permeability</strong> and activation and<strong> attraction </strong>of <strong>leukocytes. </strong>Thus, they are involved in many inflammatory or <strong>immediate hypersensitivity reactions,</strong> such as asthma. </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB0163",
      "difficulty": "medium"
    },
    {
      "text": "A 60-year-old patient presented to the casualty in an unconscious state. His blood sugars were high, the ABG(Arterial blood gas) analysis showed metabolic acidosis, and urine tests were positive for ketone bodies. The ketone bodies were not utilized in the liver because it lacks the enzyme:",
      "choices": [
        {
          "id": 1,
          "text": "β hydroxybutyrate dehydrogenase"
        },
        {
          "id": 2,
          "text": "Thiophorase"
        },
        {
          "id": 3,
          "text": "Thiolase"
        },
        {
          "id": 4,
          "text": "Ketoacyl reductase"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Ketone bodies are not utilized in the <strong>liver</strong> because it <strong>lacks</strong> the enzyme<strong> thiophorase.</strong></p>\n<p>The above clinical scenario points to the diagnosis of <strong>diabetic ketoacidosis</strong> characterized by excess production of ketone bodies. The liver cannot utilize the ketone bodies (acetoacetate, &beta;-hydroxybutyrate, and acetone) because it lacks the enzyme thiophorase (also called succinyl CoA acetoacetyl CoA transferase).</p>\n<p>Ketone bodies are synthesized in the liver mitochondria (by <strong>ketogenesis</strong>) and transported in the blood to the <strong>peripheral tissues. </strong>Here they are <strong>utilized</strong> by the following steps:</p>\n<ol>\n<li>&beta;-hydroxybutyrate (the most predominant ketone body) is oxidized to acetoacetate by <strong>&beta;-hydroxybutyrate dehydrogenase</strong> producing NADH.</li>\n<li>Acetoacetate is then activated to acetoacetyl CoA by transferring a CoA molecule from succinyl CoA by <strong>succinyl CoA-acetoacetyl CoA transferase (thiophorase).</strong></li>\n<li>Acetoacetyl CoA is cleaved into two acetyl CoA molecules by <strong>thiolase</strong> and oxidized into CO<sub>2</sub> by the TCA cycle.</li>\n</ol>\n<div class=\"page\" title=\"Page 226\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>When higher than normal ketone bodies are present in the blood or urine, it is called <strong>ketonemia</strong> or <strong>ketonuria</strong>, respectively. The overall condition is called <strong>ketosis</strong>. The metabolism of free fatty acids to produce ketone bodies is exaggerated in pathologic states such as <strong>starvation</strong> and <strong>diabetes</strong> <strong>mellitus</strong>, thus causing ketosis. The continued buffering and excretion of ketone bodies deplete the alkali reserve, causing <strong>ketoacidosis</strong>.</p>\n<p>&nbsp;</p>\n</div>\n</div>\n</div>\n</div><hr><h3>Related Pearl: Ketone body utilisation</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/c4f64f2c484149b98ae69f977b81491ax600x597.JPEG\" alt=\"Pearl Image\"><p>1.&nbsp;3-Hydroxybutyrate dehydrogenase</p>\n<p>2.&nbsp;CoA Transferase</p>\n<p>3.&nbsp;Thiolase</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD1902",
      "difficulty": "medium"
    },
    {
      "text": "A young man with a family history of coronary heart disease asks you for advice on prevention and you prescribe omega 3 capsules. To which of the following fatty acid groups does it belong?",
      "choices": [
        {
          "id": 1,
          "text": "Monounsaturated fatty acid"
        },
        {
          "id": 2,
          "text": "Saturated fatty acid"
        },
        {
          "id": 3,
          "text": "Trans fatty acid"
        },
        {
          "id": 4,
          "text": "Polyunsaturated fatty acid"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>In the given scenario, <strong>omega-3 fatty acids</strong> are useful in those with a higher preponderance of cardiovascular diseases and they come under the category of <strong>polyunsaturated fatty acids</strong>.&nbsp;</p>\n<p>They have been found to have anti-inflammatory effects and facilitate the production of less inflammatory prostaglandins and leukotrienes as compared to omega-6 fatty acids.&nbsp;</p>\n<p>Dietary omega-3 PUFA can also:</p>\n<ul>\n<li>Suppress cardiac arrhythmias</li>\n<li>Reduce blood TAG</li>\n<li>Decrease tendency for thrombosis</li>\n</ul>\n<table>\n<tbody>\n<tr>\n<td>Omega 6 fatty acids</td>\n<td>\n<ul>\n<li>Olive oil</li>\n<li>Soyabean oil</li>\n<li>Cottonseed oil</li>\n<li>Sesame oil</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>Omega 3 fatty acids</td>\n<td>\n<p>Fish and fish oil:</p>\n<ul>\n<li>S-sardines</li>\n<li>M-mackerel</li>\n<li>A-anchovies</li>\n<li>S-salmon</li>\n<li>H-herring</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Other options:</p>\n<p>Option A:&nbsp;<strong><span data-preserver-spaces=\"true\">Monounsaturated fatty acids</span></strong><span data-preserver-spaces=\"true\">&nbsp;(MUFA) contain a single double bond, Ex:&nbsp;</span><span data-preserver-spaces=\"true\">palmitoleic acid (&omega;7),&nbsp;</span><span data-preserver-spaces=\"true\">oleic acid (&omega;9), and&nbsp;</span><span data-preserver-spaces=\"true\">elaidic acid (&omega;9). They are present in most plant-based oils. When saturated fats are replaced with MUFA, they lower the total plasma cholesterol and LDL. However, they have no anti-inflammatory properties.</span></p>\n<p><span data-preserver-spaces=\"true\">Option B:&nbsp;<strong>Saturated fatty acid</strong>&nbsp;has hydrocarbon chains that <strong>do not contain any double bonds</strong>.&nbsp;Consumption of saturated fats is&nbsp;associated with <strong>high levels of total plasma cholesterol and LDL-C</strong> and an <strong>increased risk of CHD</strong>. The main sources of saturated fatty acids are dairy and meat products and some vegetable oils (coconut, palm oils).<br /></span></p>\n<p><span data-preserver-spaces=\"true\">Option C:&nbsp;<strong>Trans fatty acids</strong>&nbsp;are chemically classified as unsaturated fatty acids but behave more like saturated fatty acids in the body as they elevate LDL-C and lower HDL-C, thereby <strong>increasing the risk of CHD</strong>. They are a by-product of the&nbsp;<strong>hydrogenation of vegetable oils.</strong></span></p><hr><h3>Related Pearl: Classification of Lipids</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/d5f35995a4b148e1adfaf9792db9f9d8x1280x1682.WEBP\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD3894",
      "difficulty": "easy"
    },
    {
      "text": "A 32-year-old man is found to have right-sided colon cancer. His father had similar colon cancer and died at the age of 40. His paternal aunt suffers from endometrial cancer and his paternal uncle also suffers from urothelial cancer. There is no history of familial adenomatous polyposis. Abnormality in which of the following DNA repair mechanisms is responsible for this patient's condition?",
      "choices": [
        {
          "id": 1,
          "text": "Nucleotide excision repair"
        },
        {
          "id": 2,
          "text": "Homologous recombination"
        },
        {
          "id": 3,
          "text": "Base excision repair"
        },
        {
          "id": 4,
          "text": "Mismatch repair"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The given clinical scenario is suggestive of <strong>Lynch syndrome </strong>or<strong>&nbsp;hereditary nonpolyposis colorectal cancer</strong> (HNPCC) and <strong>mismatch repair </strong>is&nbsp;the defective DNA repair mechanism here.&nbsp;</p>\n<p><strong>HNPCC</strong> is an <strong>autosomal dominant</strong> genetic condition that is associated with a high risk of <strong>colon cancer</strong><sup id=\"cite_ref-1\" class=\"reference\"></sup>&nbsp;as well as other cancers including endometrial cancer (second most common), cancers of the stomach, ovary, ureters, etc. It is the most common cause of the syndromic form of colon cancer. Colon cancers are seen at <strong>younger</strong> ages and usually on the <strong>right</strong> side.</p>\n<p>DNA mismatch repair proteins<strong>&nbsp;function as spell checkers</strong>&nbsp;during DNA replication by correcting the&nbsp;<strong>incorrect pairing.</strong>&nbsp;In HNPCC, the proofreading function of the mismatch repair systems (majorly&nbsp;<strong><em>MLH1&nbsp;</em></strong><em>and</em><strong>&nbsp;<em>MSH2</em></strong><em>)</em>&nbsp;is lost leading to the accumulation of errors throughout the genome.&nbsp;The genomes of these patients show <strong>microsatellite instability</strong>,&nbsp;which is characterized by changes in the length of short repeats.</p>\n<p>Other options:</p>\n<p>Option A: Defects in the&nbsp;<strong>nucleotide excision repair</strong>&nbsp;pathway are seen in patients with&nbsp;<strong>xeroderma pigmentosum.</strong></p>\n<p>Option B: Defects in&nbsp;<strong>non-homologous end-joining</strong> are seen in patients with subacute combined immunodeficiency syndrome&nbsp;<strong>(SCID).</strong></p>\n<p>Option C: Defects in <strong>DNA base excision repair</strong> are seen in patients with MUTYH-associated polyposis (MAP) syndromes.&nbsp;</p><hr><h3>Related Pearl: Amsterdam Criteria II - Revised Criteria for HNPCC</h3><p>The <strong>diagnostic criteria for HNPCC</strong> are referred to as the <strong>Amsterdam criteria</strong><em>&nbsp;</em>or the <strong>3-2-1-0 rule</strong><em>.</em></p>\n<p>It includes the following:</p>\n<ul>\n<li><strong>Three or more relatives</strong> with HNPCC-associated cancer (colorectal cancer, endometrial cancer, cancer of the small bowel, ureter, or renal pelvis), <strong>one </strong>of whom is a<strong> first-degree relative of the other two</strong></li>\n<li>At least <strong>two successive generations</strong> affected</li>\n<li>At least <strong>one case </strong>diagnosed<strong> before </strong>the age of<strong> 50 years</strong></li>\n<li>Familial adenomatous polyposis excluded.</li>\n<li>Tumors verified by pathologic examination.</li>\n</ul>\n<p><strong>All of the above</strong> must be applicable for a presumptive diagnosis of HNPCC to be made in a family.</p>\n<p>&nbsp;</p>\n<p class=\"p1\">&nbsp;</p><hr><h3>Related Pearl: DNA Repair Mechanisms</h3><table>\n<tbody>\n<tr>\n<td><strong>Damaging agents</strong></td>\n<td><strong>Damage caused</strong></td>\n<td><strong>Repair mechanisms</strong></td>\n</tr>\n<tr>\n<td>\n<p>Ionizing radiation</p>\n<p>X-rays</p>\n<p>Anti-tumor drugs</p>\n</td>\n<td>\n<p>Double-strand breaks</p>\n<p>Single-strand breaks</p>\n<p>Intrastrand crosslinks</p>\n<p>Interstrand crosslinks</p>\n</td>\n<td>Non-homologous end joining (NHEJ)</td>\n</tr>\n<tr>\n<td>\n<p>UV light</p>\n<p>Chemicals</p>\n</td>\n<td>\n<p>Bulky adducts</p>\n<p>Pyrimidine dimers</p>\n</td>\n<td>Nucleotide excision repair (NER)</td>\n</tr>\n<tr>\n<td>\n<p>Oxygen radicals</p>\n<p>Hydrolysis&nbsp;</p>\n<p>Alkylating agents</p>\n</td>\n<td>\n<p>Abasic sites single-strand breaks</p>\n<p>8-oxoguanine lesions</p>\n</td>\n<td>Base excision repair (BER)</td>\n</tr>\n<tr>\n<td>Replication errors</td>\n<td>\n<p>Bases mismatch</p>\n<p>Insertions</p>\n<p>Deletions</p>\n</td>\n<td>Mismatch repair (MMR)</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Human Diseases of DNA Damage Repair</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>DNA damage repair type</strong></p>\n</td>\n<td>\n<p><strong>Diseases</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Defective Nonhomologous End Joining Repair (NHEJ)</p>\n</td>\n<td>\n<p>Severe combined immunodeficiency disease (SCID)</p>\n<p>Radiation sensitive severe combined immunodeficiency disease(RS-SCID)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Defective Homologous Repair (HR)</p>\n</td>\n<td>\n<p>AT-like disorder (ATLD)</p>\n<p>Nijmegen breakage syndrome (NBS)</p>\n<p>Bloom syndrome (BS)</p>\n<p>Werner syndrome (WS)</p>\n<p>Rothmund-Thomson syndrome (RTS)</p>\n<p>Breast cancer suspectibility 1 and 2 (BRCA1, BRCA2)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Defective DNA Nucleotide Excision Repair (NER)</p>\n</td>\n<td>\n<p>Xeroderma pigmentosum (XP)</p>\n<p>Cockayne syndrome (CS)</p>\n<p>Trichothiodystrophy (TTD)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Defective DNA Base Excision Repair (BER)</p>\n</td>\n<td>\n<p>MUTYH-associated polyposis (MAP)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Defective DNA Mismatch Repair (MMR)</p>\n</td>\n<td>\n<p>Hereditary nonpolyposis colorectal cancer (HNPCC)</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD7819",
      "difficulty": "medium"
    },
    {
      "text": "An 8-year-old girl presented to OPD  with multiple pigmented papular lesions on her face, neck, and forearm and corneal injection following exposure to the sun. Which DNA repair mechanism is defective in this condition?",
      "choices": [
        {
          "id": 1,
          "text": "DNA Base Excision Repair"
        },
        {
          "id": 2,
          "text": "DNA Mismatch Repair"
        },
        {
          "id": 3,
          "text": "Nonhomologous End Joining Repair"
        },
        {
          "id": 4,
          "text": "DNA Nucleotide Excision Repair"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The clinical picture and the history are suggestive of <strong>xeroderma pigmentosum.</strong> The DNA repair mechanism that is defective in this condition is <strong>nucleotide excision repair (NER). </strong>The given image shows hyperkeratotic lesions with some induration suspicious of actinic keratosis and early squamous cell carcinoma. Also, numerous hyper-pigmented lentigos and xerosis are seen on the entire front of the face.</p>\n<p> Xeroderma Pigmentosum (XP) is a rare <strong>autosomal recessive</strong> genetic disorder characterized by defective DNA repair which leads to clinical and cellular hypersensitivity to ultraviolet radiation and other carcinogenic agents.</p>\n<div class=\"page\" title=\"Page 6233\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Skin changes begin in infancy or early childhood, mainly in sun-exposed areas. The skin lesions include erythema, scaling, bullae, freckles, telangiectasia, keratoses, basal and squamous cell carcinomas, and malignant melanomas. Eye manifestations include photophobia, blepharitis, keratitis, corneal opacities, eyelid tumors, and possible blindness. Neurologic abnormalities occur rarely in the form of cognitive deterioration and sensorineural deafness.</p>\n</div>\n</div>\n</div>\n<p>UV radiation leads to pyrimidine dimerization in DNA strands, preventing further replication by DNA polymerase. The nucleotide excision repair mechanism corrects the dimer formation in DNA. In <strong>XP</strong>, there is an inability<span class=\"fontstyle0\"> to <strong>repair DNA pyrimidine dimers</strong> caused by <strong>UV exposure</strong>, and hence the accumulation of mutations that cause cancers.</span></p><hr><h3>Related Pearl: Human Diseases of DNA Damage Repair</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>DNA damage repair type</strong></p>\n</td>\n<td>\n<p><strong>Diseases</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Defective Nonhomologous End Joining Repair (NHEJ)</p>\n</td>\n<td>\n<p>Severe combined immunodeficiency disease (SCID)</p>\n<p>Radiation sensitive severe combined immunodeficiency disease(RS-SCID)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Defective Homologous Repair (HR)</p>\n</td>\n<td>\n<p>AT-like disorder (ATLD)</p>\n<p>Nijmegen breakage syndrome (NBS)</p>\n<p>Bloom syndrome (BS)</p>\n<p>Werner syndrome (WS)</p>\n<p>Rothmund-Thomson syndrome (RTS)</p>\n<p>Breast cancer suspectibility 1 and 2 (BRCA1, BRCA2)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Defective DNA Nucleotide Excision Repair (NER)</p>\n</td>\n<td>\n<p>Xeroderma pigmentosum (XP)</p>\n<p>Cockayne syndrome (CS)</p>\n<p>Trichothiodystrophy (TTD)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Defective DNA Base Excision Repair (BER)</p>\n</td>\n<td>\n<p>MUTYH-associated polyposis (MAP)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Defective DNA Mismatch Repair (MMR)</p>\n</td>\n<td>\n<p>Hereditary nonpolyposis colorectal cancer (HNPCC)</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: DNA Repair Mechanisms</h3><table>\n<tbody>\n<tr>\n<td><strong>Damaging agents</strong></td>\n<td><strong>Damage caused</strong></td>\n<td><strong>Repair mechanisms</strong></td>\n</tr>\n<tr>\n<td>\n<p>Ionizing radiation</p>\n<p>X-rays</p>\n<p>Anti-tumor drugs</p>\n</td>\n<td>\n<p>Double-strand breaks</p>\n<p>Single-strand breaks</p>\n<p>Intrastrand crosslinks</p>\n<p>Interstrand crosslinks</p>\n</td>\n<td>Non-homologous end joining (NHEJ)</td>\n</tr>\n<tr>\n<td>\n<p>UV light</p>\n<p>Chemicals</p>\n</td>\n<td>\n<p>Bulky adducts</p>\n<p>Pyrimidine dimers</p>\n</td>\n<td>Nucleotide excision repair (NER)</td>\n</tr>\n<tr>\n<td>\n<p>Oxygen radicals</p>\n<p>Hydrolysis&nbsp;</p>\n<p>Alkylating agents</p>\n</td>\n<td>\n<p>Abasic sites single-strand breaks</p>\n<p>8-oxoguanine lesions</p>\n</td>\n<td>Base excision repair (BER)</td>\n</tr>\n<tr>\n<td>Replication errors</td>\n<td>\n<p>Bases mismatch</p>\n<p>Insertions</p>\n<p>Deletions</p>\n</td>\n<td>Mismatch repair (MMR)</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/9201dda1318240ad9a8292f931e55f2e.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD3213",
      "difficulty": "medium"
    },
    {
      "text": "A 20-year-old bodybuilder presented with fatigue on moderate exercise. He had recently started eating raw eggs for protein. Which of the following enzymes is likely deficient in him?",
      "choices": [
        {
          "id": 1,
          "text": "Glucose-6-phosphatase"
        },
        {
          "id": 2,
          "text": "Glycogen phosphorylase"
        },
        {
          "id": 3,
          "text": "Pyruvate carboxylase"
        },
        {
          "id": 4,
          "text": "Phosphoenolpyruvate carboxykinase"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The patient developed <strong>pyruvate carboxylase</strong> enzyme <strong>deficiency.</strong></p>\n<p>Individuals who eat an excess of <strong>uncooked</strong> <strong>egg-white</strong> develop <strong>biotin deficiency</strong> and as a result carboxylase enzyme deficiency. This is because a protein called <strong>avidin</strong> present in the egg-white<strong> binds </strong>to<strong> biotin</strong> in the diet and makes biotin unavailable for intestinal absorption. Biotin deficiency can cause <strong>dermatitis</strong>, mental status changes (depression, hallucinations), paraesthesia and alopecia.</p>\n<p>Biotin serves as a co-enzyme for the synthesis of several carboxylase enzymes such as acetyl-CoA carboxylase, <strong>pyruvate carboxylase</strong>, propionyl CoA carboxylase and methylcrotonyl-CoA carboxylase. Thus these enzymes are deficient in biotin deficiency. </p><hr><h3>Related Pearl: Vitamin Deficiency States (Water-soluble Vitamins)</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Vitamin</strong></p>\n</td>\n<td>\n<p><strong>Deficiency State</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Thiamine (<strong>B<sub>1</sub></strong>)</p>\n</td>\n<td>\n<p><strong>Beriberi</strong></p>\n<p>Wernicke&ndash;Korsakoff&rsquo;s syndrome</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Riboflavin (<strong>B<span>2</span></strong>)</p>\n</td>\n<td>\n<p>Cheilosis, Magenta-coloured tongue,&nbsp;</p>\n<p>Glossitis, Seborrheic dermatitis</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Niacin (<strong>B<span>3</span></strong>)</p>\n</td>\n<td>\n<p><strong>Pellagra</strong></p>\n<p>Dermatitis, Diarrhea, Dementia</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Pantothenic acid (<strong>B<span>5</span></strong>)</p>\n</td>\n<td>\n<p><strong>Burning foot syndrome</strong> (historically called as \"Nutritional melalgia\")</p>\n<div class=\"page\" title=\"Page 90\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Dermatitis, enteritis, alopecia, ataxia</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<p>Pyridoxine (<strong>B<span>6</span></strong>)</p>\n</td>\n<td>\n<p>Microcytic anemia, convulsions, depression</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Biotin (<strong>B<span>7</span></strong>)</p>\n</td>\n<td>\n<p>Relatively unknown</p>\n<p>Dermatitis, atrophic glossitis, alopecia, paraesthesia, muscle pain, anorexia, hallucinations</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Folic acid (<strong>B<span>9</span></strong>)</p>\n</td>\n<td>\n<p>Megaloblastic anemia, neuropathy, neural tube defects, atrophic glossitis</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Cobalamin (<strong>B<span>12</span></strong>)</p>\n</td>\n<td>\n<p>Pernicious anemia, dementia, spinal cord degeneration, homocysteinemia</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Ascorbic acid (<strong>C</strong>)</p>\n</td>\n<td>\n<p><strong>Scurvy</strong></p>\n<p>Ecchymosis, bleeding gums, poor wound healing, fatigue, joint effusion, Scorbutic rosary</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3275",
      "difficulty": "medium"
    },
    {
      "text": "A research fellow in biochemistry is studying the lac operon concept of gene regulation. He cultures E. coli. in a glucose deficient and lactose present medium. Which of the following genes expressed in this condition helps lactose gain access into the cells?",
      "choices": [
        {
          "id": 1,
          "text": "1"
        },
        {
          "id": 2,
          "text": "2"
        },
        {
          "id": 3,
          "text": "3"
        },
        {
          "id": 4,
          "text": "4"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The gene marked as <strong>3</strong> is the <strong>lac Y gene</strong> which helps <strong>lactose gain access</strong> into the cells. It does so by encoding for the enzyme, lactose permease.</p>\n<p><strong>Lac operon concept</strong></p>\n<p>Jacob and Monod<span class=\"Apple-converted-space\"> studied the <strong>Lac operon model</strong> which is the </span>regulation of <strong>lactose metabolism</strong> by the intestinal bacterium <em><strong>E. coli</strong></em>.<span class=\"Apple-converted-space\"> It is switched on when the bacteria have to utilize lactose for utilization. Otherwise, it is switched off. </span>The genetic arrangement of the lac operon helps coordinate the expression of the<strong> three main enzymes </strong>(5, 6, 7 below) involved in <strong>lactose</strong> metabolism. The genes include:</p>\n<ol>\n<li><span class=\"Apple-converted-space\"><span class=\"Apple-converted-space\"><strong>lac I</strong>- it codes for the repressor protein that </span></span>prevents transcription of the distal structural genes, lac Z, lac Y, and lac A by interfering with the binding of RNA polymerase to the promoter.</li>\n<li><span class=\"Apple-converted-space\"><strong>CRE </strong>(cAMP response element)- It is activated by binding the </span>cyclic AMP activator protein (CAP). When activated, it increases the binding of RNA polymerase<span class=\"Apple-converted-space\"> and increases gene expression.</span></li>\n<li><span class=\"Apple-converted-space\"><strong>Promoter site</strong>- It is the site where RNA polymerase binds the gene for transcription. </span></li>\n<li><span class=\"Apple-converted-space\"><strong>Operator site</strong>- It is the site where repressor protein binds.</span></li>\n<li><span class=\"Apple-converted-space\"><strong>lac Z gene</strong>- It codes for </span><strong>β-Galactosidase</strong> that hydrolyzes lactose to galactose and glucose.<span class=\"Apple-converted-space\"> </span></li>\n<li><span class=\"Apple-converted-space\"><strong>lac Y</strong>- encodes for <strong>lactose permease</strong> which increases the permeability of lactose into the cells</span></li>\n<li><span class=\"Apple-converted-space\"><strong>lac A</strong>- encodes for </span><strong>thiogalactoside transacetylase<span class=\"Apple-converted-space\"> </span></strong></li>\n</ol>\n<p><span class=\"Apple-converted-space\">The image below shows the genetic arrangement of the lac operon and the process of regulation of lactose metabolism</span></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/31a9b9443c50419a85ca60ae91fdab11x1279x746.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Difference between Lac & tryptophan operon</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Lac Operon</strong></p>\n</td>\n<td>\n<p><strong>Tryptophan Operon</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Inducible gene complex</p>\n</td>\n<td>\n<p>Repressible gene complex</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Catabolic system</p>\n</td>\n<td>\n<p>Anabolic system</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Contain 3 structural genes</p>\n</td>\n<td>\n<p>Contains 5 structural gene</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Produce 3 inducible enzymes</p>\n</td>\n<td>\n<p>Produce 5 Repressible enzymes</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Repressor protein is active</p>\n</td>\n<td>\n<p>Repressor protein is inactive</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>High lactose turn transcription on , in low glucose level</p>\n</td>\n<td>\n<p>High tryptophan transcription off</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Lactose act as inducer</p>\n</td>\n<td>\n<p>Tryptophan act as co-repressor</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Has only 1 type of gene regulation-Negative&nbsp; control</p>\n</td>\n<td>\n<p>Has only 1 type of gene regulation-Negative control</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Usually OFF, Get activated under certain conditions</p>\n</td>\n<td>\n<p>Usually ON, inactive at high level of tryptophan.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>cAMP is necessary for CAP to switch transcription on</p>\n</td>\n<td>\n<p>cAMP is not&nbsp; necessary</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p><hr><h3>Related Pearl: Operon system</h3><table>\n<tbody>\n<tr>\n<td>Control of operon/ Regulation of gene expression&nbsp;</td>\n<td>Type of operon</td>\n<td>Metabolite</td>\n<td>Final outcome</td>\n<td>Examples</td>\n</tr>\n<tr>\n<td rowspan=\"2\">\n<p><strong>Negative control</strong></p>\n<p>(an active repressor <strong>inhibits transcription</strong>)</p>\n&nbsp;</td>\n<td>\n<p><strong>Inducible operons</strong></p>\n<p>(repressor bound to operon)</p>\n</td>\n<td>binds to repressor and inhibits its binding to the operon by causing a conformational change</td>\n<td>Transcription</td>\n<td><strong>lactose operon</strong></td>\n</tr>\n<tr>\n<td>\n<p><strong>Repressible operons</strong></p>\n<p>(repressor unable to bind to operon)</p>\n</td>\n<td>binds to repressor and induces its binding to the operon by causing a conformational change</td>\n<td>No&nbsp;Transcription</td>\n<td><strong>Tryptophan operon</strong></td>\n</tr>\n<tr>\n<td rowspan=\"2\">\n<p><strong>Positive control</strong></p>\n<p>(an active activator/ regulator <strong>promotes transcription</strong>)</p>\n&nbsp;</td>\n<td>\n<p><strong>Inducible operons</strong></p>\n<p>(activator unable to bind to operon)</p>\n</td>\n<td>binds to activator and induces its binding to operon by causing a conformational change</td>\n<td>Transcription</td>\n<td>cAMP-CAT operon</td>\n</tr>\n<tr>\n<td>\n<p><strong>Repressible operons&nbsp;</strong></p>\n<p>(activator bound to operon)</p>\n</td>\n<td>binds to activator and inhibits its binding to operon by causing a conformational change&nbsp;</td>\n<td>No Transcription</td>\n<td>&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/30993953bbe44f8d9ce20feb967f3289x719x599.PNG\" alt=\"Pearl Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/313625cb44864d3f9ea7dc89f4ddbe49.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF3830",
      "difficulty": "hard"
    },
    {
      "text": "A 9-year-old boy was brought with complaints of a fishy smell in his hands, feet, saliva, and urine. A urinalysis revealed the substance responsible for the odor, and a diagnosis of Fish odor syndrome was made. Which is the substance responsible for this characteristic body odor?",
      "choices": [
        {
          "id": 1,
          "text": "Trimethylamine-N-oxide"
        },
        {
          "id": 2,
          "text": "Trimethylamine"
        },
        {
          "id": 3,
          "text": "Flavin monooxygenase"
        },
        {
          "id": 4,
          "text": "Choline"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>In the given clinical scenario of <strong>fish odor syndrome</strong>, the characteristic odor is due to <strong>trimethylamine (TMA)</strong>, which is released in sweat, urine, and breath.</p>\n<p><strong>Fish odor syndrome</strong> (trimethylaminuria) is an autosomal recessive disease. It is due to a deficiency of <strong>flavin-containing monooxygenase 3 (FMO3)</strong> which converts the amino acid, TMA (trimethylamine) to TMA-N-oxide (which is non-odorous) in the liver. <strong>TMA</strong> thus builds up in the body and is released in sweat, urine, and breath, giving off a strong <strong>odor</strong> of <strong>rotting</strong> <strong>fish</strong> from the body.</p>\n<p>Patients present in <strong>childhood</strong> or early adulthood with <strong>halitosis</strong> or <strong>body odor </strong>(distinctive fishy odor). Patients suffer from <strong>psychosocial problems</strong> such as shame, anxiety, depression, etc. Diagnosis is based on high levels of excreted trimethylamine (TMA) in the patient's urine. </p>\n<p>Treatment involves <strong>avoiding foods</strong> containing choline such as egg, liver, peas, and soy products. A <strong>short course of antibiotics</strong> such as neomycin and metronidazole can be given which reduce the production of trimethylamine by the gut bacteria.</p><hr><h3>Related Pearl: Inborn Errors of Amino Acid Metabolism and Their Associated Urine Odor</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Inborn Error of Metabolism</strong></p>\n</td>\n<td>\n<p><strong>Urine Odor</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Maple syrup urine disease</p>\n</td>\n<td>\n<p>Maple syrup</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hawkinsinuria</p>\n</td>\n<td>\n<p>Swimming pool</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>3-Hydroxy-3-methylglutaric aciduria</p>\n</td>\n<td>\n<p>Cat urine</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Isovaleric acidemia</p>\n<p>Glutaric acidemia (type II)</p>\n</td>\n<td>\n<p>Sweaty feet</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hypermethioninemia</p>\n<p>Tyrosinemia</p>\n</td>\n<td>\n<p>Boiled cabbage</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Multiple carboxylase deficiency</p>\n</td>\n<td>\n<p>Tomcat urine</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Phenylketonuria</p>\n</td>\n<td>\n<p>Mousy</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Trimethylaminuria</p>\n</td>\n<td>\n<p>Rotting fish</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Oasthouse syndrome</p>\n</td>\n<td>\n<p>Dried malt/hops</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF0671",
      "difficulty": "medium"
    },
    {
      "text": "An infant presents with poor feeding. He has tachycardia and tachypnoea along with enlarged tongue, hypotonia, skeletal muscle weakness, and hepatomegaly. Laboratory investigations reveal elevated serum CK, AST,  ALT, LDH, and urine glucose tetrasaccharide. Chest X-ray is done later as shown below.  What is the most likely diagnosis?<div class='question-desc-html'><p>CK-creatine kinase ; AST-aspartate aminotransferase ; ALT-alanine aminotransferase ; LDH-lactate dehydrogenase</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Von Gierke disease"
        },
        {
          "id": 2,
          "text": "Pompe disease"
        },
        {
          "id": 3,
          "text": "Mc Ardle disease"
        },
        {
          "id": 4,
          "text": "Tarui disease"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>From the above-given clinical scenario and the radiograph showing <strong>cardiomegaly</strong> (tachycardia and tachypnoea), <strong>Pompe's disease</strong> is the most likely diagnosis. The clinical symptoms of Pompe disease are <strong>hypotonia</strong> (floppy infant), skeletal muscle weakness, <strong>hepatomegaly</strong>, hypertrophic <strong>cardiomyopathy</strong> and <strong>macroglossia.</strong> </p>\n<p><strong>Pompe's disease </strong>(Type 2 glycogen storage disease) is an autosomal recessive disorder that occurs due to <strong>α-1,4-glucosidase (acid maltase)</strong> deficiencyleading to lysosomal glycogen accumulation in cardiac, skeletal, and smooth muscle cells. It can appear within <strong>weeks or months</strong> after birth (infantile Pompe disease) or may appear late in juvenile, childhood, or adulthood disease (late-onset Pompe disease).</p>\n<p>Laboratory findings will show elevated levels of serum creatine kinase (CK), aspartate transaminase (AST), alanine transaminase (ALT), and lactate dehydrogenase (LDH). <strong>Urine glucose tetrasaccharide,</strong> a glycogen breakdown metabolite, is a reliable biomarker for disease severity and treatment response.</p>\n<p>Muscle biopsy shows the presence of vacuoles that stain positively for <strong>glycogen. </strong>It is diagnosed by detecting the decreased activity of the enzyme, <strong>α-1,4-glucosidase</strong> in the dried blood spots, leukocytes, blood mononuclear cells, muscle, or cultured skin fibroblasts.</p>\n<p>Other options</p>\n<div class=\"page\" title=\"Page 3442\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Option A- <strong>Von Gierke disease </strong>occurs due to a deficiency of <strong>glucose-6-phosphatase.</strong> Patients present commonly in 3-4 months of age with <strong>hypoglycemia, lactic acidosis,</strong> hepatomegaly, growth retardation, hyperuricemia, and hyperlipidemia.</p>\n<p>Option C- <strong>McArdle disease</strong> occurs due to <strong>myophosphorylase</strong> deficiency leading to reduced ATP generation. The typical manifestations are myoglobinuria (secondary to rhabdomyolysis), muscle pain and cramps after heavy exercise. This pain may reduce after a brief period of rest and the patient may be able to perform an exercise. This is called the <strong>second wind phenomenon</strong>. Cardiomyopathy is not seen in this condition.</p>\n<p>Option D- <strong>Tarui disease</strong> (Type VII glycogen storage disorder)<strong> </strong>occurs due to the deficiency of muscle phosphofructokinase. The main clinical features are exercise intolerance, cramps, <strong>hemolytic anemia,</strong> and myoglobinuria. There is no hypertrophic cardiomyopathy.</p>\n</div>\n</div>\n</div><hr><h3>Related Pearl: Glycogen Storage Diseases</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/782e85c36f0648698a222dca988adfabx1280x1863.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Disease</strong></p>\n</td>\n<td>\n<p><strong>Enzyme deficiency</strong></p>\n</td>\n<td>\n<p><strong>Symptoms</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type 0</p>\n</td>\n<td>\n<p>Glycogen synthase</p>\n</td>\n<td>\n<p>Hypoglycemia</p>\n<p>Early death</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type Ia</p>\n<p><strong>Von Gierke's disease</strong></p>\n</td>\n<td>\n<p>Glucose-6- phosphatase</p>\n</td>\n<td>\n<p>Hepatomegaly and renomegaly&nbsp;due to glycogen accumulation</p>\n<p>Severe fasting hypoglycemia</p>\n<p>Growth failure</p>\n<p>Lactic acidosis</p>\n<p>Hyperuricemia</p>\n<p>Hyperlipidemia</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type Ib</p>\n</td>\n<td>\n<p>Endoplasmic reticulum glucose-6- phosphate transporter</p>\n</td>\n<td>\n<p>Same as Von Gierke's disease</p>\n<p>Recurrent infections due to impaired neutrophil function</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type II</p>\n<p><strong>Pompe's disease</strong></p>\n</td>\n<td>\n<p>Lysosomal &alpha;1,4:1,6 glucosidase</p>\n<p>(Acid maltase)</p>\n</td>\n<td>\n<p>Muscle weakness</p>\n<p>Death by age ~ 2 years (infantile variant)</p>\n<p>Cardiomegaly and heart failure</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type III</p>\n<p><strong>Cori's/Forbes disease</strong></p>\n<p>(Limit dextrinosis)</p>\n</td>\n<td>\n<p>Glycogen debranching enzyme</p>\n</td>\n<td>\n<p>Muscle weakness</p>\n<p>Fasting hypoglycemia</p>\n<p>Hepatomegaly due to accumulation of branched-chain polysaccharide (limit dextrins)</p>\n<p>Growth retardation</p>\n<p>Normal lactate and uric acid levels</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type IV</p>\n<p><strong>Andersen disease</strong></p>\n</td>\n<td>\n<p>Glycogen branching enzyme</p>\n</td>\n<td>\n<p>Failure to thrive</p>\n<p>Hepatomegaly due to accumulation of polysaccharides with few branch points</p>\n<p>Death at age ~ 5 years</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type V</p>\n<p><strong>McArdle disease</strong></p>\n</td>\n<td>\n<p>Muscle glycogen phosphorylase</p>\n</td>\n<td>\n<p>Exercise-induced cramps</p>\n<p>Renal failure due to rhabdomyolysis and myoglobinuria</p>\n<p>Second wind phenomenon</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type VI</p>\n<p><strong>Her's disease</strong></p>\n</td>\n<td>\n<p>Liver glycogen phosphorylase</p>\n</td>\n<td>\n<p>Generally benign</p>\n<p>Mild hypoglycemia</p>\n<p>Hepatomegaly</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type VII</p>\n<p><strong>Tarui's disease</strong></p>\n</td>\n<td>\n<p>Muscle phosphofructokinase</p>\n</td>\n<td>\n<p>Exercise-induced muscle cramps and weakness</p>\n<p>Growth retardation</p>\n<p>Hemolytic anemia</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Enzyme Replacement Therapy for Lysosomal Storage Disorders</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>&nbsp;Lysosomal Storage Disorder</strong></p>\n</td>\n<td>\n<p><strong>Enzyme deficient</strong></p>\n</td>\n<td>\n<p><strong>Enzyme Replacement Therapy</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hurler Syndrome (MPS I)</p>\n</td>\n<td>\n<p>&alpha;-L -iduronidase</p>\n</td>\n<td>\n<p>Laronidase (Aldurazyme)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hunter Syndrome (MPS II)</p>\n</td>\n<td>\n<p>Iduronate sulfate sulfatase</p>\n</td>\n<td>\n<p>Idursulfase (Elaprase)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Morquio A Syndrome (MPS IVA)</p>\n</td>\n<td>\n<p>N-Acetylgalactosamine-6-sulfate sulfatase</p>\n</td>\n<td>\n<p>Elosulfase (Vimizim)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Maroteaux&ndash;Lamy Syndrome (MPS VI)</p>\n</td>\n<td>\n<p>N -Acetylgalactosamine-&alpha;-4-sulfate sulfatase (arylsulfatase B)</p>\n</td>\n<td>\n<p>Galsulfase (Naglazyme)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Sly syndrome (MPS VII)</p>\n</td>\n<td>&beta;-Glucuronidase</td>\n<td>\n<p>rhGUS (recombinant human&nbsp;&beta;-Glucuronidase is under Phase III trial)</p>\n</td>\n</tr>\n<tr>\n<td>Wolman disease</td>\n<td>Lysosomal acid lipase</td>\n<td>\n<p><em> Sebelipase alfa</em>(Kanuma, Alexion)</p>\n</td>\n</tr>\n<tr>\n<td>Metachromatic leukodystrophy</td>\n<td>Arylsulfatase A</td>\n<td>\n<p>rhARSA (recombinant human arylsulfatase A is under Phase I/II trial)</p>\n</td>\n</tr>\n<tr>\n<td>Fabry disease&nbsp;</td>\n<td>&alpha;-galactosidase A</td>\n<td>\n<p><em>agalsidase beta</em> (Fabrazyme, Genzyme)</p>\n<p><em>agalsidase alfa</em> (Replagal, Shire HGT)</p>\n</td>\n</tr>\n<tr>\n<td>Gaucher disease</td>\n<td>&beta;-glucosidase</td>\n<td>\n<p><em>imiglucerase </em>[Cerezyme, Genzyme]</p>\n<p><em>velaglucerase alfa </em>[VPRIV, Shire HGT]</p>\n<p><em>taliglucerase alfa </em>(Uplyso, Protalix<br />Biotherapeutics)</p>\n<p><em>eliglusta</em>t (Cerdelga, Sanofi-Genzyme)</p>\n</td>\n</tr>\n<tr>\n<td>Pompe disease</td>\n<td>acid &alpha;-1,4-glucosidase (acid maltase)&nbsp;</td>\n<td>\n<p><em>alglucosidase alfa </em>(Myozyme)</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/f7c8920e5d384fb3b49da7aecac758ce.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF0326",
      "difficulty": "easy"
    },
    {
      "text": "A 20-year-old female patient presents with the following finding as shown in the image below. On further investigation, she is found to have reduced levels of the enzyme UDP-glucuronosyltransferase. Which of the following disorders is she most likely suffering from?",
      "choices": [
        {
          "id": 1,
          "text": "Type I Crigler-Najjar syndrome"
        },
        {
          "id": 2,
          "text": "Gilbert syndrome"
        },
        {
          "id": 3,
          "text": "Dubin Johnson syndrome"
        },
        {
          "id": 4,
          "text": "Rotor syndrome"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>With the given clinical scenario and with reduced levels of enzyme UDP-glucuronosyltransferase, the patient is most likely suffering from <strong>Gilbert syndrome</strong>.&nbsp;<br /><br /><strong>Gilbert syndrome</strong> is an autosomal recessive condition characterized by <strong>decreased activity</strong> of the <strong>enzyme&nbsp;UDP-glucuronosyltransferase</strong>, which is responsible for the conjugation of bilirubin. This leads to <strong>unconjugated hyperbilirubinemia</strong>, that presents as yellowish discolouration of the sclera (icterus/jaundice) as seen in the given image.</p>\n<p>Individuals with Gilbert syndrome are usually <strong>asymptomatic</strong> except for <strong>intermittent episodes of jaundice</strong>, which usually occurs for the first time during <strong>adolescence</strong>, due to changes in the concentration of sex hormones.&nbsp;Some patients may have complaints like malaise, fatigue, nausea, anxiety, loss of appetite, and abdominal discomfort. Symptoms are usually precipitated by <strong>triggers</strong> such as fasting, intercurrent illness, menstruation, and dehydration.</p>\n<div class=\"page\" title=\"Page 2601\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Administration of <strong>phenobarbital</strong> shows normalisation of the serum bilirubin concentration and hepatic bilirubin clearance.</p>\n<p>Gilbert syndrome usually doesn't require any treatment.</p>\n</div>\n</div>\n</div>\n</div>\n<p>Other options:<br /><br />Option A: <strong>Type I Crigler-Najjar syndrome</strong> is characterized by a complete deficiency of the enzyme&nbsp;UDP-glucuronosyltransferase. It usually presents as severe congenital jaundice (serum bilirubin levels over 20 mg/dL) and accompanying brain damage.<br /><br />Options C and D: <strong>Dubin Johnson</strong> and <strong>Rotor syndrome</strong>&nbsp;both have&nbsp;elevated conjugated bilirubin in the blood, and are due to defective secretion of conjugated bilirubin into the bile.</p><hr><h3>Related Pearl: Hereditary Hyperbilirubinemias</h3><table>\n<tbody>\n<tr>\n<td><strong>Disorder</strong></td>\n<td><strong>Inheritance</strong></td>\n<td><strong>Defects in bilirubin metabolism</strong></td>\n<td><strong>Clinical course</strong></td>\n</tr>\n<tr>\n<td>\n<p><strong>Unconjugated Hyperbilirubinemia</strong></p>\n</td>\n<td> </td>\n<td> </td>\n<td> </td>\n</tr>\n<tr>\n<td>\n<p>Crigler-Najjar syndrome type I</p>\n</td>\n<td>\n<p>AR</p>\n</td>\n<td>\n<p>Absent UGT1A1 activity</p>\n</td>\n<td>\n<p>Fatal in the neonatal period</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Crigler-Najjar syndrome type II</p>\n</td>\n<td>\n<p>AR</p>\n</td>\n<td>\n<p>Decreased UGT1A1 activity</p>\n</td>\n<td>\n<p>Generally mild,</p>\n<p>occasional kernicterus</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Gilbert syndrome</p>\n</td>\n<td>\n<p>AR (common)</p>\n<p>AD (occasional)</p>\n</td>\n<td>\n<p>Decreased UGT1A1 activity</p>\n</td>\n<td>\n<p>Innocuous</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Conjugated Hyperbilirubinemia</strong></p>\n</td>\n<td> </td>\n<td> </td>\n<td> </td>\n</tr>\n<tr>\n<td>\n<p>Dubin-Johnson syndrome</p>\n</td>\n<td>\n<p>AR</p>\n</td>\n<td>\n<p>Impaired biliary excretion of bilirubin glucuronides due to a mutation in canalicular multidrug resistance protein 2 (MRP2)</p>\n</td>\n<td>\n<p>Innocuous with black pigmentation of liver</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Rotor syndrome</p>\n</td>\n<td>\n<p>AR</p>\n</td>\n<td>\n<p>Decreased hepatic uptake and storage</p>\n<p>Decreased biliary excretion</p>\n</td>\n<td>\n<p>Innocuous</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Hyperbilirubinemia- Causes</h3><table>\n<tbody>\n<tr>\n<td>&nbsp;<strong>Predominantly Unconjugated Hyperbilirubinemia&nbsp;</strong></td>\n<td><strong>Conjugated hyperbilirubinemia</strong></td>\n</tr>\n<tr>\n<td>\n<p>Excess production of bilirubin</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Hemolytic anemias</p>\n</td>\n<td>\n<p>Biliary tract obstruction</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Resorption of blood from internal hemorrhage (e.g., alimentary tract bleeding, hematomas)</p>\n</td>\n<td>\n<p>&nbsp;Biliary tract diseases like primary biliary cirrhosis and primary sclerosing cholangitis</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Ineffective erythropoiesis (e.g., pernicious anemia, thalassemia)</p>\n</td>\n<td>\n<p>Dubin Johnson syndrome</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Reduced hepatic uptake</p>\n</td>\n<td>\n<p>Rotor syndrome</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Drug interference with membrane carrier systems</p>\n</td>\n<td>Benign recurrent intrahepatic cholestasis</td>\n</tr>\n<tr>\n<td>\n<p>Some cases of Gilbert syndrome</p>\n</td>\n<td>Progressive familial intrahepatic cholestasis</td>\n</tr>\n<tr>\n<td>\n<p>Impaired bilirubin conjugation</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Physiologic jaundice of the newborn (decreased UGT1A1 activity, decreased excretion)</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Breast milk jaundice (&beta;-glucuronidases in milk)</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Genetic deficiency of UGT1A1 activity (Crigler-Najjar syndrome types I and II)</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Gilbert syndrome</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Diffuse hepatocellular disease (e.g., viral or drug-induced hepatitis, cirrhosis)</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/78245db43b2b434999b027e4090092c0.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF2795",
      "difficulty": "medium"
    },
    {
      "text": "A hormone, with the structure as shown below, is being administered to a patient. It is known that it is released during the well-fed state and that it induces the rate-limiting enzyme of a reaction. Choose the correct pair of the rate-limiting enzyme induced and the reaction it is involved in.",
      "choices": [
        {
          "id": 1,
          "text": "Glycogen phosphorylase, Glycogenolysis"
        },
        {
          "id": 2,
          "text": "Fructose-1,6-bisphosphatase, Gluconeogenesis"
        },
        {
          "id": 3,
          "text": "Phosphofructokinase-1, Glycolysis"
        },
        {
          "id": 4,
          "text": "Fructose-1,6-bisphosphatase, Glycolysis"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The hormone whose structure is shown in the image is <strong>insulin</strong> which is released in the well-fed state. Insulin induces the enzyme&nbsp;<strong>phosphofructokinase,</strong>&nbsp;which is the rate-limiting enzyme in <strong>glycolysis</strong>.</p>\n<div class=\"page\" title=\"Page 107\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Glycolysis is a pathway in which glucose is converted to pyruvate in aerobic conditions or lactate in anaerobic conditions, along with the production of a small amount of energy. The <strong>rate-limiting reaction</strong> in glycolysis is the phosphorylation of fructose-6-phosphate to fructose 1,6-bisphosphate. This is catalyzed by the enzyme <strong>phosphofructokinase</strong>.</p>\n</div>\n</div>\n</div>\n<p>There are two phosphofructokinases,&nbsp;<strong>PFK-1 and PFK-2</strong> which participate in this reaction.&nbsp;<strong>PFK-1</strong> plays a key role in regulating glycolysis and is subject to<strong> feedback control</strong>. It converts&nbsp;fructose-6-phosphate to&nbsp;fructose-1-6-bis-phosphate.<br /> <br /><strong>Inhibitors</strong> <strong>of PFK-1</strong>:</p>\n<ul>\n<li>ATP</li>\n<li>Citrate</li>\n</ul>\n<p><strong>Allosteric activators of PFK-1</strong>:</p>\n<ul>\n<li>AMP</li>\n<li>Fructose 2,6 bisphosphate (most<strong>&nbsp;potent activator</strong>)</li>\n</ul>\n<p><strong>Hormonal regulation:</strong></p>\n<ul>\n<li><strong>Inducer&mdash;</strong>Insulin</li>\n<li><strong>Repressor&mdash;</strong>Glucagon</li>\n</ul>\n<div class=\"page\" title=\"Page 187\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Due to the inhibition of phosphofructokinase-1 by ATP, there is an accumulation of glucose-6-phosphate, which in turn inhibits the uptake of glucose in extrahepatic tissues.</p>\n</div>\n</div>\n</div>\n</div>\n<p><strong>PFK-2</strong> phosphorylates fructose-6-phosphate to form fructose-2-6-bis-phosphate in the fed state. PFK-2 also acts as <strong>fructose bisphosphatase-2 (FBPase-2)</strong> and breaks down fructose 2,6-bisphosphate to fructose-6-phosphate in the fasting state. Hence, PFK-2 is a <strong>bifunctional</strong> enzyme whose function is reversed by the presence of insulin or glucagon in the fed and fasting states respectively.&nbsp;</p><div><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\"><strong>The primary structure of insulin&nbsp;</strong></span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">consists of 2 polypeptide chains:&nbsp;</span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\"><strong>A-chain (21 amino acids)&nbsp;</strong></span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">and&nbsp;</span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\"><strong>B-chain (30 amino acids)</strong></span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">.</span></div>\n<div>&nbsp;</div>\n<div><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">It has&nbsp;</span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\"><strong>two interchain disulfide bonds,&nbsp;</strong></span></div>\n<ul class=\"listtype-bullet listindent1 list-bullet1\">\n<li><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">Between the&nbsp;</span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\"><strong>7<sup>th</sup>&nbsp;</strong></span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">amino acid of the A chain and the&nbsp;</span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\"><strong>7<sup>th</sup>&nbsp;</strong></span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">amino acid of the B chain&nbsp;</span></li>\n<li><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">Between the&nbsp;</span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\"><strong>20<sup>th</sup>&nbsp;</strong></span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">amino acid of the A chain and the&nbsp;</span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\"><strong>19<sup>th</sup>&nbsp;</strong></span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">amino acid of the B chain</span></li>\n</ul>\n<p><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">One <strong>intrachain disulfide bond&nbsp;</strong>is present between the&nbsp;<strong>6<sup>th</sup>&nbsp;</strong>amino acid of the A-chain and the&nbsp;<strong>11<sup>th&nbsp;</sup></strong>amino acid in the A-chain.</span></p><hr><h3>Related Pearl: Rate determining enzymes and their key regulators</h3><table>\n<tbody>\n<tr>\n<td>Pathway</td>\n<td>Enzyme&nbsp;</td>\n<td>Regulating factors</td>\n</tr>\n<tr>\n<td>Glycolysis</td>\n<td>Phosphofructokinase (PFK-1)</td>\n<td>\n<p>AMP+, Fructose 2,6 bi-phosphate+</p>\n<p>ATP-, Citrate-</p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;gluconeogenesis</td>\n<td>Fructose-1,6-bisphosphatase</td>\n<td>\n<p>ATP+, Acetyl CoA+</p>\n<p>AMP-, Fructose 2,6 bi-phosphate-</p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;Krebs cycle</td>\n<td>Isocitrate dehydrogenase</td>\n<td>\n<p>ADP+,</p>\n<p>ATP-, NADH-</p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;glycogenesis</td>\n<td>Glycogen synthase</td>\n<td>\n<p>Glucose-6-phosphate+, insulin+, cortisol+,</p>\n<p>Epinephrine-, glucagon-</p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;glycogenolysis</td>\n<td>Glycogen phosphorylase</td>\n<td>\n<p>Epinephrine+, glucagon+, AMP+</p>\n<p>Glucose-6-phosphate-, insulin-, ATP-</p>\n</td>\n</tr>\n<tr>\n<td>HMP shunt&nbsp;</td>\n<td>Glucose-6-phosphate dehydrogenase (G6PD)</td>\n<td>\n<p>NADP+</p>\n<p>NADPH-</p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;Denovo pyrimidine synthesis</td>\n<td>Carbamoyl phosphate synthetase II</td>\n<td>\n<p>ATP+</p>\n<p>UTP-</p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;Denovo purine synthesis</td>\n<td>Glutamine-phosphoribosylpyrophosphate (PRPP) amidotransferase</td>\n<td>AMP-, IMP-, GMP-</td>\n</tr>\n<tr>\n<td>&nbsp;Urea cycle</td>\n<td>Carbamoyl phosphate synthetase I</td>\n<td>N-acetyl glutamate (NAG)+</td>\n</tr>\n<tr>\n<td>&nbsp;Fatty acid synthesis</td>\n<td>Acetyl-CoA carboxylase (ACC)</td>\n<td>\n<p>Insulin+, citrate+</p>\n<p>Glucagon-, palmitoyl-CoA-</p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;Fatty acid oxidation</td>\n<td>Carnitine acyltransferase I</td>\n<td>Malonyl-CoA-</td>\n</tr>\n<tr>\n<td>&nbsp;Cholesterol synthesis</td>\n<td>HMG-CoA reductase</td>\n<td>\n<p>Insulin+, thyroxine+</p>\n<p>Glucagon-, cholesterol-</p>\n</td>\n</tr>\n<tr>\n<td>Ketogenesis</td>\n<td>HMG-CoA synthase</td>\n<td>&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>+ Positive effect on the pathway.</p>\n<p>- Negative effect on the pathway.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/cd2bd9a62cab4428bb508e4294fd165a.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8221",
      "difficulty": "easy"
    },
    {
      "text": "A 26-year-old female patient comes with a history of chronic weight loss, loss of appetite, and diarrhea along with pale bulky stools and is diagnosed with malabsorption syndrome. Steatorrhea is defined in this patient by stool fat exceeding:",
      "choices": [
        {
          "id": 1,
          "text": "7 g per day"
        },
        {
          "id": 2,
          "text": "14 g per day"
        },
        {
          "id": 3,
          "text": "28 g per day"
        },
        {
          "id": 4,
          "text": "32 g per day"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Steatorrhea is a symptom&nbsp;defined by stool fat exceeding <strong>7 g per day.</strong></p>\n<p>Steatorrhea is the passage of <strong>greasy, foul-smelling, difficult-to-flush</strong> stools.&nbsp;It is often associated with weight loss &amp; nutritional deficiencies due to concomitant malabsorption of amino acids &amp; fat-soluble vitamins. It is one of the clinical features of <strong>fat malabsorption</strong> and is noted in many conditions causing intraluminal maldigestion, mucosal malabsorption, or lymphatic obstruction.</p>\n<p>Causes of steatorrhea:</p>\n<ul>\n<li class=\"half_rhythm\">\n<div>Exocrine <strong>pancreatic insufficiency</strong>: Chronic pancreatitis, cystic fibrosis (CF), pancreatic tumors</div>\n</li>\n<li class=\"half_rhythm\">\n<div><strong>Bile acid deficiency</strong>: Primary biliary cholangitis&nbsp;(PBC), primary sclerosing cholangitis (PSC), ileal resection, Crohn disease, small&nbsp;intestinal bacterial overgrowth (SIBO)</div>\n</li>\n<li class=\"half_rhythm\">\n<div><strong>Enteropathy </strong>or<strong>&nbsp;</strong>Malabsorption syndrome: Celiac disease (most common), tropical sprue, giardiasis, Whipple disease, amyloidosis, SIBO, abetalipoproteinemia</div>\n</li>\n</ul>\n<p>Screening of steatorrhea is by the detection of fat&nbsp;by <strong>Sudan III staining. </strong>Stool fat can be quantified&nbsp;by calculating the coefficient of fat absorption <strong>(CFA), </strong>which is an essential step in the diagnosis.</p><hr><h3>Related Pearl: Investigations in  Malabsorption Syndrome</h3><p>The following are the general tests for malabsorption:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Disorder</strong></td>\n<td><strong>Investigation</strong></td>\n</tr>\n<tr>\n<td>Fat malabsorption</td>\n<td>\n<p>Quantitative: 24h fecal fat &gt;7g</p>\n<p>Qualitative: Sudan III staining</p>\n<p>C<sup>14</sup> Triolein breath test</p>\n<p>Fecal steatocrit</p>\n</td>\n</tr>\n<tr>\n<td>Carbohydrate malabsorption</td>\n<td>\n<p>D-xylose test</p>\n<p>Lactose hydrogen breath test</p>\n</td>\n</tr>\n<tr>\n<td>Protein malabsorption</td>\n<td>C<sup>13</sup> egg-white breath test</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>The following are the specific tests for malabsorption:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Disorder</strong></td>\n<td><strong>Investigation</strong></td>\n</tr>\n<tr>\n<td>Celiac disease</td>\n<td>\n<p>Anti-tissue transglutaminase (anti-tTG)</p>\n<p>Anti-endomysial antibodies</p>\n<p>Mucosal biopsy showing villous atrophy, crypt hyperplasia, lamina propria infiltrates, and normal mucosal thickness.</p>\n</td>\n</tr>\n<tr>\n<td>Whipple's disease</td>\n<td>Mucosal biopsy showing PAS +ve macrophages in lamina propria</td>\n</tr>\n<tr>\n<td>Pancreatic insufficiency</td>\n<td>\n<p>Fecal elastase</p>\n<p>Fecal chymotrypsin</p>\n</td>\n</tr>\n<tr>\n<td>Small intestinal bacterial overgrowth (SIBO)</td>\n<td>\n<p>Due to Enterobacter or Pseudomonas - jejunal aspirate&nbsp;&gt;10<sup>3</sup>&nbsp;CFU</p>\n<p>Due to other organisms - jejunal aspirate&nbsp;&gt;10<sup>5</sup> CFU</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2862",
      "difficulty": "medium"
    },
    {
      "text": "A 5-year-old female child with polyneuropathy, sensorineural deafness, and cerebellar ataxia has the following finding on fundus examination. Lab reveals increased blood levels of phytanic acid. Which of the following is the most likely diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Refsum's disease"
        },
        {
          "id": 2,
          "text": "Usher syndrome"
        },
        {
          "id": 3,
          "text": "Zellweger syndrome"
        },
        {
          "id": 4,
          "text": "Adrenoleukodystrophy"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The image shows fundoscopy findings of <strong>retinitis pigmentosa</strong>. This along with the given clinical scenario is suggestive of <strong>Refsum’s disease. </strong></p>\n<p>Refsum's disease is a rare autosomal recessive disorder that results from the <strong>defect</strong> in <strong>alpha oxidation</strong> of fatty acids such as phytanic acid in the <strong>peroxisome</strong> leading to <strong>elevated levels</strong> of<strong> phytanic acid</strong> in the blood. </p>\n<p>In this condition, the enzyme <strong>phytanoyl CoA hydroxylase</strong> is defective and causes the accumulation of phytanic acid. Clinically, patients present with dysmorphic facies and <strong>severe neurological symptoms </strong>such as polyneuropathy, retinitis pigmentosa, nerve deafness, ichthyosis, and cerebellar ataxia. Regression of symptoms is observed with <strong>restricted dietary intake</strong> of phytanic acid. Therefore, management includes avoiding sources of phytanic acid such as dairy products, meat, nuts, and green leafy vegetables.</p>\n<p>Note: The <strong>Zellweger spectrum</strong> is a continuum of diseases of persoxisome defects with Zellweger syndrome (most severe) at one end, neonatal adrenoleukodystrophy in the middle (intermediate severity) and infantile Refsum's disease (least severe) at the other end.</p>\n<p>Option B- <strong>Usher syndrome</strong> is characterized by <strong>sensorineural deafness </strong>and<strong> retinitis pigmentosa</strong> (but symptoms are not affected by restricting phytanic acid)</p>\n<p>Option C- <strong>Zellweger Syndrome</strong> is also known as <strong>cerebrohepatorenal syndrome.</strong> It is caused by mutations in the PEX/Peroxin<strong> </strong>family of genes involved in peroxisome biogenesis /peroxisomal enzymes. There is severe neurologic symptoms and patients usually die in the 1st year of life.</p>\n<p>Option D- <strong>Adrenoleukodystrophy</strong> is a <strong>disorder</strong> of <strong>β-oxidation</strong> of fatty acids. There is a very large chain fatty acids buildup in the <strong>adrenal glands</strong>, the <strong>white matter</strong> of the brain, and <strong>testes</strong>.</p><hr><h3>Related Pearl: Types, Location and Properties of Fatty acid oxidation</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Types of Oxidation</strong></p>\n</td>\n<td>\n<p><strong>Location</strong></p>\n</td>\n<td>\n<p><strong>Properties</strong></p>\n</td>\n<td>\n<p><strong>Associated Disease</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Beta oxidation</p>\n</td>\n<td>\n<p>Mitochondria</p>\n</td>\n<td>\n<p>A catabolic process by which two-carbons are cleaved from the fatty acid molecule and released as acetyl CoA starting from the carboxyl end.</p>\n<p>The chain is broken between the &alpha;(2) and&nbsp;&beta;(3) carbon.</p>\n<p>1 round of beta-oxidation yield 1FADH2, 1NADH, and 1 Acetyl CoA.</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Alpha oxidation</p>\n</td>\n<td>\n<p>Peroxisome</p>\n</td>\n<td>\n<p>The presence of the 3-methyl group of phytanic acid prevents degradation by beta-oxidation.</p>\n<p>The chain is broken between the terminal carboxyl group and &alpha;(2) carbon removing that carbon as CO2. The remaining chain is activated with CoA and then undergoes&nbsp;&beta;-Oxidation.</p>\n<p>It is not an energy-yielding process.</p>\n</td>\n<td>\n<p>Classic Refsum's Disease</p>\n<p>Defective enzyme- Phytanoyl Coa hydroxylase.</p>\n<p>Clinical features include:</p>\n<p>Ichthyosis, Retinitis pigmentosa, Decreased vision, Peripheral neuropathy, Ataxia</p>\n<p class=\"p2\">&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Omega oxidation</p>\n</td>\n<td>\n<p>Endoplasmic Reticulum</p>\n</td>\n<td>\n<p>An alternative pathway to beta-oxidation occurs in microsomes.</p>\n<p>Involves the&nbsp;oxidation&nbsp;of the &omega; carbon (terminal methyl group) resulting in dicarboxylic acid.</p>\n<p>It is not an energy-yielding process.</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Peroxisomal Beta oxidation</p>\n</td>\n<td>\n<p>Peroxisome</p>\n</td>\n<td>\n<p>Very-long-chain fatty acids undergo preliminary &beta;-oxidation in peroxisomes up to&nbsp;octanoyl CoA.&nbsp;The shortened fatty acids undergo further &beta;-oxidation in the mitochondria.</p>\n<p>It is not an energy-yielding process.</p>\n</td>\n<td>\n<p>Zellweger (cerebrohepatorenal) syndrome</p>\n<p>A rare inherited absence of peroxisomes in all tissues.</p>\n<p class=\"p2\">They accumulate C<span class=\"s1\">26</span>&mdash;C<span class=\"s1\">38 </span>polyenoic acids in brain tissue and also exhibit a generalized loss of peroxisomal functions. The disease causes severe neurologic symptoms, and most patients die in the first year of life.</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/7da552f5916f4124a97bb1856ae86a20.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF1175",
      "difficulty": "easy"
    },
    {
      "text": "An undernourished child is brought for consultation. You prescribe a mineral supplement that is absorbed by the mechanism shown in the image below. Identify the supplement.",
      "choices": [
        {
          "id": 1,
          "text": "Copper"
        },
        {
          "id": 2,
          "text": "Iron"
        },
        {
          "id": 3,
          "text": "Calcium"
        },
        {
          "id": 4,
          "text": "Zinc"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given image shows <strong>iron absorption and transport</strong> from a duodenal enterocyte into the blood, hence the mineral supplement prescribed can be identified as an <strong>iron</strong> supplement.</p>\n<p>The following image shows in detail, the absorption of iron from a duodenal enterocyte.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/434650ea843645ec80e4a24389d0209dx1280x1210.JPEG\" alt=\"Explanation Image\"><p>Dietary iron is available in two forms - heme and non-heme iron. Initially, the ferric <strong>non-heme iron</strong> is <strong>reduced</strong> to ferrous iron by <strong>duodenal cytochrome B (ferric reductase)</strong>&nbsp;or by <strong>vitamin C</strong>.<strong>&nbsp;</strong>The reduced ferrous iron is then transferred into the enterocyte by <strong>DMT 1 (divalent metal transporter)</strong>.&nbsp;</p>\n<p>Heme iron moves into the cytoplasm with the help of transporters. Here, it is metabolized to release ferrous iron, which then follows the same pathway as non-heme iron.</p>\n<p>Once inside the enterocyte, it can <strong>either</strong> get <strong>stored as ferritin</strong> or <strong>transferred</strong> across the basolateral membrane<strong> by ferroportin.</strong>&nbsp;In the <strong>plasma</strong>, iron is transported in the <strong>Fe<sup>3+</sup> form bound to transferrin</strong>, which is a transport protein. Hephaestin is a ferroxidase that oxidizes Fe<sup>2+</sup> to Fe<sup>3+</sup> before it is transported.</p>\n<p><strong>Hepcidin</strong>, a protein secreted from the liver plays a major role in the regulation of iron absorption. When the body&rsquo;s iron stores are adequate it downregulates the expression of <strong>ferroportin</strong> and thereby iron absorption too. Thus,<strong> iron is trapped</strong> in the intestinal cells which is eventually sloughed off. Hepcidin also <strong>inhibits</strong> the release of <strong>iron from macrophages</strong> by binding to ferroportin.&nbsp;High hepcidin levels are seen in systemic inflammation and low hepcidin levels are seen in hemochromatosis.</p>\n<p><strong>Iron</strong> is an important <strong>component</strong> of</p>\n<ul>\n<li>Hemoglobin</li>\n<li>Myoglobin</li>\n<li>Cytochrome P450 groups of enzymes</li>\n<li>Components of the electron transport chain</li>\n<li>Ribonucleotide reductase</li>\n</ul><hr><h3>Related Pearl: Factors affecting iron absorption</h3><p><strong>Enhancers:</strong></p>\n<ul>\n<li>Ascorbic acid</li>\n<li>Citric acid</li>\n<li>Amino acid</li>\n<li>Sugars in the diet</li>\n</ul>\n<p><strong>Inhibitors:</strong></p>\n<ul>\n<li>Tannins</li>\n<li>Carbonate</li>\n<li>Oxalate</li>\n<li>Phosphate</li>\n</ul>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/45ea55be372e490c8d03a381df054d76.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0514",
      "difficulty": "easy"
    },
    {
      "text": "Which among the following enzymes does not contribute in the reversible phase of the pentose phosphate pathway?",
      "choices": [
        {
          "id": 1,
          "text": "Transketolase"
        },
        {
          "id": 2,
          "text": "Keto-isomerase"
        },
        {
          "id": 3,
          "text": "Phosphohexose isomerase"
        },
        {
          "id": 4,
          "text": "6-phosphogluconate dehydrogenase"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>6-phosphogluconate dehydrogenase</strong> is involved in the <strong>irreversible oxidative phase</strong> of the pentose phosphate pathway. <strong>Transketolase</strong>,<strong>&nbsp;keto-isomerase</strong>, and<strong> phosphohexose isomerase</strong> are involved in the <strong>reversible non-oxidative phase</strong>.</p>\n<p>The pentose phosphate pathway, also known as the HMP shunt pathway, is an alternative route for the <strong>metabolism of glucose</strong>.&nbsp;It contributes by two major ways:</p>\n<ul>\n<li><strong>Formation of NADPH&nbsp;</strong>for the synthesis of fatty acids and steroids and maintenance of reduced glutathione for antioxidant activity</li>\n<li><strong>Formation of ribose&nbsp;</strong>for the synthesis of nucleic acid and nucleotides</li>\n</ul>\n<p>The enzymes for this pathway are found in the cytosol. There are two phases:</p>\n<ol>\n<li><strong>Irreversible oxidative phase</strong>: Glucose-6-phosphate is dehydrogenated and decarboxylated to form ribulose-5- phosphate.</li>\n<li><strong>Reversible nonoxidative phase</strong>: Ribulose-5-phosphate is converted back to glucose-6-phosphate.</li>\n</ol><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/85f8c4aa0d0349c3b79968f54752d21fx1280x2237.JPEG\" alt=\"Explanation Image\"><p>Clinical significance:</p>\n<ul>\n<li><strong>Protection against hemolysis</strong>: <strong>NADPH</strong>&nbsp;is utilized for the reduction of oxidized glutathione. Reduced glutathione removes H<sub>2</sub>O<sub>2</sub>, thereby preventing oxidative damage to RBCs and hemolysis. Thus, deficiency of glucose-6-phosphate dehydrogenase results in <strong>hemolytic anemia</strong>.</li>\n<li><strong>Formation of glucoronate</strong>: Glucose-6-phosphate gives rise to <strong>glucoronate</strong>&nbsp;via the uronic acid pathway. Glucoronate is important as a precursor for proteoglycans and as a conjugate for substances like steroid hormones and drugs for their excretion in bile or urine. A deficiency in the uronic acid pathway results in <strong>essential pentosuria</strong>.</li>\n<li><strong>Fructose and galactose metabolism</strong>:&nbsp;Fructose bypasses the regulatory step in the HMP pathway and undergoes rapid glycolysis in the liver. This results in increased fatty acid synthesis and VLDL secretion. Galactose formed from glucose is an essential constituent of lactose, glycolipids, proteoglycans, and glycoproteins.&nbsp;Deficiencies of enzymes in these reactions lead to metabolic diseases like <strong>essential fructosuria</strong>, <strong>hereditary fructose intolerance</strong>, and <strong>galactosemia</strong>.</li>\n<li><strong>Formation of amino sugars</strong>: Amino sugars are formed from glucose and are important components of glycoproteins, glycosphingolipids, and glycosaminoglycans.</li>\n</ul><hr><h3>Related Pearl: Phases of HMP Shunt and the Enzymes Involved</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Phases</strong></p>\n</td>\n<td>\n<p><strong>Enzymes</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Irreversible oxidative phase</p>\n<p>&nbsp;</p>\n</td>\n<td>\n<p>Glucose-6-phosphate dehydrogenase</p>\n<p>6-Phosphogluconate dehydrogenase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Reversible non-oxidative phase</p>\n<p>&nbsp;</p>\n</td>\n<td>\n<p>3-Epimerase or Keto-isomerase</p>\n<p>Transketolase</p>\n<p>Transaldolase</p>\n<p>Phosphohexose isomerase</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Rate determining enzymes and their key regulators</h3><table>\n<tbody>\n<tr>\n<td>Pathway</td>\n<td>Enzyme&nbsp;</td>\n<td>Regulating factors</td>\n</tr>\n<tr>\n<td>Glycolysis</td>\n<td>Phosphofructokinase (PFK-1)</td>\n<td>\n<p>AMP+, Fructose 2,6 bi-phosphate+</p>\n<p>ATP-, Citrate-</p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;gluconeogenesis</td>\n<td>Fructose-1,6-bisphosphatase</td>\n<td>\n<p>ATP+, Acetyl CoA+</p>\n<p>AMP-, Fructose 2,6 bi-phosphate-</p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;Krebs cycle</td>\n<td>Isocitrate dehydrogenase</td>\n<td>\n<p>ADP+,</p>\n<p>ATP-, NADH-</p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;glycogenesis</td>\n<td>Glycogen synthase</td>\n<td>\n<p>Glucose-6-phosphate+, insulin+, cortisol+,</p>\n<p>Epinephrine-, glucagon-</p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;glycogenolysis</td>\n<td>Glycogen phosphorylase</td>\n<td>\n<p>Epinephrine+, glucagon+, AMP+</p>\n<p>Glucose-6-phosphate-, insulin-, ATP-</p>\n</td>\n</tr>\n<tr>\n<td>HMP shunt&nbsp;</td>\n<td>Glucose-6-phosphate dehydrogenase (G6PD)</td>\n<td>\n<p>NADP+</p>\n<p>NADPH-</p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;Denovo pyrimidine synthesis</td>\n<td>Carbamoyl phosphate synthetase II</td>\n<td>\n<p>ATP+</p>\n<p>UTP-</p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;Denovo purine synthesis</td>\n<td>Glutamine-phosphoribosylpyrophosphate (PRPP) amidotransferase</td>\n<td>AMP-, IMP-, GMP-</td>\n</tr>\n<tr>\n<td>&nbsp;Urea cycle</td>\n<td>Carbamoyl phosphate synthetase I</td>\n<td>N-acetyl glutamate (NAG)+</td>\n</tr>\n<tr>\n<td>&nbsp;Fatty acid synthesis</td>\n<td>Acetyl-CoA carboxylase (ACC)</td>\n<td>\n<p>Insulin+, citrate+</p>\n<p>Glucagon-, palmitoyl-CoA-</p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;Fatty acid oxidation</td>\n<td>Carnitine acyltransferase I</td>\n<td>Malonyl-CoA-</td>\n</tr>\n<tr>\n<td>&nbsp;Cholesterol synthesis</td>\n<td>HMG-CoA reductase</td>\n<td>\n<p>Insulin+, thyroxine+</p>\n<p>Glucagon-, cholesterol-</p>\n</td>\n</tr>\n<tr>\n<td>Ketogenesis</td>\n<td>HMG-CoA synthase</td>\n<td>&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>+ Positive effect on the pathway.</p>\n<p>- Negative effect on the pathway.</p><hr><h3>Related Pearl: Reducing Equivalents and Their Uses</h3><table>\n<tbody>\n<tr>\n<td>\n<p>Reducing agents</p>\n</td>\n<td>\n<p>Uses</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>NADPH</p>\n</td>\n<td>\n<p>Lipid synthesis</p>\n<p>Cholesterol synthesis&nbsp;</p>\n<p>Fatty acid chain elongation</p>\n<p>Cytochrome P450&nbsp;hydroxylation&nbsp;of&nbsp;aromatic compounds, steroids,&nbsp;alcohols, and&nbsp;drugs</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>NADH</p>\n</td>\n<td>\n<p>Metabolizes alcohol</p>\n<p>Glycolysis &amp; Krebs cycle</p>\n<p>Oxidative phosphorylation</p>\n<p>&beta;- Oxidation of fatty acid</p>\n<p>Catalyzes reactions in muscle and liver cells</p>\n<p>Electron Transport Chain</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>FADH<sub>2</sub></p>\n</td>\n<td>\n<p>Krebs cycle</p>\n<p>Electron Transport Chain</p>\n<p>Oxidative Phosphorylation</p>\n<p>Cytochrome P450 hydroxylase cycle</p>\n<p>&beta;-Oxidation of fatty acid</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD3832",
      "difficulty": "medium"
    },
    {
      "text": "While conducting a health camp, you host an awareness campaign on healthy dietary practices. Which of the following substances would you say has the highest respiratory quotient immediately after consumption?",
      "choices": [
        {
          "id": 1,
          "text": "Mixed diet"
        },
        {
          "id": 2,
          "text": "Ghee"
        },
        {
          "id": 3,
          "text": "Wine"
        },
        {
          "id": 4,
          "text": "Meat"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The food item with the <strong>highest respiratory quotient (RQ)</strong> immediately after consumption&nbsp;is a&nbsp;<strong>mixed diet.&nbsp;</strong></p>\n<div class=\"page\" title=\"Page 833\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>This is because, <strong>immediately</strong> after a <strong>mixed meal</strong> (containing carbohydrates, protein, and fat), carbohydrates is the most commonly metabolized component, so the<strong> RQ reaches 1</strong>. But, a few hours after, the body would have used up the readily available carbohydrates, and the RQ reaches 0.70, due to fat metabolism.</p>\n</div>\n</div>\n</div>\n</div>\n<p>The respiratory quotient is the&nbsp;<strong>ratio&nbsp;</strong>of<strong>&nbsp;carbon dioxide produced</strong>/<strong>oxygen consumed.&nbsp;</strong>The<strong>&nbsp;respiratory quotient&nbsp;</strong>for various substances:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Substance</strong></td>\n<td><strong>RQ</strong></td>\n</tr>\n<tr>\n<td>Carbohydrate</td>\n<td>1.00&nbsp;</td>\n</tr>\n<tr>\n<td>Protein (option D)</td>\n<td>0.81&nbsp;</td>\n</tr>\n<tr>\n<td>Fat (option B)</td>\n<td>0.71&nbsp;&nbsp;</td>\n</tr>\n<tr>\n<td>Alcohol (option C)</td>\n<td>0.66&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>In diabetes, the rate of utilization of carbohydrates reduces in relation to fats, hence RQ falls (approximately 0.7). The RQ is lowest when ketosis is very active.</p>\n<p>Note: For all metabolic fuels, the <strong>energy</strong> produced is the same (<strong>20 kJ/L of oxygen</strong>).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7217",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following tools of recombinant DNA technology is correctly paired with its use?<div class='question-desc-html'><table>\n<tbody>\n<tr>\n<td><strong>Enzyme</strong></td>\n<td><strong>Function</strong></td>\n</tr>\n<tr>\n<td>\n<p>1. DNA ligase</p>\n</td>\n<td>a. Labels DNA or RNA with <sup>32</sup>P</td>\n</tr>\n<tr>\n<td>\n<p>2. Polynucleotide kinase</p>\n</td>\n<td>b. Production of cDNA from mRNA</td>\n</tr>\n<tr>\n<td>3. Reverse transcriptase</td>\n<td>c. Homopolymer tailing</td>\n</tr>\n<tr>\n<td>4. Terminal transferase</td>\n<td>d. Joining of DNA molecules</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "1-d, 2-b, 3-a, 4-c"
        },
        {
          "id": 2,
          "text": "1-d, 2-a, 3-b, 4-c"
        },
        {
          "id": 3,
          "text": "1-b, 2-a, 3-d, 4-c"
        },
        {
          "id": 4,
          "text": "1-c, 2-b, 3-a, 4-d"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The correctly matched option is <strong>option B: 1-d, 2-a, 3-b, 4-c.</strong></p>\n<p><strong>DNA ligase</strong> catalyzes the formation of bonds between DNA molecules and helps in the joining of these DNA molecules.</p>\n<p><strong>Reverse transcriptase</strong> is an&nbsp;<span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\"><strong>RNA-dependant-DNA polymerase&nbsp;</strong></span><span class=\" author-d-1gg9uz65z1iz85zgdz68zmqkz84zo2qoxwyy7z90zx1z73zz86z8z72z3z70zvjbz81zz122znz90zz74z1z78zz67zz66zz122zz83zjz73ziz69z\">that synthesizes DNA from RNA. It is usually found in some viruses such as&nbsp;<strong>retroviruses.&nbsp;</strong>It is used in the synthesis of cDNA from mRNA and in studies for mapping RNA.</span></p>\n<p><strong> Polynucleotide kinase </strong>transfers the terminal phosphorous from ATP to 3' OH groups of DNA or RNA.</p>\n<p><strong>Terminal transferase</strong>&nbsp;catalyzes&nbsp;the addition of&nbsp;nucleotides&nbsp;to the&nbsp;3' terminus&nbsp;of a DNA molecule. It is used in homopolymer tailing.&nbsp;</p>\n<p>&nbsp;</p><hr><h3>Related Pearl: Some Enzymes Used in Recombinant DNA Research</h3><table>\n<tbody>\n<tr>\n<td>\n<p>Enzymes</p>\n</td>\n<td>\n<p>Use</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Phosphatases</p>\n</td>\n<td>\n<p>Removal of 5&prime;-PO4 groups prior to kinase labeling; also used to prevent self-ligation</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>DNA ligase</p>\n</td>\n<td>\n<p>Joining of DNA molecules</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>DNA polymerase I</p>\n</td>\n<td>\n<p>Synthesis of double-stranded cDNA; nick translation; generation of blunt ends from sticky ends</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Thermostable DNA polymerases</p>\n</td>\n<td>\n<p>Polymerase chain reaction (DNA synthesis)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>DNAse I</p>\n</td>\n<td>\n<p>Nick translation; mapping of hypersensitive sites; mapping protein-DNA interactions</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Exonuclease III</p>\n</td>\n<td>\n<p>DNA sequencing; ChIP-exo, mapping of DNA-protein interactions</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>&lambda; Exonuclease</p>\n</td>\n<td>\n<p>DNA sequencing</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Polynucleotide kinase</p>\n</td>\n<td>\n<p>32P end-labeling of DNA or RNA</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Reverse transcriptase</p>\n</td>\n<td>\n<p>Synthesis of cDNA from mRNA; RNA (5&prime; end) mapping studies</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>RNAse H</p>\n</td>\n<td>\n<p>Synthesis of cDNA from mRNA</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>S1 nuclease</p>\n</td>\n<td>\n<p>Removal of &ldquo;hairpin&rdquo; in synthesis of cDNA; RNA mapping studies (both 5&prime; and 3&prime; ends)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Terminal transferase</p>\n</td>\n<td>\n<p>Homopolymer tailing</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Recombinases (CRE, INT, FLP)</p>\n</td>\n<td>\n<p>Generation of specific chimeric DNA molecules, work both in vitro and in vivo</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Enzymes Involved in DNA Replication</h3><p>Prokaryotic DNA replication enzymes and their function:</p>\n<table>\n<tbody>\n<tr>\n<td>Enzyme</td>\n<td>Function</td>\n</tr>\n<tr>\n<td>DNA Polymerase I (Pol I)</td>\n<td>Gap filling following DNA replication, repair, and recombination</td>\n</tr>\n<tr>\n<td>DNA polymerase II (Pol II)</td>\n<td>DNA proofreading and repair</td>\n</tr>\n<tr>\n<td>DNA polymerase III (Pol III)</td>\n<td>\n<p>Processive, leading strand synthesis, DNA proofreading</p>\n</td>\n</tr>\n<tr>\n<td>DnaG</td>\n<td>\n<p>Primase&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>Helicase</td>\n<td>ATP-driven processive unwinding of DNA.</td>\n</tr>\n<tr>\n<td>Primase</td>\n<td>Initiates synthesis of RNA primers.</td>\n</tr>\n<tr>\n<td>Topoisomerase</td>\n<td>Relieve torsional strain that results from helicase-induced unwinding.</td>\n</tr>\n<tr>\n<td>Single-strand binding proteins (SSBs)</td>\n<td>Prevents premature reannealing of dsDNA.</td>\n</tr>\n<tr>\n<td>DNA ligase</td>\n<td>Seals the single strand nick between the nascent chain and Okazaki fragments on lagging strand.</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<p>Eukaryotic DNA polymerases:</p>\n<table>\n<tbody>\n<tr>\n<td>Eukaryotic DNA Polymerases</td>\n<td>Functions</td>\n<td>Proofreading</td>\n</tr>\n<tr>\n<td>&alpha;&nbsp;</td>\n<td>Primase (initiates DNA synthesis)</td>\n<td>-</td>\n</tr>\n<tr>\n<td><em>&beta;</em></td>\n<td>DNA repair</td>\n<td>-</td>\n</tr>\n<tr>\n<td>\n<p>&gamma;</p>\n</td>\n<td>Mitochondrial DNA synthesis</td>\n<td>+</td>\n</tr>\n<tr>\n<td>&nbsp;&delta;&nbsp;</td>\n<td>Processive, lagging strand synthesis(forms and elongates Okazaki fragments from primer)</td>\n<td>+</td>\n</tr>\n<tr>\n<td>&nbsp;<em>&epsilon;&nbsp;</em></td>\n<td>Processive, leading strand synthesis</td>\n<td>+</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD7074",
      "difficulty": "easy"
    },
    {
      "text": "A young man with chronic bacterial prostatitis was treated with cotrimoxazole. During treatment, he developed malaise, jaundice, abdominal pain, and dark urine. His blood picture is given below. What is the most likely diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Hemolytic uremic syndrome"
        },
        {
          "id": 2,
          "text": "Autoimmune hemolytic anemia"
        },
        {
          "id": 3,
          "text": "Paroxysmal nocturnal hemoglobinuria"
        },
        {
          "id": 4,
          "text": "Glucose 6 phosphate dehydrogenase deficiency"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The most likely diagnosis in the above case scenario is glucose-6-phosphate dehydrogenase <strong>(G6PD) deficiency.</strong></p>\n<p>The clinical features are suggestive of an <strong>acute hemolytic reaction</strong> following the administration of <strong>cotrimoxazole</strong>. A hemolytic attack starts with abrupt onset of malaise, weakness, and abdominal or lumbar pain. After an interval of several hours to 2–3 days, the patient develops jaundice and often dark urine, due to hemoglobinuria. </p>\n<p>The peripheral smear shows characteristic <strong>\"bite cells\"</strong> or <strong>degmacytes</strong> or <strong>blister cells</strong>. In G6PD deficiency uncontrolled oxidative stress causes hemoglobin to denature and form Heinz bodies. Bite cells result from the <strong>removal of Heinz bodies</strong> by macrophages in the spleen.</p>\n<p>Cotrimoxazole contains <strong>sulfamethoxazole</strong> which triggers a <strong>hemolytic reaction</strong> in persons with <strong>G6PD deficiency</strong>.</p>\n<p>Drugs that carry a risk of clinical hemolysis in persons with G6PD Deficiency:</p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><span><strong>Drugs</strong></span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span>Antimalarials</span></p>\n</td>\n<td>\n<ul>\n<li><span>Primaquine</span></li>\n<li><span><strong>Chloroquine</strong></span></li>\n<li><span>Dapsone/chlorproguanil</span></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p><span>Sulphonamides/</span></p>\n<p><span>sulphones</span></p>\n</td>\n<td>\n<ul>\n<li><span><strong>Sulfamethoxazole</strong></span></li>\n<li><span>Sulfasalazine</span></li>\n<li><span>Sulfisoxazole</span></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p><span>Antibacterial/</span></p>\n<p><span>antibiotics</span></p>\n</td>\n<td>\n<ul>\n<li><span><strong>Cotrimoxazole</strong></span></li>\n<li><span>Ciprofloxacin</span></li>\n<li><span>Chloramphenicol</span></li>\n<li><span>Nalidixic acid</span></li>\n<li><span>Norfloxacin</span></li>\n<li><span><strong>Nitrofurantoin</strong></span></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p><span>Others</span></p>\n</td>\n<td>\n<ul>\n<li><span>Naphthalene</span></li>\n<li><span><strong>Methylene blue</strong></span></li>\n<li><span>Rasburicase </span></li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/349620e0e0954b4f9f57bb5b46e9dcf6.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD1277",
      "difficulty": "easy"
    },
    {
      "text": "Restriction fragment length polymorphism (RFLP) is used in order to identify the five different species of staphylococci in a surgical ICU. Which of the following site does the restriction enzyme act on?",
      "choices": [
        {
          "id": 1,
          "text": "5'-ATGGAC-3'"
        },
        {
          "id": 2,
          "text": "5'-GATATC-3'"
        },
        {
          "id": 3,
          "text": "5'-TAGATA-3'"
        },
        {
          "id": 4,
          "text": "5'-AATATA-3'"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The<strong> restriction enzyme</strong> is likely to <strong>act</strong> on <strong>5'-GATATC-3' </strong>(Option B).</p>\n<p><strong>Restriction endonuclease(RE)</strong> enzymes usually act at specific <strong>palindromic sequences</strong> which create DNA fragments of different lengths. A palindromic sequence is one that reads the same in opposite directions. By analyzing the fragments produced after cutting the DNA by RE, specific species of bacteria can be identified. Option B, when expanded after writing the complementary sequence, appears the same while reading both DNA strands in the 5' to 3' direction and is hence a palindrome.</p>\n<p>5' --GATATC-- 3'<br />3' --CTATAG-- 5'&nbsp;</p>\n<p>Restriction <strong>endonucleases</strong>&nbsp;are enzymes that&nbsp;<strong>recognize and cleave a specific double-stranded DNA sequence</strong>. These DNA cuts result in&nbsp;<strong>sticky ends</strong> or <strong>blunt ends.</strong>&nbsp;Sticky ends are then used to build hybrid DNA.&nbsp;</p>\n<p>A <strong>Restriction fragment length poly&shy;morphism (RFLP)</strong> is a genetic variant that can be studied by cleaving the DNA into fragments known as restriction fragments. This is done <strong>using a restriction enzyme</strong>. The length of the restriction fragments changes if the genetic variant alters the DNA and creates or abolishes the site of restriction endonuclease cleavage. RFLPs can thus be used to find the variation in different staphylococci species.</p>\n<p>The sequences given in<strong> Options A, C and D are not palindromes,</strong> as they do not read the same forwards and backwards after expanding. So they <strong>cannot be recognized by Restriction endonuclease</strong> enzymes.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9469",
      "difficulty": "easy"
    },
    {
      "text": "A man presented with slurred speech and festinating shuffling gait. He tells that a course of levodopa was advised by his previous doctor but didn't show any effect. Which of the following mineral toxicity/ deficiency causes such features?",
      "choices": [
        {
          "id": 1,
          "text": "Selenium"
        },
        {
          "id": 2,
          "text": "Zinc"
        },
        {
          "id": 3,
          "text": "Manganese"
        },
        {
          "id": 4,
          "text": "Magnesium"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Manganese</strong> toxicity can cause <strong>secondary parkinsonism </strong>with features similar to atypical parkinsonism.</p>\n<div class=\"page\" title=\"Page 3430\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Secondary parkinsonism</strong> is characterized by Parkinson-like disease caused by agents/factors that cause <strong>basal ganglia dysfunction</strong>. These factors include drugs (tetrabenazine, metoclopramide, neuroleptics, flunarizine), stroke, tumor, infection, or toxins. Clinical features will be based on the region of the basal ganglia that has been damaged.</p>\n<p>Toxins such as carbon monoxide or manganese produce<strong> damage to the globus pallidus</strong>, and hence present with features resembling<strong> atypical parkinsonism </strong>such as:</p>\n</div>\n</div>\n</div>\n<ul>\n<li>Early speech and gait impairment</li>\n<li>Repeated early falls</li>\n<li><strong>Absence of rest tremor</strong></li>\n<li><strong>No motor asymmetry</strong></li>\n<li><strong>Poor or no response to levodopa</strong></li>\n<li>Aggressive clinical course</li>\n<li>Symptoms of severe early autonomic involvement</li>\n</ul>\n<div class=\"page\" title=\"Page 3430\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Manganese</strong> deficiency on the other hand can result in poor growth, bone demineralization, ataxia, convulsions, and abnormalities in carbohydrate and lipid metabolism.</p>\n<p>Other options</p>\n</div>\n</div>\n</div>\n<p>Option A:<strong> Selenium deficiency</strong> causes <strong>Keshan disease</strong> (cardiomyopathy in endemic regions of China); Excess selenium intake leads to <strong>selenosis </strong>(with hair loss, brittle nails, garlic breath odor, myopathy, and neurologic symptoms).</p>\n<p>Option B: <strong>Zinc toxicity</strong> leads to nausea, vomiting, headache, fever, and hypersalivation. <strong>Zinc deficiency</strong> causes dwarfism, hypogonadism, hypopigmented hair, hypogeusia, and impaired immunity.</p>\n<p>Option D: <strong>Hypomagnesemia</strong> is characterized by neurologic symptoms like tremors, muscle weakness, ataxia, delirium, and psychosis. <strong>Hypermagnesemia</strong> causes lethargy, weakness, hypotonia, weak tendon reflexes, and coma.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD3215",
      "difficulty": "medium"
    },
    {
      "text": "A middle-aged man with a history of chronic alcohol comsuption presented to the casualty with confusion, ataxia and diplopia. What is the protocol to treat this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Thiamine injection followed by glucose infusion"
        },
        {
          "id": 2,
          "text": "Glucose infusion followed thiamine injection"
        },
        {
          "id": 3,
          "text": "Glucose infusion alone"
        },
        {
          "id": 4,
          "text": "Thiamine injection alone"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Diplopia, ataxia and confusion in a patient with chronic alcohol consumption  is suggestive of <strong>Wernicke's encephalopathy. </strong>The current standard of treatment for patients with symptoms of Wernicke's encephalopathy is to give<strong> thiamine 100 mg intravenously before</strong> administering<strong> glucose-containing</strong> IV<strong> fluids.</strong></p>\n<p>Thiamine deficiency leads to the following:</p>\n<ol>\n<li><strong>Wernicke’s encephalopathy: </strong>It is more commonly seen in alcoholics with chronic thiamine deficiency. It is characterized by global confusion, truncal ataxia, ophthalmoplegia and horizontal nystagmus.</li>\n<li><strong>Korsakoff psychosis:</strong> Symptoms in addition to those of Wernicke's encephalopathy include memory loss and <strong>confabulation</strong></li>\n<li><strong>Beriberi: </strong>It can be either -\n<ul>\n<li><strong>Dry</strong> beriberi: Sensorimotor peripheral neuropathy, muscle weakness</li>\n<li><strong>Wet</strong> beriberi: Tachycardia, cardiomegaly, high-output cardiac failure</li>\n</ul>\n</li>\n</ol><hr><h3>Related Pearl: Vitamin Deficiency States (Water-soluble Vitamins)</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Vitamin</strong></p>\n</td>\n<td>\n<p><strong>Deficiency State</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Thiamine (<strong>B<sub>1</sub></strong>)</p>\n</td>\n<td>\n<p><strong>Beriberi</strong></p>\n<p>Wernicke&ndash;Korsakoff&rsquo;s syndrome</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Riboflavin (<strong>B<span>2</span></strong>)</p>\n</td>\n<td>\n<p>Cheilosis, Magenta-coloured tongue,&nbsp;</p>\n<p>Glossitis, Seborrheic dermatitis</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Niacin (<strong>B<span>3</span></strong>)</p>\n</td>\n<td>\n<p><strong>Pellagra</strong></p>\n<p>Dermatitis, Diarrhea, Dementia</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Pantothenic acid (<strong>B<span>5</span></strong>)</p>\n</td>\n<td>\n<p><strong>Burning foot syndrome</strong> (historically called as \"Nutritional melalgia\")</p>\n<div class=\"page\" title=\"Page 90\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Dermatitis, enteritis, alopecia, ataxia</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<p>Pyridoxine (<strong>B<span>6</span></strong>)</p>\n</td>\n<td>\n<p>Microcytic anemia, convulsions, depression</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Biotin (<strong>B<span>7</span></strong>)</p>\n</td>\n<td>\n<p>Relatively unknown</p>\n<p>Dermatitis, atrophic glossitis, alopecia, paraesthesia, muscle pain, anorexia, hallucinations</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Folic acid (<strong>B<span>9</span></strong>)</p>\n</td>\n<td>\n<p>Megaloblastic anemia, neuropathy, neural tube defects, atrophic glossitis</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Cobalamin (<strong>B<span>12</span></strong>)</p>\n</td>\n<td>\n<p>Pernicious anemia, dementia, spinal cord degeneration, homocysteinemia</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Ascorbic acid (<strong>C</strong>)</p>\n</td>\n<td>\n<p><strong>Scurvy</strong></p>\n<p>Ecchymosis, bleeding gums, poor wound healing, fatigue, joint effusion, Scorbutic rosary</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB3257",
      "difficulty": "medium"
    },
    {
      "text": "A young woman presents with a 2-week history of progressive severe headache and blurry vision. Examination showed bilateral papilledema. A lumbar puncture revealed elevated opening pressure with normal CSF composition and no space-occupying lesions were seen on MRI. She has recently started taking high-dose vitamin supplements.  Which vitamin excess is likely to cause the above scenario?",
      "choices": [
        {
          "id": 1,
          "text": "Vitamin A"
        },
        {
          "id": 2,
          "text": "Vitamin D"
        },
        {
          "id": 3,
          "text": "Vitamin E"
        },
        {
          "id": 4,
          "text": "Vitamin K"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The clinical scenario of increased intracranial pressure in the absence of space-occupying lesion points towards the diagnosis of <strong>pseudotumor cerebri</strong>. <strong>Vitamin A excess</strong> is the likely cause.</p>\n<p><strong>Clinical features</strong> of hypervitaminosis A:</p>\n<ul>\n<li><strong>CNS:</strong> Symptoms of raised intracranial pressure (<strong>pseudotumor cerebri</strong>) such as headache, nausea, vomiting, blurring of vision, ataxia, anorexia</li>\n<li><strong>Liver</strong>: Hepatomegaly and hyperlipidemia</li>\n<li><strong>Musculoskeletal</strong>: Thickening of the long bones (<strong>bony exostosis</strong>), hypercalcemia, soft tissue calcification</li>\n<li><strong>Dermatological</strong>: Dryness, <strong>exfoliative dermatitis</strong>, alopecia</li>\n<li><strong>Teratogenesis</strong>: Pregnant women should not ingest excessive quantities as it can cause congenital malformations in the developing fetus. <strong>Isotretinoin</strong>(13-cis retinoic acid) is a drug that is<strong> teratogenic </strong>and absolutely <strong>contraindicated </strong>in<strong> pregnancy.</strong></li>\n</ul><hr><h3>Related Pearl: Fat-soluble vitamins</h3><table>\n<tbody>\n<tr>\n<td rowspan=\"2\"><strong>Vitamin</strong></td>\n<td rowspan=\"2\"><strong>Active form</strong></td>\n<td rowspan=\"2\"><strong>Deficiency</strong></td>\n<td rowspan=\"2\"><strong>Toxicity</strong></td>\n<td colspan=\"3\"><strong>Required dietary allowance</strong></td>\n</tr>\n<tr>\n<td>Children</td>\n<td>Male</td>\n<td>Female</td>\n</tr>\n<tr>\n<td>Vitamin A</td>\n<td>\n<p>Retinol</p>\n<p>Retinal</p>\n<p>Retinoic acid</p>\n</td>\n<td>\n<p>Night blindness, xerophthalmia,</p>\n<p>Acne, psoriasis,</p>\n<p>Impaired immunity</p>\n</td>\n<td>\n<p>Affects lysosomes</p>\n<p>Acute- pseudotumor cerebrii, exfoliative dermatitis</p>\n<p>Chronic-fractures</p>\n</td>\n<td>\n<p>390-630mcg (1-9 years)</p>\n<p>770-1000mcg (10-18 years)</p>\n</td>\n<td>1000mcg&nbsp;</td>\n<td>&nbsp;\n<p>Adult - 840mcg</p>\n<p>Pregnancy - 900mcg</p>\n<p>Lactation - 950 mcg</p>\n</td>\n</tr>\n<tr>\n<td>Vitamin D</td>\n<td>1,25-Dihydro-cholecalciferol</td>\n<td>\n<p>Children- Rickets</p>\n<p>Adults-osteomalacia</p>\n</td>\n<td>Calcinosis</td>\n<td>&nbsp;\n<p>400 IU (&lt;1 year)</p>\n<p>600 IU (&gt;1 year)</p>\n</td>\n<td>&nbsp;600 IU</td>\n<td>\n<p>Adult - 600 IU</p>\n<p>Pregnancy - 600 IU</p>\n<p>Lactation - 600 IU</p>\n</td>\n</tr>\n<tr>\n<td>Vitamin E</td>\n<td>&alpha;-tocopherol</td>\n<td>\n<p>Hemolytic anemia,</p>\n<p>axonal degeneration,</p>\n<p>spinocerebellar ataxia</p>\n</td>\n<td>\n<p>Reduced platelet aggregation,&nbsp;</p>\n<p>Interferes with vitamin K</p>\n</td>\n<td>&nbsp;5-8 mg</td>\n<td>&nbsp;10 mg</td>\n<td>\n<p>Adult - 8 mg</p>\n<p>Pregnancy - 10 mg</p>\n<p>Lactation - 12 mg</p>\n</td>\n</tr>\n<tr>\n<td>Vitamin K</td>\n<td>\n<p>Menedione</p>\n<p>Menoquinone</p>\n<p>Phyloquinone</p>\n</td>\n<td>\n<p>Elevated prothrombin time and bleeding</p>\n<p>Haemorrhagic disease of newborn</p>\n</td>\n<td>\n<p>Hemolysis</p>\n<p>Hyperbilirubinemia</p>\n<p>Kernicterus</p>\n</td>\n<td>\n<p>&lt;1 year - 2-3&nbsp;&micro;g</p>\n<p>Children - 30-50&nbsp;&micro;g</p>\n&nbsp;</td>\n<td>55 &micro;g&nbsp;</td>\n<td>55 &micro;g&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Note:The <strong>RDA</strong> for <strong>Vitamin D</strong> in the <strong>elderly</strong> (&gt;60 years) is <strong>800 IU</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD3523",
      "difficulty": "easy"
    },
    {
      "text": "A 25-year-old patient was brought to the emergency room in a state of altered sensorium, irritability, and aggression. His relatives give a history of a headache earlier that day, for which the patient had taken a paracetamol tablet. On further investigation, he was found to have a deficiency of citrin. What is the most likely diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Type I Citrullinemia"
        },
        {
          "id": 2,
          "text": "Type II Citrullinemia"
        },
        {
          "id": 3,
          "text": "Hartnup disease"
        },
        {
          "id": 4,
          "text": "Type I Hyperammonemia"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The most likely diagnosis for the given clinical scenario is <strong>t</strong><strong>ype II citrullinemia</strong>.</p>\n<p>Type II citrullinemia is an <strong>autosomal recessive</strong> disorder characterized by the deficiency of <strong>c</strong><strong>itrin</strong> due to mutations in the SLC25A13 gene. Citrin is a membrane transport protein in the urea cycle that facilitates the transfer of <strong>aspartate</strong> from mitochondria to the cytoplasm.</p>\n<p>Patients usually present between <strong>20</strong> and <strong>50</strong> years of age, with neuropsychiatric symptoms like altered mental status, confusion, seizures, flapping tremors, irritability, or even a coma-like state resulting from <strong>hepatic encephalopathy</strong>. There are recurrent episodes of <strong>hyperammonemia</strong> which are usually precipitated by triggers like surgery, drugs (like <strong>acetaminophen</strong>), alcohol consumption,&nbsp;and high sugar intake. The patient will also have a history of<strong> aversion to carbohydrate-rich foods</strong> like rice, bread, and potato.</p>\n<p>During an acute attack, elevated levels of ammonia, citrulline, and arginine are observed with low or normal levels of glutamine. Levels of galactose-1-phosphate in the RBCs are also increased.<strong> Demonstration of the gene mutation</strong> is useful for confirmation of the diagnosis.</p>\n<p>It is managed with a diet that is rich in fats and proteins and low in carbohydrates with <strong>supplements</strong> of medium-chain triglycerides, arginine, and pyruvate. Liver<strong>&nbsp;</strong>transplantation helps to prevent the progression of symptoms.</p>\n<div class=\"page\" title=\"Page 219\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Note: Deficiency of any of the urea cycle enzymes would result in <strong>hyperammonemia</strong></p>\n</div>\n</div>\n</div>\n</div>\n<p>Other options:</p>\n<p>Option A: <strong>Type I citrullinemia</strong> is a urea cycle disorder caused by a deficiency of&nbsp;<strong>argininosuccinate synthase</strong>, which catalyzes the synthesis of argininosuccinate from citrulline and aspartate; Patients have a history of protein aversion, lethargy progressing to coma, and liver failure.</p>\n<p>Option C: <strong>Hartnup disease</strong> is caused due to a defective intestinal transport of the essential amino acids such as&nbsp;<strong>tryptophan</strong> and<strong> niacin.&nbsp;</strong>Clinical features include pellagra like rash and neurologic manifestations such as cerebellar ataxia and delirium.</p>\n<p>Option D: <strong>Type I hyperammonemia</strong> is also a urea cycle disorder caused due to a deficiency of the enzyme <strong>carbamoyl phosphate synthase-I</strong>, which is essential for the condensation of CO<sub>2</sub>, ammonia, and ATP to form carbamoyl phosphate. Clinical features include irritability, vomiting, lethargy (especially a few days after birth).</p><hr><h3>Related Pearl: Urea Cycle and its disorders</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/18bcc23295f14f9f9b7463912fdb6eeax1280x2235.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF2592",
      "difficulty": "medium"
    },
    {
      "text": "A 7-year-old child is brought with a history of impaired vision and severe photophobia. On examination, he has light hair, light skin color, and pale blue eyes. A disorder due to deficiency in the enzyme tyrosinase is suspected. What is the likely diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Albinism"
        },
        {
          "id": 2,
          "text": "Tyrosinemia type 1"
        },
        {
          "id": 3,
          "text": "Tyrosinemia type 2"
        },
        {
          "id": 4,
          "text": "Homocystinuria"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><span data-preserver-spaces=\"true\">The clinical scenario along with the deficiency of the&nbsp;</span><span data-preserver-spaces=\"true\">enzyme&nbsp;</span><strong><span data-preserver-spaces=\"true\">tyrosinase&nbsp;</span></strong><span data-preserver-spaces=\"true\">point to the diagnosis of <strong>albinism</strong>.&nbsp;</span></p>\n<p><strong><span data-preserver-spaces=\"true\">Oculocutaneous albinism</span></strong><span data-preserver-spaces=\"true\">&nbsp;<strong>(OCA)</strong> is a group of inherited disorders characterized by a reduction or complete lack of <strong>melanin</strong> pigment in the <strong>skin, hair,</strong> and<strong> eyes</strong> leading to hypopigmentation.&nbsp;It is either due to defective melanosomes or defective protein involved in the formation and transfer of melanin. </span></p>\n<p><span data-preserver-spaces=\"true\">There are 7 types of&nbsp;nonsyndromic albinism (OCA1 to OCA7).<strong> OCA type 1</strong> is characterised by reduced or absent <strong>tyrosinase</strong> activity.&nbsp;</span><span data-preserver-spaces=\"true\">The<strong> first step</strong> in <strong>melanin synthesis</strong> involves the oxidation of L-tyrosine to DOPA by the enzyme tyrosinase.&nbsp;</span>Tyrosinase further acts on DOPA to form dopaquinone, which undergoes a series of reactions to form melanin.&nbsp;</p>\n<p><span data-preserver-spaces=\"true\">Clinical features include&nbsp;<strong>white hair,</strong>&nbsp;<strong>white skin, </strong>and&nbsp;<strong>iris</strong> appearing&nbsp;<strong>blue-grey</strong> in oblique light. Ocular manifestations include&nbsp;<strong>photophobia,</strong> nystagmus, and&nbsp;<strong>decreased visual acuity.&nbsp;</strong></span></p>\n<p><span data-preserver-spaces=\"true\">Other options-</span></p>\n<p>Option B- <strong>Tyrosinemia type 1</strong> is caused due to the deficiency of the enzyme <strong>fumarylacetoacetate hydrolase</strong>. Clinical findings include&nbsp;cirrhosis, liver failure, rickets, failure to thrive, peripheral neuropathy, and boiled cabbage odour.&nbsp;</p>\n<p>Option C- <strong>Tyrosinemia type 2</strong> is caused due to the deficiency of the enzyme <strong>tyrosine transaminase.</strong> Clinical findings include palmoplantar keratosis, painful corneal erosions with photophobia, and <strong>learning disability.&nbsp;</strong></p>\n<p>Option D- <strong>Homocystinuria</strong> is caused due to <strong>cystathionine beta-synthase</strong> deficiency. Clinical findings include lens dislocation, thrombotic vascular disease, <strong>intellectual</strong> <strong>disability</strong>, and osteoporosis.</p>\n<p>Given below is an image of a young child with OCA showing white hair, skin, and pale iris:</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/36fbf01e9a85437596b312b2a4c032cex794x527.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Amino acid Enzymatic Disorders and the Associated Enzymes</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Disorder</strong></p>\n</td>\n<td>\n<p><strong>Enzyme defect</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Phenylketonuria</p>\n</td>\n<td>\n<p>Phenylalanine hydroxylase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Tyrosinosis (Tyrosinemia type I)</p>\n</td>\n<td>\n<p>Maleyl Acetate isomerase or Fumarylacetoacetate hydrolase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Maple syrup urine disease&nbsp;</p>\n</td>\n<td>\n<p>Branched-chain alpha-keto acid dehydrogenase(BCKAD)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Alkaptonuria</p>\n</td>\n<td>\n<p>Homogentisate oxidase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Albinism</p>\n</td>\n<td>\n<p>Tyrosinase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Homocystinuria type I</p>\n</td>\n<td>\n<p>Cystathionine synthase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Homocystinuria type II</p>\n</td>\n<td>\n<p>Defect in methylcobalamin formation</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Cystathioninuria</p>\n</td>\n<td>\n<p>Cystathionase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Tyrosinemia type II or Richner-Hanhart syndrome</p>\n</td>\n<td>\n<p>Tyrosine transaminase or Tyrosine aminotransferase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Primary hyperoxaluria</p>\n</td>\n<td>\n<p>Alanine glyoxalate aminotransferase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hypervalinemia</p>\n</td>\n<td>\n<p>Valine transaminase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Isovaleric acidemia</p>\n</td>\n<td>\n<p>Isovaleryl CoA dehydrogenase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Histidinemia</p>\n</td>\n<td>\n<p>Histidase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hyperprolinemia type I</p>\n</td>\n<td>\n<p>Proline oxidase</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF2886",
      "difficulty": "easy"
    },
    {
      "text": "You are evaluating the metabolic changes in patients with various conditions. Increased basal metabolic rate will be seen in patients with which of the following condition?",
      "choices": [
        {
          "id": 1,
          "text": "Acromegaly"
        },
        {
          "id": 2,
          "text": "Starvation"
        },
        {
          "id": 3,
          "text": "Protein energy malnutrition"
        },
        {
          "id": 4,
          "text": "Addison disease"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Increased basal metabolic rate (BMR)</strong> is seen in patients with <strong>acromegaly</strong>.</p>\n<p><strong>High energy-requiring states</strong> such as fever, pregnancy, pheochromocytoma, adrenergic agonist drugs, cancer, congestive heart failure, <strong>acromegaly</strong>, polycythemia, and Paget&rsquo;s disease of the bone are associated with high BMR. Obesity, <strong>starvation</strong> or anorexia, hypogonadism, <strong>Addison's</strong> syndrome, and immobilization are associated with <strong>low BMR.</strong></p>\n<p><strong>BMR</strong> is the energy required by an awake individual during rest. It is the minimum energy required to carry out vital functions of the body such as respiration, circulation, etc.&nbsp;</p>\n<p>It is calculated using oxygen consumption, calorific value (energy produced by 1 liter of oxygen), and surface area.</p>\n<p><strong>BMR</strong> is dependent on various factors:</p>\n<ul>\n<li><strong>Men</strong> have <strong>more BMR</strong> than women of the same body weight and age because women&rsquo;s bodies contain proportionally more adipose tissue and fewer muscles.&nbsp;</li>\n<li><strong>Elderly people</strong> have <strong>less BMR</strong>&nbsp;as the muscle tissue gets infiltrated with fat as age advances.</li>\n<li>Low environmental temperature is associated with high BMI.</li>\n<li>Exercise increases BMR.</li>\n<li>The thyroid hormone has a direct role in increasing BMR.</li>\n</ul><hr><h3>Related Pearl: Basal Metabolic Rate</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>BMR is increased in</strong></p>\n</td>\n<td>\n<p><strong>BMR is decreased in</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Fever</p>\n</td>\n<td>\n<p>Protein energy malnutrition</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hyperthyroidism</p>\n</td>\n<td>\n<p>Hypothyroidism</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Cold environment</p>\n</td>\n<td>\n<p>Addison disease</p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\">\n<p>Cachexia</p>\n<p>&nbsp;</p>\n</td>\n<td>\n<p>Starvation</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Cushing&rsquo;s syndrome</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD2160",
      "difficulty": "medium"
    },
    {
      "text": "A 45-year-old male patient presents with recent onset of photosensitivity and development of vesicles and bullae on the sun-exposed areas of his skin as shown below. A urine analysis showed the presence of elevated levels of uroporphyrin I and normal red cell uroporphyrin. Identify the false statement regarding the patient's illness.<div class='question-desc-html'><p>UROD- Uroporphyrinogen decarboxylase</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Mutations in UROD gene present"
        },
        {
          "id": 2,
          "text": "Hepatic iron stores are normal"
        },
        {
          "id": 3,
          "text": "Low dose hydroxychloroquine is used in management"
        },
        {
          "id": 4,
          "text": "Associated with increased risk of hepatocellular carcinoma"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The most likely diagnosis is <strong>p</strong><strong>orphyria cutanea tarda</strong>. The false statement regarding the patient's illness is that the hepatic iron stores are normal. The hepatic iron stores will be increased in this condition.</p>\n<p><strong>Porphyria cutanea tarda</strong> (PCT) is the most common type of porphyria and presents with cutaneous and hepatic features. It is caused due to a deficiency in the enzyme <strong>u</strong><strong>roporphyrinogen decarboxylase</strong>, which converts uroporphyrinogen III to coproporphyrinogen III. Mutations of the&nbsp;<strong>uroporphyrinogen decarboxylase&nbsp;</strong>(UROD) <strong>gene&nbsp;</strong>are present in the familial type PCT.</p>\n<p>The accumulated porphyrins are transported to the skin and act as photosensitizers. Hence, the patients usually present with <strong>skin friability,</strong>&nbsp;milia, and <strong>bullae</strong> on the sun-exposed skin of the dorsal aspect of the hands, forearms, face, legs, and feet.<strong> Hypertrichosis, mottled pigmentary change,</strong> and <strong>scleroderma-like induration</strong> are associated features.</p>\n<p>The porphyrins accumulate in the liver and are excreted in urine and bile. <strong>Hepatic iron stores</strong> are <strong>increased</strong> as PCT is an iron-related disorder.&nbsp;<strong>Liver dysfunction</strong> is common in these patients and the risk of developing <strong>hepatocellular carcinoma</strong> is increased.&nbsp;</p>\n<p>Diagnosis is made by the classical clinical feature of photosensitivity with&nbsp;<strong>elevated urine, stool,&nbsp;</strong>and&nbsp;<strong>plasma uroporphyrin&nbsp;</strong>with&nbsp;<strong>normal red cell uroporphyrin.</strong>&nbsp;</p>\n<p>Management includes:</p>\n<ul>\n<li><strong>Repeated phlebotomies</strong> to deplete hepatic iron stores.&nbsp;Iron administration can lead to a recurrence of the disease.</li>\n<li><strong>Low dose hydroxychloroquine</strong> which forms complexes and removes the excess porphyrins from the liver.</li>\n</ul><hr><h3>Related Pearl: Types of porphyria</h3><p>Clinically porphyrias can be classified into:</p>\n<ul>\n<li>Hepatic porphyria: The overproduction of heme pathway intermediates occurs primarily in the liver.</li>\n<li>Erythropoietic porphyria: The overproduction of heme pathway intermediates occurs primarily in bone marrow erythroid cells.</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/2370f6a3e9e64db5b0d342d7fc4a410fx1280x1964.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td>\n<div><span><strong>Porphyria type</strong></span></div>\n</td>\n<td>\n<div><span><strong>Deficient </strong> <strong>enzyme</strong></span></div>\n</td>\n<td>\n<div><span><strong>Lab findings</strong></span></div>\n</td>\n<td> </td>\n<td>\n<div><span><strong>Symptoms</strong></span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>X-linked dominant protoporphyria</span></div>\n<div><span>(XLDPP)</span></div>\n</td>\n<td>\n<div><span>δ-aminolevulinate synthase 2</span></div>\n<div><span>(ALAS - 2)</span></div>\n</td>\n<td><span>Decreased RBC count and hemoglobin</span></td>\n<td>\n<div><span>Cutaneous photosensitivity</span></div>\n</td>\n<td>\n<div><span>Photosensitivity</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Aminolevulinate dehydratase deficiency porphyria</span></div>\n<div><span>(ALADP)</span></div>\n</td>\n<td>\n<div><span>δ-aminolevulinate dehydratase</span></div>\n<div><span>(ALAD)</span></div>\n</td>\n<td><span>Increased urinary ALA and coproporphyrin III </span></td>\n<td><span>Neurovisceral symptoms</span></td>\n<td>\n<div><span>Abdominal pain, neuropathy</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Acute intermittent porphyria</span></div>\n<div><span>(AIP)</span></div>\n</td>\n<td>\n<div><span>Hydroxymethylbilane synthase</span></div>\n<div><span>(Uroporphyrin I synthase)</span></div>\n</td>\n<td><span>Increased urinary ALA and PBG </span></td>\n<td><span>Neurovisceral symptoms </span></td>\n<td>\n<div><span>Periodic abdominal pain, peripheral neuropathy, psychiatric symptoms, tachycardia</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Congenital Erythropoietic porphyria</span></div>\n<div><span>(CEP)</span></div>\n</td>\n<td>\n<div><span>Uroporphyrinogen III synthase</span></div>\n<div><span>(UROS)</span></div>\n</td>\n<td><span>Increased urinary, fecal and red cell uroporphyrin I</span></td>\n<td><span>Cutaneous photosensitivity</span></td>\n<td>\n<div><span>Severe photosensitivity with erythema, swelling and blistering, hemolytic anemia, splenomegaly</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Porphyria cutanea tarda (PCT)</span></div>\n</td>\n<td>\n<div><span>Uroporphyrinogen decarboxylase</span></div>\n<div><span>(UROD)</span></div>\n</td>\n<td><span>Increased uroporphyrin I</span></td>\n<td><span> </span>\n<div><span>Cutaneous photosensitivity</span></div>\n</td>\n<td>\n<div><span>Photosensitivity with vesicles and bullae</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Hereditary coproporphyria</span></div>\n<div><span>(HCP)</span></div>\n</td>\n<td>\n<div><span>Coproporphyrinogen oxidase</span></div>\n<div><span>(CPOX)</span></div>\n</td>\n<td><span>Increased urinary ALA, PBG, and coproporphyrin III and fecal coproporphyrin III</span></td>\n<td><span>Both</span></td>\n<td>\n<div><span>Photosensitivity, neurologic symptoms, abdominal colic</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Variegate porphyria</span></div>\n<div><span>(VP)</span></div>\n</td>\n<td>\n<div><span>Protoporphyrinogen oxidase</span></div>\n<div><span>(PPOX)</span></div>\n</td>\n<td><span>Increased urinary ALA, PBG, and coproporphyrin III and fecal protoporphyrin IX</span></td>\n<td><span>Both</span></td>\n<td>\n<div><span>Photosensitivity, neurologic symptoms, developmental delay</span></div>\n</td>\n</tr>\n<tr>\n<td>\n<div><span>Erythropoietic protoporphyria</span></div>\n<div><span>(EPP)</span></div>\n</td>\n<td>\n<div><span>Ferrochelatase</span></div>\n<div><span>(FECH)</span></div>\n</td>\n<td><span>Increased fecal and red cell protoporphyrin IX </span></td>\n<td><span>Cutaneous photosensitivity</span></td>\n<td>\n<div><span>Non-blistering Photosensitivity with skin lesions</span></div>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<div><span> </span></div>\n<div><span>Most porphyrias are <strong>autosomal dominant</strong> <strong>except:</strong></span></div>\n<div>\n<ul>\n<li><span>ALAD enzyme deficiency porphyria</span></li>\n<li><span>Congenital erythropoietic porphyria</span></li>\n<li><span>Erythropoietic protoporphyria</span></li>\n<li><span>X-linked protoporphyria</span></li>\n</ul>\n</div><hr><h3>Related Pearl: Drugs precipitating porphyria: \"BOOST CHAP\"</h3><p>The mnemonic \"<strong>BOOST CHAP</strong>\" can be used to remember the drugs precipitating porphyria.</p>\n<p><strong>B</strong>: Barbiturates</p>\n<p><strong>O</strong>: OCPs</p>\n<p><strong>O</strong>: Orphenadrine</p>\n<p><strong>S</strong>: Sulphonamides</p>\n<p><strong>T</strong>: Tetracyclines</p>\n<p><strong>C</strong>: Chloramphenicol, carbamazepine</p>\n<p><strong>H</strong>: Halothane, Hydralazine</p>\n<p><strong>A</strong>: Alcohol</p>\n<p><strong>P</strong>: Phenytoin</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/bd9e9867e6354f279f218f2c13b95f2c.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF2389",
      "difficulty": "medium"
    },
    {
      "text": "A 15-month-old child is brought because of developmental delay and clouded appearance of the cornea in both eyes. The other examination findings of the child are shown in the image below. The elder sibling of the child also has similar findings. What is the most likely diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Mucopolysaccharidoses"
        },
        {
          "id": 2,
          "text": "Von Gierke’s disease"
        },
        {
          "id": 3,
          "text": "Down’s syndrome"
        },
        {
          "id": 4,
          "text": "Refsum disease"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The given image shows coarse facial features, umbilical hernia, claw hand, and thoracolumbar gibbus. These features along with corneal opacity and developmental delay are highly suggestive of <strong>mucopolysaccharidoses (MPS)</strong>.</p>\n<p>The features mentioned in the above question are suggestive of <strong>MPS type 1</strong>. It is caused by the deficiency of <strong>&alpha;-l-iduronidase</strong>, leading to the storage of dermatan and heparan sulfate. The classical form of MPS 1 is known as <strong>Hurler syndrome</strong>, the intermediate form as <strong>Hurler&ndash;Scheie</strong>, and the most attenuated form is known as <strong>Scheie syndrome</strong>.</p>\n<p>Mucopolysaccharidoses <strong>(MPS)</strong> are a group of genetic disorders (inborn errors of metabolism) affecting <strong>glycosaminoglycans</strong> (GAGs). They are inherited in an<strong> autosomal recessive </strong>manner and involve mutations of genes encoding <strong>lysosomal hydroxylases</strong>.&nbsp;Diagnosis is by demonstration of GAGs in urine or tissue biopsy samples, assays of suspected defective enzymes in white blood cells, fibroblasts, or serum, and testing for specific genes.</p>\n<p>The given image shows cloudy cornea in mucopolysaccharidosis:</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/d08c76ac37d3434aaadbe26cc4fb9755x300x254.PNG\" alt=\"Explanation Image\"><p>Other options -</p>\n<p>Option B: <strong>Von Gierke&rsquo;s disease </strong>or glycogen storage disease type 1a - Occurs due to the deficiency of glucose-6-phosphatase, and affected children present with hepatosplenomegaly and fasting hypoglycemia.</p>\n<p>Option C: <strong>Down's syndrome</strong>&nbsp;occurs due to trisomy 21. Affected children present with a flattened facial profile,&nbsp;oblique palpebral fissures, and epicanthic folds. Patients may be intellectually disabled.</p>\n<p>Option D: <strong>Refsum disease&nbsp;</strong>- It is a disorder of fatty acid metabolism. It occurs due to deficiency of <strong>alpha-hydroxylase</strong> causing <strong>phytanic acid accumulation</strong> in the tissues. It presents with neurological symptoms, cerebellar ataxia, retinitis pigmentosa, and polyneuropathy.</p><hr><h3>Related Pearl: MPS and Their Respective Enzyme Deficiencies</h3><table>\n<tbody>\n<tr>\n<td><strong>Disease</strong></td>\n<td><strong>MPS</strong></td>\n<td><strong>Enzyme defective</strong></td>\n<td><strong>GAGs affected</strong></td>\n<td><strong>Symptoms</strong></td>\n</tr>\n<tr>\n<td>Hurler-, Scheie-,&nbsp;<br />Hurler-scheie syndrome</td>\n<td>MPS I</td>\n<td>&alpha;-L-Iduronidase</td>\n<td>\n<p>Dermatan sulfate,<br />Heparan sulfate</p>\n</td>\n<td>Mental retardation,<br />coarse facial features,&nbsp;<br />Hepatosplenomegaly<br />Cloudy cornea</td>\n</tr>\n<tr>\n<td>Hunter syndrome</td>\n<td>MPS II</td>\n<td>Iduronate sulfatase</td>\n<td>Dermatan sulfate,&nbsp;<br />Heparan sulfate</td>\n<td>Mental retardation</td>\n</tr>\n<tr>\n<td>Sanfilippo&nbsp;syndrome A</td>\n<td>MPS IIIA</td>\n<td>Heparan sulfate-N-sulfatase</td>\n<td>Heparan sulfate</td>\n<td>Delay in development<br />Motor dysfunction</td>\n</tr>\n<tr>\n<td>Sanfilippo&nbsp;syndrome B</td>\n<td>MPS III B</td>\n<td>&alpha;-N-Acetylglucosaminidase</td>\n<td>Heparan sulfate</td>\n<td>As MPS III A</td>\n</tr>\n<tr>\n<td>Sanfilippo&nbsp;syndrome C</td>\n<td>MPS III C</td>\n<td>&alpha;-glucosaminide N-acetyltransferase</td>\n<td>Heparan sulfate</td>\n<td>As MPS III A &nbsp;</td>\n</tr>\n<tr>\n<td>Sanfilippo&nbsp;syndrome D</td>\n<td>MPS III D</td>\n<td>N-acetylglucosamine 6-sulfatase</td>\n<td>Heparan sulfate</td>\n<td>As MPS III A &nbsp;</td>\n</tr>\n<tr>\n<td>Morquio syndrome A</td>\n<td>MPS IV A</td>\n<td>Galactosamine&nbsp;6-sulfatase</td>\n<td>Keratan sulfate&nbsp;<br />Chondroitin 6-sulfate&nbsp;</td>\n<td>Skeletal dysplasia<br />short stature</td>\n</tr>\n<tr>\n<td>Morquio syndrome B</td>\n<td>MPS IV B</td>\n<td>&beta;-galactosidase</td>\n<td>Keratan sulfate</td>\n<td>As MPS IV A</td>\n</tr>\n<tr>\n<td>Maroteaux-lamy&nbsp;syndrome&nbsp;</td>\n<td>MPS VI</td>\n<td>N-acetylgalactosamine 4-sulfatase</td>\n<td>Dermatan sulfate</td>\n<td>Curvature of the spine,<br />Short stature<br />Skeletal dysplasia<br />Cardiac defects</td>\n</tr>\n<tr>\n<td>Sly&nbsp;syndrome&nbsp;</td>\n<td>MPS VII</td>\n<td>&beta;-glucuronidase</td>\n<td>Dermatan sulfate<br />Heparan sulfate<br />Chondroitin 4-sulfate&nbsp;<br />Chondroitin 6-sulfate&nbsp;<br /><br /></td>\n<td>Short stature<br />Skeletal dysplasia<br />Hepatomegaly<br />Cloudy cornea</td>\n</tr>\n<tr>\n<td>Natowicz&nbsp;syndrome&nbsp;</td>\n<td>MPS IX</td>\n<td>Hyaluronidase</td>\n<td>Hyaluronic acid</td>\n<td>Joint Pain<br />Short stature&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Enzyme Replacement Therapy for Lysosomal Storage Disorders</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>&nbsp;Lysosomal Storage Disorder</strong></p>\n</td>\n<td>\n<p><strong>Enzyme deficient</strong></p>\n</td>\n<td>\n<p><strong>Enzyme Replacement Therapy</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hurler Syndrome (MPS I)</p>\n</td>\n<td>\n<p>&alpha;-L -iduronidase</p>\n</td>\n<td>\n<p>Laronidase (Aldurazyme)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hunter Syndrome (MPS II)</p>\n</td>\n<td>\n<p>Iduronate sulfate sulfatase</p>\n</td>\n<td>\n<p>Idursulfase (Elaprase)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Morquio A Syndrome (MPS IVA)</p>\n</td>\n<td>\n<p>N-Acetylgalactosamine-6-sulfate sulfatase</p>\n</td>\n<td>\n<p>Elosulfase (Vimizim)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Maroteaux&ndash;Lamy Syndrome (MPS VI)</p>\n</td>\n<td>\n<p>N -Acetylgalactosamine-&alpha;-4-sulfate sulfatase (arylsulfatase B)</p>\n</td>\n<td>\n<p>Galsulfase (Naglazyme)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Sly syndrome (MPS VII)</p>\n</td>\n<td>&beta;-Glucuronidase</td>\n<td>\n<p>rhGUS (recombinant human&nbsp;&beta;-Glucuronidase is under Phase III trial)</p>\n</td>\n</tr>\n<tr>\n<td>Wolman disease</td>\n<td>Lysosomal acid lipase</td>\n<td>\n<p><em> Sebelipase alfa</em>(Kanuma, Alexion)</p>\n</td>\n</tr>\n<tr>\n<td>Metachromatic leukodystrophy</td>\n<td>Arylsulfatase A</td>\n<td>\n<p>rhARSA (recombinant human arylsulfatase A is under Phase I/II trial)</p>\n</td>\n</tr>\n<tr>\n<td>Fabry disease&nbsp;</td>\n<td>&alpha;-galactosidase A</td>\n<td>\n<p><em>agalsidase beta</em> (Fabrazyme, Genzyme)</p>\n<p><em>agalsidase alfa</em> (Replagal, Shire HGT)</p>\n</td>\n</tr>\n<tr>\n<td>Gaucher disease</td>\n<td>&beta;-glucosidase</td>\n<td>\n<p><em>imiglucerase </em>[Cerezyme, Genzyme]</p>\n<p><em>velaglucerase alfa </em>[VPRIV, Shire HGT]</p>\n<p><em>taliglucerase alfa </em>(Uplyso, Protalix<br />Biotherapeutics)</p>\n<p><em>eliglusta</em>t (Cerdelga, Sanofi-Genzyme)</p>\n</td>\n</tr>\n<tr>\n<td>Pompe disease</td>\n<td>acid &alpha;-1,4-glucosidase (acid maltase)&nbsp;</td>\n<td>\n<p><em>alglucosidase alfa </em>(Myozyme)</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/3d247ef161f74e56a905f5cd133eb105.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD6309",
      "difficulty": "easy"
    },
    {
      "text": "You are a researcher studying the mechanism of action of statins which inhibit the enzyme HMG-CoA reductase by acting as a structural analog to its natural substrate. The Lineweaver Burk Plot for the interaction is given below. Which of the following is true about this type of inhibition?",
      "choices": [
        {
          "id": 1,
          "text": "Vmax of the reaction increases"
        },
        {
          "id": 2,
          "text": "Vmax of the reaction decreases"
        },
        {
          "id": 3,
          "text": "Km of the reaction increases"
        },
        {
          "id": 4,
          "text": "Km of the reaction decreases"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The given example of statin inhibiting cholesterol synthesis by acting on HMG-CoA reductase and the graph is a type of <strong>competitive inhibition.</strong> True about competitive inhibition is that the <strong>K<sub>m</sub></strong> of the<strong> reaction increases.</strong></p>\n<p>Important parameters in a reaction include:</p>\n<ul>\n<li>The affinity of the enzyme for its substrate is given by the<strong> Michaelis constant </strong>or <strong>K<sub>m</sub></strong><strong>. </strong>A <strong>low K<sub>m</sub></strong> reflects a <strong>high affinity</strong> of the <strong>enzyme</strong> for substrate and vice versa. The value of Km is given by the substrate concentration at which the reaction velocity is equal to one-half V<sub>max</sub>. It does not change with changes in enzyme concentration. </li>\n<li>The <strong>rate</strong> of the<strong> reaction</strong> is directly <strong>proportional</strong> to the <strong>enzyme concentration.</strong></li>\n</ul>\n<p><strong>Competitive inhibition </strong>is when the inhibitor binds reversibly to the substrate-binding site and competes with the substrate for the active enzyme binding site.</p>\n<p>This effect of competitive inhibition can be overcome by increasing the substrate concentration by which maximum velocity can still be achieved. Therefore, <strong>V<sub>max</sub></strong> is <strong>unaltered</strong> in this type of inhibition. However, the concentration of the substrate required to achieve half of the maximum velocity is increased. Therefore, <strong>K<sub>m</sub></strong> is <strong>increased</strong> in this condition.</p>\n<p><strong>Noncompetitive inhibition </strong>is by <strong>binding</strong> of inhibitors to enzymes in locations<strong> remote</strong> from the active <strong>site.</strong> Increasing the concentration of the substrate does not overcome non-competitive inhibition. Thus, noncompetitive inhibitors <strong>decrease </strong>the<strong> V<sub>max</sub></strong> of the reaction. They do not interfere with the binding of the substrate to the enzyme. Thus, the enzyme shows the<strong> same K<sub>m</sub></strong> in the presence or absence of noncompetitive inhibitors.</p>\n<div class=\"ng-scope\">\n<div class=\"ng-scope\">\n<p>Graph showing the changes in V<sub>max</sub> and K<sub>m</sub> in competitive and noncompetitive inhibition.</p>\n</div>\n</div><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/b2d1c8cc6956485ab5d1c4109e670023x1280x2317.JPEG\" alt=\"Explanation Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/ffd327a25fb045959c699d4ffb05e602x1280x2235.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Difference between Reversible and Irreversible Inhibitors</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Reversible Inhibitors</strong></p>\n</td>\n<td>\n<p><strong>Irreversible Inhibitors</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Binds via non-covalent interaction</p>\n</td>\n<td>\n<p>Binds via covalent interactions</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>No chemical change</p>\n</td>\n<td>\n<p>Inhibitor binds to the substrate &amp; prevent catalytic activity of enzymes</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Can be reversed, as there is no bonding between the inhibitor &amp; substrate</p>\n</td>\n<td>\n<p>Irreversibility due to strong covalent bonding</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Difference between Competitive & Non-Competitive inhibitors</h3><p>Reversible inhibitors are of two types:</p>\n<ul>\n<li>Competitive inhibitors</li>\n<li>Non-Competitive inhibitors</li>\n</ul>\n<p>Difference between Competitive &amp; Non-Competitive inhibitors</p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Competitive inhibitors</strong></p>\n</td>\n<td>\n<p><strong>Non-Competitive inhibitors</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Succinate dehydrogenase is inhibited by Malonate</p>\n</td>\n<td>\n<p>Pyruvate kinase is inhibited by alanine</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Substrate &amp; inhibitor are chemically similar &amp; have same shape</p>\n</td>\n<td>\n<p>Substrate &amp; inhibitor are chemically not similar &amp; have different shape</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Inhibitor binds to active site</p>\n</td>\n<td>\n<p>Inhibitor binds away from active site, i.e., at allosteric site</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Inhibitor does not change the shape of the active site</p>\n</td>\n<td>\n<p>Inhibitor changes the shape of the active site</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Increase in substrate concentration reduces the inhibition</p>\n</td>\n<td>\n<p>Increase in substrate concentration does not affect the inhibition</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Vmax remains constant</p>\n</td>\n<td>\n<p>Vmax decreases</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Km Increases</p>\n</td>\n<td>\n<p>Km remains constant</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/0b7c647c969d4c03b617bf8d7cd88c9b.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF0381",
      "difficulty": "easy"
    },
    {
      "text": "A 55-year-old lady presented with chronic pain in the lower back and knees. On physical examination, there were black pigmentary deposits on the sclera of both eyes and on the fingers and nailbeds. The urine turned black on exposure to Benedict's reagent and showed large amounts of a particular metabolite which is responsible. Identify the metabolite from the image below",
      "choices": [
        {
          "id": 1,
          "text": "2"
        },
        {
          "id": 2,
          "text": "1"
        },
        {
          "id": 3,
          "text": "4"
        },
        {
          "id": 4,
          "text": "3"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The clinical vignette is suggestive of <strong>alkaptonuria,&nbsp;</strong>which is characterised by excretion of the metabolite&nbsp;<strong>homogentisate </strong>(marked as <strong>2&nbsp;</strong>in the flowchart)&nbsp;in urine.</p>\n<p>Alkaptonuria is an autosomal recessive disorder of <strong>tyrosine metabolism</strong>. It occurs due to a defect in <strong>homogentisate oxidase</strong>&nbsp;(which&nbsp;oxidizes homogentisate to maleylacetoacetate) leading to the <strong>accumulation of homogentisate</strong>. The&nbsp;excreted homogentisate in urine makes it appear black when it gets oxidized on exposure to air or an oxidizing agent.</p>\n<p>Accumulation of oxidized homogentisic acid pigment (benzoquinone acetate) in joints and connective tissues leads to arthritis and connective tissue pigmentation respectively. This is known as <strong>ochronosis</strong>.&nbsp;Pigmentation of heart valves, larynx, tympanic membranes, and skin, with occasional renal pigment calculi, can also be seen.</p>\n<p>Most patients are diagnosed early based on the<strong> darkening of urine</strong> with standing or the addition of alkali. Around the age of 30 years, gray-brown pigmentation of sclera and generalized darkening of the concha, anthelix and helix of the ear is seen.Some patients present in middle age with a <strong>degenerative joint disease</strong> (ochronotic arthritis) with pain, stiffness, and limitation of motion of the lower back, hips, knees, and shoulders. Small joints are usually spared.</p>\n<p>Treatment:</p>\n<div class=\"page\" title=\"Page 3065\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<ul>\n<li><strong>Symptomatic</strong> treatment with pain medications, spinal surgery, and arthroplasty&nbsp;</li>\n<li>Ascorbic acid and protein restriction&nbsp;</li>\n<li><strong>Nitisinone</strong> - reduces urinary excretion of homogentisic acid and delays progression of the disease.</li>\n</ul>\n</div>\n</div>\n</div>\n</div><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/0fe5b17563d94403887314b8c37e2099x1280x2566.3187588152327.JPEG\" alt=\"Explanation Image\"><p>The images below show<strong> pigmentation of the skin </strong>and an<strong> x-ray of the spine </strong>that shows<strong> calcification of intervertebral discs,</strong> both symptoms of ochronosis.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/69bb0d10ce66436eb0e4e36807c443aex408x267.JPEG\" alt=\"Explanation Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/114c954855d74f0cbc4ab61cf0d8073fx972x1198.JPEG\" alt=\"Explanation Image\"><p>Image showing darkening of urine on standing:</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/94e733d3439e40659d77dd54cc40ce9dx512x358.PNG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Amino acid Enzymatic Disorders and the Associated Enzymes</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Disorder</strong></p>\n</td>\n<td>\n<p><strong>Enzyme defect</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Phenylketonuria</p>\n</td>\n<td>\n<p>Phenylalanine hydroxylase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Tyrosinosis (Tyrosinemia type I)</p>\n</td>\n<td>\n<p>Maleyl Acetate isomerase or Fumarylacetoacetate hydrolase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Maple syrup urine disease&nbsp;</p>\n</td>\n<td>\n<p>Branched-chain alpha-keto acid dehydrogenase(BCKAD)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Alkaptonuria</p>\n</td>\n<td>\n<p>Homogentisate oxidase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Albinism</p>\n</td>\n<td>\n<p>Tyrosinase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Homocystinuria type I</p>\n</td>\n<td>\n<p>Cystathionine synthase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Homocystinuria type II</p>\n</td>\n<td>\n<p>Defect in methylcobalamin formation</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Cystathioninuria</p>\n</td>\n<td>\n<p>Cystathionase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Tyrosinemia type II or Richner-Hanhart syndrome</p>\n</td>\n<td>\n<p>Tyrosine transaminase or Tyrosine aminotransferase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Primary hyperoxaluria</p>\n</td>\n<td>\n<p>Alanine glyoxalate aminotransferase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hypervalinemia</p>\n</td>\n<td>\n<p>Valine transaminase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Isovaleric acidemia</p>\n</td>\n<td>\n<p>Isovaleryl CoA dehydrogenase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Histidinemia</p>\n</td>\n<td>\n<p>Histidase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hyperprolinemia type I</p>\n</td>\n<td>\n<p>Proline oxidase</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/e9bc394fe9e74628864dabf89d358f30.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "ME9229",
      "difficulty": "easy"
    },
    {
      "text": "A young boy with a metabolic disorder has long slender fingers, tall stature, and a high arched palate. He is fair-skinned, with blue eyes and a malar flush. On ophthalmological examination, there is a bilateral inferonasal subluxation of the lens. This disorder is due to abnormal metabolism of:",
      "choices": [
        {
          "id": 1,
          "text": "Methionine"
        },
        {
          "id": 2,
          "text": "Valine"
        },
        {
          "id": 3,
          "text": "Threonine"
        },
        {
          "id": 4,
          "text": "Leucine"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The given clinical scenario with tall stature, long limbs, inferonasal subluxation of the lens, with blue eyes, fair skin, and a malar flush is suggestive of <strong>homocystinuria</strong>,&nbsp;which&nbsp;is due to the abnormal metabolism&nbsp;of <strong>methionine</strong>.</p>\n<p><strong>Homocystinuria</strong> is an <strong>autosomal recessive</strong> disorder of methionine metabolism. It is due to a defect in the enzyme <strong>cystathionine &beta;-synthase</strong> whose function is to convert homocysteine to cystathionine.&nbsp;This leads to an abnormal accumulation of homocysteine and its metabolites (homocysteine, homocysteine-cysteine complex, and others) in blood and urine, along with low levels of cysteine in plasma.&nbsp;</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/7b6294e79b5142639fb495d8a17ccd8bx580x104.JPEG\" alt=\"Explanation Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/3264faa010744c97be3ba3212bba8a55x1280x1774.JPEG\" alt=\"Explanation Image\"><p>Clinical features:</p>\n<ul>\n<li>Affected infants appear&nbsp;<strong>normal at birth</strong>.&nbsp;</li>\n<li aria-level=\"1\"><strong>Ectopia lentis</strong>&nbsp;(inferonasal subluxation of the lens) is seen first, after 3 years of age. There may be severe myopia and iridodonesis (quivering iris).</li>\n<li aria-level=\"1\"><strong>Intellectual disability</strong>&nbsp;and psychiatric and behavioral disorders.</li>\n<li aria-level=\"1\">Thromboembolic episodes especially in the large and small vessels of the brain.</li>\n<li aria-level=\"1\">Skeletal abnormalities resembling those of Marfan syndrome: They are&nbsp;<strong>tall</strong>&nbsp;and&nbsp;<strong>thin</strong>&nbsp;with&nbsp;<strong>elongated limbs</strong>&nbsp;and&nbsp;<strong>arachnodactyly (slender fingers)</strong>. There may be scoliosis, a high arched palate, and crowding of teeth.</li>\n<li aria-level=\"1\">Fair skin, blue eyes, and a malar flush</li>\n</ul>\n<p>Diagnosis is by&nbsp;<strong>elevated levels</strong>&nbsp;of&nbsp;<strong>methionine</strong>&nbsp;and&nbsp;<strong>homocysteine</strong>&nbsp;in body fluids.&nbsp;Additional tests include molecular analysis of cystathionine &beta;-synthase (CBS) and enzyme assay in cultured fibroblasts, lymphocytes, or liver biopsy specimens.</p>\n<p>Treatment includes&nbsp;<strong>restriction of methionine intake</strong>&nbsp;and supplementation with&nbsp;<strong>cysteine, betaine, vitamins B6, </strong>and&nbsp;<strong>folate.</strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/3b20a4c5de4447ed991f0c7c48f00d66x1280x1922.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Amino acid Enzymatic Disorders and the Associated Enzymes</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Disorder</strong></p>\n</td>\n<td>\n<p><strong>Enzyme defect</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Phenylketonuria</p>\n</td>\n<td>\n<p>Phenylalanine hydroxylase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Tyrosinosis (Tyrosinemia type I)</p>\n</td>\n<td>\n<p>Maleyl Acetate isomerase or Fumarylacetoacetate hydrolase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Maple syrup urine disease&nbsp;</p>\n</td>\n<td>\n<p>Branched-chain alpha-keto acid dehydrogenase(BCKAD)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Alkaptonuria</p>\n</td>\n<td>\n<p>Homogentisate oxidase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Albinism</p>\n</td>\n<td>\n<p>Tyrosinase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Homocystinuria type I</p>\n</td>\n<td>\n<p>Cystathionine synthase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Homocystinuria type II</p>\n</td>\n<td>\n<p>Defect in methylcobalamin formation</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Cystathioninuria</p>\n</td>\n<td>\n<p>Cystathionase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Tyrosinemia type II or Richner-Hanhart syndrome</p>\n</td>\n<td>\n<p>Tyrosine transaminase or Tyrosine aminotransferase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Primary hyperoxaluria</p>\n</td>\n<td>\n<p>Alanine glyoxalate aminotransferase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hypervalinemia</p>\n</td>\n<td>\n<p>Valine transaminase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Isovaleric acidemia</p>\n</td>\n<td>\n<p>Isovaleryl CoA dehydrogenase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Histidinemia</p>\n</td>\n<td>\n<p>Histidase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hyperprolinemia type I</p>\n</td>\n<td>\n<p>Proline oxidase</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p><hr><h3>Related Pearl: Homocystinuria</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/c84307c25b08404ebad0ed6c97f95b35x1280x1169.JPEG\" alt=\"Pearl Image\"><p>The concept for treatment:</p>\n<ul>\n<li>Since homocysteine is produced from methionine, decreased dietary intake of methionine decreases the formation of homocysteine.</li>\n<li>As the end product of this cycle is cysteine, increased dietary intake of cysteine will decrease the conversion of methionine to homocysteine through negative feedback.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8457",
      "difficulty": "easy"
    },
    {
      "text": "An eight-year-old girl presents with a red and pruritic rash on the sun-exposed areas of the body along with a history of wide-based, unsteady gait. On examination, serum electrolytes are normal and urine is positive for neutral amino acids. The pattern of inheritance of the disease is given in the image below.  What is the cause of this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Tryptophan transport defect"
        },
        {
          "id": 2,
          "text": "Uroporphyrinogen I synthase defect"
        },
        {
          "id": 3,
          "text": "Methylcobalamin formation defect"
        },
        {
          "id": 4,
          "text": "Tyrosine transaminase defect"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><span data-preserver-spaces=\"true\">The above clinical history of pellagra-like symptoms with autosomal recessive inheritance as shown in the image is suggestive of <strong>H</strong></span><strong><span data-preserver-spaces=\"true\"><strong>artnup</strong></span></strong> disease. It is due to<strong><span data-preserver-spaces=\"true\"> </span></strong><span data-preserver-spaces=\"true\">a <strong>tryptophan transport defect</strong>.</span></p>\n<p><span data-preserver-spaces=\"true\"><strong>Hartnup disease</strong> is an </span><strong><span data-preserver-spaces=\"true\">autosomal recessive</span></strong><span data-preserver-spaces=\"true\"> condition caused due to a single </span><strong><span data-preserver-spaces=\"true\">defect </span></strong>in renal and intestinal<span data-preserver-spaces=\"true\"> </span><strong><span data-preserver-spaces=\"true\">transport </span>of tryptophan </strong>due to a mutation of the<strong><span data-preserver-spaces=\"true\"> SLC6A19 gene </span></strong>on Chromosome 5<span data-preserver-spaces=\"true\">. This results in decreased availability of tryptophan for niacin synthesis. Thus, manifesting as pellagra-like symptoms.</span></p>\n<p>Clinical features<span data-preserver-spaces=\"true\"> include <strong>intermittent, reversible episodes</strong> affecting the skin and nervous system that are <strong>aggravated</strong> by sunlight, febrile illness, stress and nutritional deficiency. <strong>Skin</strong> manifestations present after sun exposure and include erythematous, scaly patches, similar to <strong>pellagra</strong>. <strong>Neurologic</strong> manifestations include <strong>ataxia</strong>(wide-based unsteady gait), tremors, mood disorder, depression, convulsions, and psychosis.</span></p>\n<p>Diagnosis<strong><span data-preserver-spaces=\"true\"> </span></strong><span data-preserver-spaces=\"true\">is made by demonstrating the presence of <strong>neutral amino acids in the urine</strong>, distinguishing it from pellagra. Indican can also be present in the urine, produced as a by-product of tryptophan metabolism. </span></p>\n<p>Treatment<span data-preserver-spaces=\"true\"> involves <strong>supplementation</strong> with nicotinic acid or nicotinamide and a high-protein diet. </span> </p>\n<p><strong>Other options :</strong></p>\n<p><span data-preserver-spaces=\"true\">Option B: <strong>Uroporphyrinogen I synthase</strong> defect is seen in <strong>acute intermittent porphyria, </strong>which is inherited as an <strong>autosomal dominant</strong> trait. It presents with abdominal pain and neuropsychiatric symptoms. There will be <strong>elevated aminolevulinic acid </strong>and<strong> porphobilinogen</strong> in the urine and plasma.</span></p>\n<p><span data-preserver-spaces=\"true\">Option C: <strong>Methylcobalamin formation</strong> defect results in <strong>methylmalonic acidemia</strong>, which<strong> </strong>follows <strong>autosomal recessive inheritance.</strong> The clinical manifestations would include vomiting, dehydration, failure to thrive, lethargy, hypotonia, and seizures. </span></p>\n<p><span data-preserver-spaces=\"true\">Option D: <strong>Tyrosine aminotransferase deficiency </strong>results in<strong> tyrosinemia type II </strong>or<strong> Richner-Hanhart syndrome. </strong>It is an autosomal recessive disorder. Patients present with corneal inflammation, painful palmoplantar hyperkeratosis, and mental retardation. </span></p><hr><h3>Related Pearl: Conditions Associated with Pellagra-like Symptoms</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Condition/Disease</strong></p>\n</td>\n<td>\n<p><strong>Reason for niacin deficiency</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hartnup disease</p>\n</td>\n<td>\n<p>Intestinal &amp; renal malabsorption of tryptophan</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Carcinoid syndrome</p>\n</td>\n<td>\n<p>Overproduction of serotonin that causes diversion of  tryptophan from NAD+ Pathway</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Vitamin B6 deficiency</p>\n</td>\n<td>\n<p>Defective kynureninase pathway</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Maize rich diet</p>\n</td>\n<td>\n<p>Niacin is in unavailable niacytin form</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Jowar diet (Sorghum)</p>\n</td>\n<td>\n<p>Increase leucine content inhibit QPRTase enzyme</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Inheritance pattern of important diseases</h3><table class=\"t1\">\n<tbody>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span><strong>Autosomal dominant</strong></span></div>\n</td>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span><strong>Autosomal recessive</strong></span></div>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span><strong>HEAV</strong>y<strong> DOMINANT</strong></span></div>\n</td>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span><strong>ABC DEF GHI</strong></span></div>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span><strong>H</strong>: <strong>H</strong>ereditary spherocytosis, <strong>H</strong>ypercholesterolemia,&nbsp;<strong>H</strong>ypertrophic obstructive cardiomyopathy,&nbsp; <strong>H</strong>untington&rsquo;s disease</span></div>\n</td>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\">\n<div class=\"p1\"><span><strong>A</strong>: <strong>A</strong>taxia-telangiectasia,&nbsp;<strong>A</strong>lbinism, <strong>A</strong>lkaptonuria,&nbsp;</span></div>\n</div>\n<div class=\"p1\"><span><strong>A</strong>utosomal-recessive polycystic kidney disease</span></div>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span><strong>E</strong>: <strong>E</strong>hler-Danlos syndrome</span></div>\n</td>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span><strong>B</strong>: <strong>B</strong>lood disorders like&nbsp;<strong>b</strong>eta-thalassemia and sickle-cell anemia</span></div>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span><strong>A</strong>: <strong>A</strong>chondroplasia</span></div>\n</td>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\">\n<div class=\"p1\"><span><strong>C</strong>: <strong>C</strong>ystic fibrosis,&nbsp;</span></div>\n</div>\n<div class=\"p1\"><span><strong>C</strong>ongenital adrenal hyperplasia</span></div>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span><strong>V</strong>: <strong>V</strong>on Willebrand disease, Von Hippel Lindau disease</span></div>\n</td>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span><strong>D</strong>: Sensorineural <strong>d</strong>eafness</span></div>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span><strong>D</strong>: <strong>D</strong>ystrophia myotonica</span></div>\n</td>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\">\n<div class=\"p1\"><span><strong>E</strong>: <strong>E</strong>mphysema&nbsp;</span></div>\n</div>\n<div class=\"p1\"><span>(alpha1- antitrypsin deficiency)</span></div>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span><strong>O</strong>: <strong>O</strong>steogenesis imperfecta,&nbsp;<strong>O</strong>tosclerosis (variable)</span></div>\n</td>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span><strong>F</strong>: <strong>F</strong>riedrich ataxia</span></div>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span><strong>M</strong>: <strong>M</strong>arfans syndrome, Multiple endocrine neoplasias (MEN)</span></div>\n</td>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span><strong>G</strong>: <strong>G</strong>aucher&rsquo;s disease, <strong>G</strong>alactosemia, glycogen storage diseases</span></div>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span><strong>I</strong>: <strong>I</strong>ntermittent porphyria</span></div>\n</td>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span><strong>H</strong>: <strong>H</strong>omocystinuria, <strong>H</strong>emochromatosis</span></div>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span><strong>N</strong>: <strong>N</strong>eurofibromatosis 1 and 2</span></div>\n</td>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span><strong>I</strong>: <strong>I</strong>nborn errors of metabolism- Phenylketonuria, lysosomal storage diseases</span></div>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\"><span><strong>A</strong>: <strong>A</strong>utosomal-dominant polycystic kidney disease</span></td>\n<td class=\"td1\" valign=\"top\">Other conditions: Wilson's disease, sickle cell anemia, thalassemias, spinal muscular atrophy, Kartagener syndrome,&nbsp;</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\"><span><strong>N</strong>: <strong>N</strong>oonan's syndrome</span></td>\n<td class=\"td1\" valign=\"top\">Mucopolysaccharidoses (except Hunter syndrome)</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\"><span><strong>T</strong>: <strong>T</strong>uberous sclerosis</span></td>\n<td class=\"td1\" valign=\"top\">Sphingolipidoses (except Fabry disease)</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\"><span>Other conditions:<strong>&nbsp;</strong>Familial adenomatous polyposis, Hereditary hemorrhagic telangiectasia, Li-Fraumeni syndrome, Pseudohypoparathyroidism</span></td>\n<td class=\"td1\" valign=\"top\">&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p><table class=\"t1\">\n<tbody>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span><strong>X-linked recessive</strong></span></div>\n</td>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span><strong>X-linked dominant</strong></span></div>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span><strong>Lady Hardinge College Girls Don&rsquo;t Care About Foolish Words</strong></span></div>\n</td>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span><strong>Red Rose </strong>for<strong> All Children</strong></span></div>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\">\n<div class=\"p1\"><span>(<strong>L</strong>ady) <strong>L</strong>esch&ndash;Nyhan syndrome,&nbsp;<strong>L</strong>owe syndrome</span></div>\n</div>\n</td>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span>(<strong>R</strong>ed) <strong>R</strong>ett&rsquo;s syndrome</span></div>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span>(<strong>H</strong>ardinge) <strong>H</strong>unter's syndrome, <strong>H</strong>emophilia A and B</span></div>\n</td>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span>(<strong>R</strong>ose) <strong>R</strong>ickets</span></div>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span>(<strong>C</strong>ollege) <strong>C</strong>hronic granulomatous disease</span></div>\n</td>\n<td class=\"td1\" valign=\"top\">\n<div><span>(<strong>A</strong>ll) <strong>A</strong>lport syndrome&nbsp;(common inheritance pattern)</span></div>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span>(<strong>G</strong>irls) <strong>G</strong>-6-PD deficiency</span></div>\n</td>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span>(<strong>C</strong>hildren) Type X <strong>C</strong>harcot&ndash;Marie&ndash;Tooth disease</span></div>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span>(<strong>D</strong>on&rsquo;t) <strong>D</strong>uchenne muscular dystrophy, <strong>D</strong>iabetes insipidus</span></div>\n</td>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\">&nbsp;</div>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span>(<strong>C</strong>are) <strong>C</strong>olor blindness</span></div>\n</td>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p2\">&nbsp;</div>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\">\n<div class=\"p1\"><span>(<strong>A</strong>bout) <strong>A</strong>gammaglobulinemia,&nbsp;<strong>A</strong>lport syndrome, Ocular&nbsp;<strong>a</strong>lbinism</span></div>\n</div>\n</td>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p2\">&nbsp;</div>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span>(Foolish)&nbsp;<strong>F</strong>abry disease</span></div>\n</td>\n<td class=\"td1\" valign=\"top\">&nbsp;</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\"><span>(<strong>W</strong>ords) <strong>W</strong>iskott&ndash;Aldrich syndrome</span></div>\n</td>\n<td class=\"td1\" valign=\"top\">&nbsp;</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<div class=\"p1\">\n<div class=\"p1\"><span>Other conditions: Menke's disease,&nbsp;</span>Ornithine transcarbamylase deficiency</div>\n</div>\n</td>\n<td class=\"td1\" valign=\"top\">&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><span>&nbsp;</span></p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/d18a710d2d494663b421c9f5ad71fdab.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8614",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following statements are correct with respect to the histones in state A (methylation) and state B (acetylation) in the given image?<div class='question-desc-html'><ol>\n<li>A results in the expression of genes. </li>\n<li>B is associated with chromosomal assembly during DNA replication.</li>\n<li>Both A and B are epigenetic changes,</li>\n<li>Both A and B are types of post-translational modifications (PTMs).</li>\n<li>Both A and B are reversible. </li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "1, 2, 3, 4, 5"
        },
        {
          "id": 2,
          "text": "1, 2, 3, 4"
        },
        {
          "id": 3,
          "text": "2, 3, 4, 5"
        },
        {
          "id": 4,
          "text": "1, 3, 4, 5"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The given image shows histone modification by <strong>methylation</strong> (state <strong>A</strong>) and <strong>acetylation</strong> (state <strong>B</strong>). <strong>2, 3, 4, and 5</strong> are the correct statements regarding the <strong>two images.</strong></p>\n<p>In state A, <strong>methylation</strong> of DNA and Histones causes nucleosomes to be tightly packed<strong> together</strong>. Transcription factors cannot bind to the DNA, therefore the <strong>genes will not be expressed (statement 1</strong> is false).<strong> </strong>In state B, histone <strong>acetylation</strong> results in <strong>loose packing</strong> of the nucleosomes. The target gene is accessible and transcription factors can bind to the DNA and <strong>genes are expressed</strong>. </p>\n<p>Acetylation and methylation are <strong>epigenetic changes</strong>, i.e, additional DNA changes that alter gene expression without altering the structure of the inherited base sequence of DNA. (Statement 3).</p><p>The organizational unit of the soluble chromatin is the <strong>nucleosome</strong>. Chromatin contain <strong>DNA</strong> and<strong> histones </strong>(small basic proteins), non-histone proteins and RNA (in smaller quantities).</p>\n<p>Four major types of histones:<strong> H2A, H2B, H3, and H4</strong> are <strong>tightly</strong> bound, have a fixed sequence and form the nucleosome, hence called the <strong>core histones</strong>. <strong>H1</strong> histones are <strong>least tightly</strong> bound to chromatin.</p>\n<p>These four core histones undergo covalent <strong>modification</strong> or posttranslational modifications (<strong>PTMs</strong>) (Statement 4). These histone modifications play important roles in chromatin structure and function and can be of 6 types:</p>\n<ul>\n<li>Acetylation</li>\n<li>Methylation</li>\n<li>Phosphorylation</li>\n<li>ADP-ribosylation</li>\n<li>Monoubiquitylation</li>\n<li>Sumoylation. </li>\n</ul>\n<p><strong>Roles</strong> of modified histones:</p>\n<ul>\n<li><strong>Acetylation </strong>of all core histones helps in <strong>chromosomal assembly during DNA replication </strong><strong>(statement 2).</strong></li>\n<li><strong>Methylation</strong> of histones is correlated with repression of <strong>gene transcription.</strong></li>\n<li><strong>Acetylation</strong> of H3 and H4 causes <strong>activation or inactivation of gene transcription</strong>.</li>\n<li>ADP-ribosylation of histones is for<strong> DNA repair</strong>.</li>\n<li>Phosphorylation of histone H1 causes <strong>condensation of chromosomes</strong> during the replication cycle.</li>\n<li>Monoubiquitylation is associated with gene activation, repression, and heterochromatic<strong> gene silencing.</strong></li>\n</ul>\n<p>Note: All PTMs are <strong>reversible</strong> (statement 5). </p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/f0789959f5ed41799df580642e9bba6dx993x932.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Role of Histones</h3><table>\n<tbody>\n<tr>\n<td>\n<p>Types</p>\n</td>\n<td>\n<p>Function</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>H1 histones</p>\n</td>\n<td>\n<p>Stabilize the 30-nm chromatin fiber</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>H2 histones</p>\n</td>\n<td>\n<p>H2A&ndash;H2B dimers stabilize the primary particle and firmly bind two additional half-turns of DNA</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>H3 histones</p>\n</td>\n<td rowspan=\"2\">\n<p>(H3&ndash;H4)2 tetramer has a central role in the formation</p>\n<p>of the nucleosome</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>H4 histones</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/e3e8467046464b4ca2d066565accf54b.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8898",
      "difficulty": "medium"
    },
    {
      "text": "A patient with a history of using well water for cooking and consumption presents with vomiting, diarrhea and abdominal pain. On examination, there is jaundice, hemoglobinuria, Mees lines on the nails, and features of hypovolemic shock. A toxicology screen is done, and the 24-hour urine sample is found to contain high amounts of a toxin.  Which enzyme of Kreb's cycle will be inhibited by this toxin?",
      "choices": [
        {
          "id": 1,
          "text": "Glyceraldehyde 3-phosphate dehydrogenase"
        },
        {
          "id": 2,
          "text": "Alpha-ketoglutarate deydrogenase"
        },
        {
          "id": 3,
          "text": "Aconitase"
        },
        {
          "id": 4,
          "text": "Succinate dehydrogenase"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given clinical scenario is suggestive of <strong>arsenic toxicity</strong>. <strong>Alpha-ketoglutarate dehydrogenase (AKG)</strong> of Kreb's cycle is inhibited by this toxin, <strong>arsenite</strong> (inorganic arsenic salt).</p>\n<p><strong>α-Ketoglutarate </strong>is a rate-determining intermediate in Kreb's cycle. It has a crucial role in cellular energy metabolism as it acts as a precursor of glutamate and glutamine and promotes protein synthesis.</p>\n<p><strong>Alpha-ketoglutarate</strong> undergoes oxidative decarboxylation to form <strong>succinyl-CoA</strong> and CO<sub>2</sub> with the help of the multienzyme complex, <strong>AKG dehydrogenase</strong>. This enzyme complex requires the cofactors, thiamin diphosphate, lipoate, NAD+, flavin adenine dinucleotide (FAD), and coenzyme A.</p>\n<p><strong>Arsenite</strong> inhibits this decarboxylation reaction and causes the substrate, α-ketoglutarate, to accumulate. </p>\n<div class=\"page\" title=\"Page 6797\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Arsenic toxicity </strong>is either due to inhalation of toxic arsenic gas or chronic consumption of foods cooked in contaminated well water. It presents with malaise, headache, nausea, vomiting, abdominal pain, jaundice, hemoglobinuria, and renal failure. There may be <strong>hemorrhagic gastroenteritis, hypovolemic shock, and cardiovascular manifestations</strong> such as QT prolongation, polymorphous ventricular tachycardia, and congestive cardiomyopathy. <strong>Mees lines</strong> is a common dermatologic manifestation characterized by transverse white striae on the nail.</p>\n<p>Arsenic toxicity is detected by measuring the 24-hour urine excretion of arsenic.</p>\n</div>\n</div>\n</div>\n</div><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/37a8b2f16ea247a4b1be3539c7dc55f9x1280x4900.JPEG\" alt=\"Explanation Image\"><p><br />Other options: </p>\n<p>Option A: <strong>Glyceraldehyde 3-phosphate dehydrogenase </strong>is inhibited by <strong>iodoacetate</strong>. It is not a part of Kreb's cycle.</p>\n<p>Option C: <strong>Aconitase</strong> is inhibited by <strong>fluoroacetate</strong>.</p>\n<p>Option D: <strong>Succinate dehydrogenase</strong> is inhibited by <strong>malonate</strong>.</p><hr><h3>Related Pearl: Inhibitors of metabolic pathways</h3><p><strong>Inhibitors of glycolysis</strong></p>\n<table>\n<tbody>\n<tr>\n<td><strong>Agent</strong></td>\n<td><strong>Enzyme</strong></td>\n</tr>\n<tr>\n<td>Iodoacetate</td>\n<td>Glyceraldehyde 3-phosphate dehydrogenase</td>\n</tr>\n<tr>\n<td>Arsenate</td>\n<td>Phosphoglycerate kinase</td>\n</tr>\n<tr>\n<td>Fluoride</td>\n<td>Enolase</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<p><strong>Inhibitors of TCA cycle</strong></p>\n<table>\n<tbody>\n<tr>\n<td><strong>Agent</strong></td>\n<td><strong>Enzyme</strong></td>\n</tr>\n<tr>\n<td>Fluoroacetate</td>\n<td>Aconitase</td>\n</tr>\n<tr>\n<td>\n<div class=\"page\" title=\"Page 176\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Arsenite</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n<td>&alpha;-ketoglutarate dehydrogenase</td>\n</tr>\n<tr>\n<td>Malonate</td>\n<td>Succinate dehydrogenase</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<p><strong>Inhibitors of electron transport</strong></p>\n<table>\n<tbody>\n<tr>\n<td><strong>Complex</strong></td>\n<td><strong>Inhibitors</strong></td>\n</tr>\n<tr>\n<td>Complex I</td>\n<td>Piercidin, Amobarbital, Rotenone</td>\n</tr>\n<tr>\n<td>Complex II</td>\n<td>TTFA, Carboxin, Malonate</td>\n</tr>\n<tr>\n<td>Complex III</td>\n<td>BAL, Antimycin A</td>\n</tr>\n<tr>\n<td>Complex IV</td>\n<td>Hydrogen sulphide, Carbon monoxide, Cyanide</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<p><strong>Inhibitors of oxidative phosphorylation</strong></p>\n<table>\n<tbody>\n<tr>\n<td><strong>Agent</strong></td>\n<td><strong>Mechanism</strong></td>\n</tr>\n<tr>\n<td>Atractyloside</td>\n<td>Inhibits ADP and ATP Transporter</td>\n</tr>\n<tr>\n<td>Oligomycin</td>\n<td>Blocks flow of protons through Fo complex</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Steps involved in TCA cycle</h3><table>\n<tbody>\n<tr>\n<td><strong>Step 1</strong></td>\n</tr>\n<tr>\n<td>\n<p>Acetyl CoA + Oxaloacetate &rarr; Citrate</p>\n<p>&nbsp; &nbsp; &nbsp;(2C &nbsp;+ 4C &nbsp;= &nbsp; 6C)</p>\n<p>Enzyme: Citrate Synthase</p>\n<p><strong>Irreversible</strong>, Exothermic reaction</p>\n</td>\n</tr>\n<tr>\n<td><strong>Step 2</strong></td>\n</tr>\n<tr>\n<td>\n<p>Citrate &rarr; Cis &ndash;aconitate&nbsp; &rarr; Isocitrate&nbsp;</p>\n<p>( 6C &nbsp; &nbsp;&rarr; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;6C &rarr; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 6C)</p>\n<p>Enzyme:&nbsp;&nbsp; <strong>Aconitase</strong></p>\n<p>Cofactor:&nbsp;&nbsp; Fe<sup>2+</sup></p>\n<p>The Reaction occurs in 2 steps: &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</p>\n<p>1<sup>st</sup> step:&nbsp; Dehydration&nbsp; &nbsp; &nbsp;&nbsp;</p>\n<p>2<sup>nd</sup> step:&nbsp; Rehydration</p>\n<p>Inhibited by:<strong> Fluoroacetate (Non- Competitive)</strong></p>\n</td>\n</tr>\n<tr>\n<td><strong>Step 3</strong></td>\n</tr>\n<tr>\n<td>\n<p>Isocitrate &rarr;[Oxalosuccinate]&rarr;&alpha;- Keto glutarate</p>\n<p>&nbsp; &nbsp; &nbsp; &nbsp; (6C) &rarr; &nbsp; &nbsp; &nbsp; &nbsp; [6C] &nbsp; &nbsp; &nbsp; &nbsp; &rarr; &nbsp; &nbsp; &nbsp; &nbsp; (<strong>5C</strong>)</p>\n<p>Enzyme:&nbsp; Isocitrate Dehydrogenase</p>\n<p>Cofactor:&nbsp;&nbsp; Mn<sup>2+ </sup>or Mg<sup>2+</sup></p>\n<p>Reaction: &nbsp;Oxidative &nbsp;Decarboxylation</p>\n<p><strong>Intermediate:&nbsp;&nbsp; Oxalosuccinate [ Unstable]</strong></p>\n<p>Release:&nbsp;&nbsp;&nbsp; 1 NADH and CO2</p>\n</td>\n</tr>\n<tr>\n<td><strong>Step 4</strong></td>\n</tr>\n<tr>\n<td>\n<p>&alpha;- Keto glutarate &rarr; Succcinyl Co A&nbsp;</p>\n<p>&nbsp; &nbsp; &nbsp; &nbsp;(5C &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &rarr; &nbsp; &nbsp; &nbsp; &nbsp; 4C)</p>\n<p>Enzyme: &alpha;- Ketoglutarate Dehydrogenase(Multienzyme complex)</p>\n<p>Reaction:&nbsp; Oxidative Decarboxylation</p>\n<p>Inhibited by: <strong>Arsenite&nbsp; (Non &ndash; Competitive)</strong></p>\n<p>Physiologically <strong>unidirectional</strong> step.</p>\n<p>Release: 1 NADH and CO2</p>\n</td>\n</tr>\n<tr>\n<td><strong>Step 5</strong></td>\n</tr>\n<tr>\n<td>\n<p>Succinyl- CoA&nbsp; &rarr; Succinate</p>\n<p>&nbsp; &nbsp; &nbsp; ( 4C &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&rarr; &nbsp; &nbsp; &nbsp; &nbsp; 4C )</p>\n<p>Enzyme<strong>:&nbsp; Succinate Thiokinase</strong></p>\n<p>Cofactor: Mg<sup>2+</sup></p>\n<p>Release:&nbsp; 1 ATP / GTP</p>\n<p><strong>Substrate level phosphorylation</strong></p>\n</td>\n</tr>\n<tr>\n<td><strong>Step 6</strong></td>\n</tr>\n<tr>\n<td>\n<p>Succinate&nbsp; &rarr;&nbsp;&nbsp; Fumarate</p>\n<p>( 4C &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&rarr; &nbsp; &nbsp; &nbsp; &nbsp; 4C )</p>\n<p>Enzyme:&nbsp; Succinate Dehydrogenase (Part of 2<sup>nd</sup> complex ETC)</p>\n<p>Cofactor:&nbsp; <strong>FAD and Fe-S protein</strong>&nbsp;</p>\n<p>The only enzyme of TCA cycle attached to the <strong>inner</strong> <strong>mitochondrial membrane.</strong></p>\n<p>Inhibited by:&nbsp;<strong>Malonate</strong>&nbsp;(<strong> competitive)</strong></p>\n<p>Release: FADH<sub>2</sub></p>\n</td>\n</tr>\n<tr>\n<td><strong>Step 7</strong></td>\n</tr>\n<tr>\n<td>\n<p>Fumarate&nbsp; &rarr;&nbsp;&nbsp; Malate</p>\n<p>( 4C &nbsp; &nbsp; &nbsp; &nbsp; &rarr; &nbsp; &nbsp; 4C )</p>\n<p>Enzyme:&nbsp; Fumarate Hydratase</p>\n<p>Reaction: Hydration</p>\n</td>\n</tr>\n<tr>\n<td><strong>Step 8</strong></td>\n</tr>\n<tr>\n<td>\n<p>Malate&nbsp; &rarr;&nbsp; Oxaloacetate &nbsp;</p>\n<p>( 4C &nbsp; &nbsp; &rarr; &nbsp; &nbsp; &nbsp; &nbsp;4C )</p>\n<p>Enzyme:&nbsp; Malate Dehydrogenase</p>\n<p>Release:&nbsp; 1 NADH</p>\n<p>Oxaloacetate<strong> is</strong> <strong>regenerated.</strong></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/76825a8fa7b34db89430c4b5211dd573x1280x1018.JPEG\" alt=\"Pearl Image\"><hr><h3>Related Pearl: Arsenic poisoning</h3><p>Summary of Arsenic poisoning</p>\n<p><strong>Source of exposure</strong>:&nbsp;Arsenic-containing pesticides, natural sources - drinking water and soil</p>\n<p><strong>Route of absorption</strong>:&nbsp;GI tract</p>\n<p><strong>Mechanism of action</strong>:&nbsp;binds to sulfhydryl groups and inhibits pyruvate dehydrogenase, gluconeogenesis, glutathione metabolism</p>\n<p>Characteristic clinical findings are as follows: Mnemonic-ARSENIC</p>\n<p><strong>A-&nbsp;</strong>Aldrich mees lines</p>\n<p><strong>R-&nbsp;</strong>raindrop pigmentation, rash,&nbsp;red velvety mucosa</p>\n<p><strong>S-&nbsp;</strong>subendocardial haemorrhage</p>\n<p><strong>E-&nbsp;</strong>Excessive pigmentation- Blackfoot&nbsp;disease</p>\n<p><strong>N-&nbsp;</strong>Neuritis</p>\n<p><strong>I-&nbsp;</strong>Iron oxide + BAL &ndash;treatment</p>\n<p><strong>C-&nbsp;</strong>Cholera like illness</p>\n<p><strong>Diagnosis</strong>:&nbsp;24-hour urine arsenic</p>\n<p><strong>Treatment</strong>:&nbsp;BAL; succimer(DMSA)</p>\n<p>Clinicopathological findings in acute and chronic arsenic poisoning:</p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>System</strong></p>\n</td>\n<td>\n<p><strong>Acute</strong></p>\n</td>\n<td>\n<p><strong>Chronic</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Skin</p>\n</td>\n<td>\n<p>Delayed hair loss (alopecia)</p>\n</td>\n<td>\n<p>Melanosis, Bowen&rsquo;s disease facial edema, hyperkeratosis, cutaneous cancer, hyperpigmentation.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Nails</p>\n</td>\n<td>\n<p>Mees&rsquo;s lines in 2-3 weeks post ingestion.</p>\n</td>\n<td>\n<p><strong>Mees' lines</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Neurologic</p>\n</td>\n<td>\n<p>Hyperpyrexia, convulsions, tremors, coma</p>\n</td>\n<td>\n<p>Encephalopathy, polyneuropathy, tremors, axonal degeneration</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GI tract</p>\n</td>\n<td>\n<p>Abdominal pain, dysphagia, vomiting, bloody or rice water diarrhea, mucosal erosions.</p>\n</td>\n<td>\n<p>Nausea, vomiting, diarrhea, anorexia, weight loss</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Liver</p>\n</td>\n<td>\n<p>Fatty infiltration</p>\n</td>\n<td>\n<p>Hepatomegaly, jaundice, cirrhosis</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Kidney</p>\n</td>\n<td>\n<p>Tubular and glomerular changes &ndash; oliguria and uremia</p>\n</td>\n<td>\n<p>Nephritic finding</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Haemetologic</p>\n</td>\n<td>\n<p>thrombocytopenia, impaired folate metabolism</p>\n</td>\n<td>\n<p>Bone marrow hypoplasia, anemia, leukopenia, basophilic stippling, and karyorrhexis.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Cardiovascular</p>\n</td>\n<td>\n<ul>\n<li>S-T wave abnormalities,</li>\n<li>prolonged QT interval</li>\n<li>ventricular fibrillation</li>\n<li>atypical ventricular tachycardia&nbsp;</li>\n</ul>\n</td>\n<td>\n<p>There is platelet activation and hypercoagulability of blood in peripheral arteries leading to blackfoot disease</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Reproductive system</p>\n</td>\n<td>\n<p>Maternal ingestion of inorganic</p>\n<p>Arsenic crosses the placental barrier and infant death shortly after birth.</p>\n</td>\n<td>\n<p>-Nil-</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF2859",
      "difficulty": "medium"
    },
    {
      "text": "A 4-year-old child has a history of biting his lips and fingers. On evaluation, you notice lip lacerations, missing portions of fingers of his hands, and developmental delay. On inquiry, the parents say that two male cousins on the mother's side with similar complaints have been diagnosed with a genetic disorder. Lab reports reveal hyperuricemia. Which enzyme is most likely deficient in this child?",
      "choices": [
        {
          "id": 1,
          "text": "Purine nucleoside phosphorylase"
        },
        {
          "id": 2,
          "text": "Hypoxanthine-guanine phosphoribosyltransferase"
        },
        {
          "id": 3,
          "text": "Adenine phosphoribosyltransferase"
        },
        {
          "id": 4,
          "text": "Adenosine deaminase"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given clinical scenario of <strong>self-mutilating behavior,</strong> <strong>delayed developmental milestones, positive family history and hyperuricemia</strong> is highly suggestive of <strong>Lesch-Nyhan syndrome</strong>. It occurs due to the <strong>complete&nbsp;deficiency</strong> of<strong>&nbsp;</strong>the enzyme<strong> hypoxanthine-guanine phosphoribosyltransferase (HGPRT)&nbsp;</strong>involved in the salvage pathway.</p>\n<p><strong>Purines</strong> produced in the body or introduced through diet can be converted to <strong>nucleoside triphosphates</strong> to be reused by the body. This pathway is called the <strong>salvage pathway</strong> for purines and is shown below</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/d295845ea4924b19ab07ca33a23f65bex1280x1203.JPEG\" alt=\"Explanation Image\"><p>Lesch-Nyhan syndrome is an <strong>X-linked recessive</strong> disorder due to a complete deficiency of the HGPRT enzyme. This deficiency results in an <strong>inability to salvage</strong> hypoxanthine or guanine resulting in increased levels of <strong>phospho-ribosyl pyrophosphate (PRPP)</strong> and decreased levels of inosine monophosphate (IMP) and guanosine monophosphate (GMP). There is&nbsp;<strong>increased de novo purine synthesis</strong> which produces excessive amounts of<strong> uric</strong> <strong>acid</strong>.</p>\n<p>The clinical features include <strong>compulsive self-mutilation</strong>,&nbsp;intellectual disability, delayed milestones, dystonic movements, and hyperuricemia. The excess uric acid can form kidney stones&nbsp;(<strong>urolithiasis</strong>) or deposit in joints as urate crystals (<strong>gouty arthritis</strong>).</p>\n<p>The treatment of this condition includes:</p>\n<ul>\n<li><strong>Allopurinol</strong>&nbsp;or febuxostat for hyperuricemia</li>\n<li>Behavioral management using restraints for self-mutilation</li>\n<li>High fluid intake, reduced fructose and purine intake</li>\n</ul>\n<p><strong>Partial deficiency</strong> of <strong>HGPRT</strong> leads to&nbsp;<strong>Kelley-Seegmiller syndrome.</strong></p>\n<p>Other options:</p>\n<p>Option A:<strong>Purine nucleoside phosphorylase</strong> deficiency leads to severe T cell deficiency with normal B cell function. Patients present with autoimmune diseases and opportunistic infections.</p>\n<p>Option C:&nbsp;<strong>Adenine phosphoribosyltransferase (APRT)&nbsp;</strong>is another enzyme along with HGPRT to be involved in the salvage of purine bases to nucleotides.&nbsp;</p>\n<p>Option D:&nbsp;<strong>Adenosine deaminase</strong> deficiency leads to sparse or defective T cells and B cells. Patients suffer from sever immunodeficiency and often succumb to fatal infections.&nbsp;</p>\n<div class=\"page\" title=\"Page 346\">&nbsp;</div><hr><h3>Related Pearl: Purine salvage deficiencies: Lesch-Nyhan syndrome and Adenosine deaminase deficiency(SCID)</h3><p><strong>Severe Combined Immunodeficiency(SCID):</strong></p>\n<p><strong>Adenosine deaminase</strong>&nbsp;enzyme deficiency is one of the major cause of SCID. It is also called as&nbsp;<strong>Glanzmann&ndash;Riniker syndrome.</strong></p>\n<p>SCID patients are usually affected by severe bacterial, viral, or fungal infections early in life and often present with interstitial lung disease, chronic diarrhea, and failure to thrive.</p>\n<p><strong>Lesch-Nyhan syndrome:</strong></p>\n<p>It is due to deficiency of the enzyme<strong> Hypoxanthine-guanine phosphoribosyltransferase(HGPRT). </strong>It is an X-linked recessive disease.</p>\n<p>Clinical features:</p>\n<ul>\n<li><span class=\"fontstyle0\">Intellectual disability</span></li>\n<li><span class=\"fontstyle0\">Self-mutilation</span></li>\n<li><span class=\"fontstyle0\">Aggression</span></li>\n<li>Hyperuricemia&nbsp;</li>\n<li><span class=\"fontstyle0\">Gout<br /></span></li>\n</ul>\n<p><span class=\"fontstyle0\">Treatment:</span></p>\n<ul>\n<li><span class=\"fontstyle0\">Allopurinol</span></li>\n<li><span class=\"fontstyle0\">Febuxostat</span></li>\n</ul><hr><h3>Related Pearl: Classification of Gout</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Clinical Category</strong></p>\n</td>\n<td>\n<p><strong>Uric Acid Production</strong></p>\n</td>\n<td>\n<p><strong>Uric Acid Excretion</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Primary Gout (90%)</strong></p>\n</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Unknown enzyme defects</p>\n<p>(85%-90%)</p>\n</td>\n<td>\n<p>&uarr; (majority)</p>\n<p>&uarr;&uarr; (minority)</p>\n<p>Normal</p>\n</td>\n<td>\n<p>Normal</p>\n<p>&uarr;</p>\n<p>&darr;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Secondary Gout (10%)</strong></p>\n</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Increased nucleic acid turnover (e.g., leukemia)</p>\n</td>\n<td>\n<p>&uarr;&uarr;</p>\n</td>\n<td>\n<p>&uarr;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Chronic renal disease</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>&darr;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Congenital (e.g., Lesch-Nyhan syndrome HGPRT deficiency)</p>\n</td>\n<td>\n<p>&uarr;&uarr;</p>\n</td>\n<td>\n<p>&uarr;</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>HGPRT: Hypoxanthine-guanine phosphoribosyltransferase</p><hr><h3>Related Pearl: Enzymes and Steps Involved in Purine Degradation</h3><table>\n<tbody>\n<tr>\n<td>\n<p>Enzymes</p>\n</td>\n<td>\n<p>Reaction</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>AMP deaminase</p>\n</td>\n<td>\n<p>AMP to IMP</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Adenosine deaminase</p>\n</td>\n<td>\n<p>Adenosine to Inosine</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>5'-nucleotidase</p>\n</td>\n<td>\n<p>IMP &amp; GMP to Inosine &amp; Guanosine respectively</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Purine nucleoside phosphorylase</p>\n</td>\n<td>\n<p>Inosine &amp; Guanosine to Hypoxanthine &amp; guanine respectively</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Xanthine oxidase</p>\n</td>\n<td>\n<p>Hypoxanthine to Xanthine &amp; Xanthine to uric acid</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD7937",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following modifications occur posttranscriptionally to produce a mature eukaryotic mRNA?<div class='question-desc-html'><ol>\n<li>Capping</li>\n<li>Polyadenylation</li>\n<li>Phosphorylation</li>\n<li>Trimming</li>\n<li>Splicing</li>\n<li>Hydroxylation</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "1, 2, 4"
        },
        {
          "id": 2,
          "text": "1, 2, 5"
        },
        {
          "id": 3,
          "text": "3, 4, 6"
        },
        {
          "id": 4,
          "text": "3, 5, 6"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Capping</strong>,&nbsp;<strong>polyadenylation</strong>, and&nbsp;<strong>splicing&nbsp;</strong>are the modifications that occur <strong>posttranscriptionally</strong> to produce a mature eukaryotic mRNA.&nbsp;<strong>Phosphorylation</strong>,&nbsp;<strong>hydroxylation</strong>, and&nbsp;<strong>trimming&nbsp;</strong>are modifications that occur&nbsp;<strong>posttranslationally</strong>.</p>\n<p>A mature eukaryotic mRNA is formed after the pre-mRNA components of the heterogenous nuclear RNA (hnRNA) undergo the following posttranscriptional modifications in the nucleus:</p>\n<ol>\n<li><strong>Addition of a 5&prime; cap</strong>: A 7-methylguanosine is attached to the 5&prime; terminal end of the mRNA via a 5&prime;-to-5&prime; triphosphate linkage. This stabilizes the mRNA and allows initiation of translation.</li>\n<li><strong>Addition of a 3&prime;-poly-A tail</strong>: The poly-A tail is added by the nuclear enzyme, polyadenylate polymerase, after clevage of the polyadenylation signal sequence (AAUAAA) found near the 3&prime; end of the mRNA. This terminates eukaryotic transcription. Furthermore, it stabilizes the mRNA, allows it to exit from the nucleus, and helps in translation.</li>\n<li><strong>Splicing</strong>: This is the process of removing introns (intervening sequences that do not code for proteins) and joining exons (the coding or expressed sequences), carried out by the spliceosome. Alternative splicing occurs in different tissues to produce varied number of proteins from a limited set of genes.</li>\n</ol><hr><h3>Related Pearl: Types of RNA</h3><table>\n<tbody>\n<tr>\n<td>\n<p>Protein coding RNA</p>\n</td>\n<td>\n<p>Non Protein coding RNA</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>mRNA</p>\n</td>\n<td>\n<p>Ribosomal RNAs (rRNA)</p>\n<p>Long noncoding RNAs (lncRNAs)</p>\n<p>Transfer RNAs (tRNA)</p>\n<p>Small nuclear RNAs (snRNAs)</p>\n<p>Micro and silencing RNAs (miRNAs and siRNAs)</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "ME4723",
      "difficulty": "easy"
    },
    {
      "text": "A 14-year-old boy is brought to the emergency room with excruciating burning pain over the palms and soles, diarrhea, abdominal pain, and ringing sensation in the ears. On examination, he has thickening of lips, frontal bossing, corneal opacities, and skin lesions as shown in the image below. This X-linked disorder is caused due to which enzyme deficiency?",
      "choices": [
        {
          "id": 1,
          "text": "α-Galactosidase"
        },
        {
          "id": 2,
          "text": "β-Glucosidase"
        },
        {
          "id": 3,
          "text": "Sphingomyelinase"
        },
        {
          "id": 4,
          "text": "Ceramidase"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The given clinical scenario is suggestive of <strong>Fabry's disease</strong> and it is caused due to the deficiency of <strong>α-Galactosidase</strong>.<strong> </strong></p>\n<p><strong>Fabry disease</strong> is an <strong>X-linked</strong>, multisystem,<strong> lysosomal storage disorder</strong> caused due to mutations in the gene that codes for α-Galactosidase, resulting in decreased activity of the enzyme. This leads to accumulation of <strong>globotriaosylceramide</strong>. It is seen in both men and women (less severe).</p>\n<p>It usually manifests in childhood or adolescence, with symptoms of <strong>severe agonizing pain</strong> in the palms of hands, soles of feet, and proximal extremities called <strong>acroparesthesia</strong>, aggravated by changes in temperature, exercise, fatigue, or fever and may last anywhere from a few minutes to many days.</p>\n<p>There is a characteristic facial appearance of <strong>frontal bossing</strong>, thickening of the lips, and prominent supraorbital ridges. <strong>Angiokeratomas,</strong> as seen in the image above are present,<strong> </strong>which are lesions that are dark-red to blue-black, flat or slightly raised, punctate, and usually seen between the umbilicus and the knees (called the '<strong>bathing suit area'</strong>) and the trunk.</p>\n<p>Patients also have diarrhea, abdominal distension, heat intolerance, and tinnitus. Late presentations include <strong>renal failure</strong>, and cardiovascular or cerebrovascular disease, which are the leading causes of death in these patients.</p>\n<p>Urinalysis shows <strong>proteinuria</strong>. An enzyme assay, genetic testing, or a skin or kidney biopsy showing <strong>glycolipid deposits</strong> helps establish the diagnosis.</p>\n<p>Treatment is with <strong>enzyme replacement therapy</strong> (recombinant alpha-Gal A or migalastat).</p>\n<div class=\"layoutArea\">Other options:</div>\n<p>Option B: <strong>β-Glucosidase deficiency </strong>manifests as <strong>Gaucher disease</strong>, which gives rise to symptoms of hepatosplenomegaly, erosion of long bones and mental retardation in infants.</p>\n<p>Option C: <strong>Sphingomyelinase deficiency</strong> manifests as <strong>Niemann-Pick disease</strong>, with patients presenting with symptoms of hepatosplenomegaly and mental retardation. It is usually fatal in early life.</p>\n<p>Option D: <strong>Ceramidase deficiency</strong> manifests as <strong>Farber disease</strong>, characterised by dermatitis, hoarseness, skeletal deformities and mental retardation. It is fatal in early life.</p><hr><h3>Related Pearl: Examples of Sphingolipidoses (Lipids-Storage Disease)</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/eaf86bca861342ff84c303230efbb8bax1280x2017.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td>\n<p><strong>S. No.</strong></p>\n</td>\n<td>\n<p><strong>Disease</strong></p>\n</td>\n<td>\n<p><strong>Enzyme Deficiency</strong></p>\n</td>\n<td>\n<p><strong>Lipid </strong></p>\n<p><strong>Accumulating</strong></p>\n</td>\n<td>\n<p><strong>Clinical Symptoms</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>1</p>\n</td>\n<td>\n<p>Tay–Sachs disease</p>\n</td>\n<td>\n<p>Hexosaminidase A</p>\n</td>\n<td>\n<p>Ganglioside</p>\n</td>\n<td>\n<p>Mental retardation, blindness, muscular weakness</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>2</p>\n</td>\n<td>\n<p>Sandhoff's disease</p>\n</td>\n<td>\n<p>Hexosaminidase A and B</p>\n</td>\n<td>\n<p>Globoside &amp; Ganglioside</p>\n</td>\n<td>\n<p>Similar to Tay–Sachs disease but also has hepatosplenomegaly and skeletal dysplasias</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>3</p>\n</td>\n<td>\n<p>Fabry's disease</p>\n</td>\n<td>\n<p>α-Galactosidase</p>\n</td>\n<td>\n<p>Globotriaosyl-ceramide</p>\n</td>\n<td>\n<p>Skin rash, kidney failure (full symptoms only in males; X-linked recessive)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>4</p>\n</td>\n<td>\n<p>Metachromatic leukodystrophy</p>\n</td>\n<td>\n<p>Arylsulfatase A</p>\n</td>\n<td>\n<p>3-Sulfogalactosyl-ceramide</p>\n</td>\n<td>\n<p>Mental retardation and psychologic disturbances in adults; demyelination</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>5</p>\n</td>\n<td>\n<p>Krabbe disease</p>\n</td>\n<td>\n<p>β-Galactosidase</p>\n</td>\n<td>\n<p>Galactosylceramide</p>\n</td>\n<td>\n<p>Mental retardation; myelin almost absent</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>6</p>\n</td>\n<td>\n<p>Gaucher's disease</p>\n</td>\n<td>\n<p>β-Glucosidase</p>\n</td>\n<td>\n<p>Glucosylceramide</p>\n</td>\n<td>\n<p>Enlarged liver and spleen, erosion of long bones, mental retardation in infants</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>7</p>\n</td>\n<td>\n<p>Niemann–Pick disease</p>\n</td>\n<td>\n<p>Sphingomyelinase</p>\n</td>\n<td>\n<p>Sphingomyelin</p>\n</td>\n<td>\n<p>Enlarged liver and spleen, mental retardation; fatal in early life</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>8</p>\n</td>\n<td>\n<p>Farber's disease</p>\n</td>\n<td>\n<p>Ceramidase</p>\n</td>\n<td>\n<p>Ceramide</p>\n</td>\n<td>\n<p>Hoarseness, dermatitis, skeletal deformation, mental retardation; fatal in early life</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/97c02e25c4004937b64f1f5e0bf6185f.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF3124",
      "difficulty": "medium"
    },
    {
      "text": "Match the type of collagen with its associated disease entity.<div class='question-desc-html'><table>\n<tbody>\n<tr>\n<td><strong>Types of collagen</strong></td>\n<td><strong>Collagen defect disorders</strong></td>\n</tr>\n<tr>\n<td>1. Type I</td>\n<td>\n<p><span data-preserver-spaces=\"true\">A. Stickler syndrome</span></p>\n</td>\n</tr>\n<tr>\n<td>2. Type II</td>\n<td><span data-preserver-spaces=\"true\">B. Alport syndrome</span></td>\n</tr>\n<tr>\n<td>3. Type III</td>\n<td><span data-preserver-spaces=\"true\">C. Ehler Danlos syndrome (vascular subtype)</span></td>\n</tr>\n<tr>\n<td>4. Type IV</td>\n<td><span data-preserver-spaces=\"true\">D. Osteogenesis imperfecta</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div>",
      "choices": [
        {
          "id": 1,
          "text": "1-D, 2-A, 3-B, 4-C"
        },
        {
          "id": 2,
          "text": "1-D, 2-A, 3-C, 4-B"
        },
        {
          "id": 3,
          "text": "1-C, 2-B, 3-A, 4-D"
        },
        {
          "id": 4,
          "text": "1-C, 2-B, 3-D, 4-A"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The correctly matched type of collagen with its associated disease entity is <strong>1-D, 2-A, 3-C, 4-B</strong>. </p>\n<div class=\"page\" title=\"Page 620\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Collagen</strong> is the most abundant protein and approximately 28 types have been isolated. The structure of collagen is a <strong>triple helix</strong> composed of 3 polypeptide chains having <strong>glycine</strong> residues at every third position.</p>\n<p><span>Genetic defects in the various types of collagen found predominantly at specific sites lead to various diseases summarized in the table below.</span></p>\n</div>\n</div>\n</div>\n</div>\n<table>\n<tbody>\n<tr>\n<td>Type of Collagen</td>\n<td>Distribution</td>\n<td>Defect</td>\n</tr>\n<tr>\n<td>Type I</td>\n<td>\n<div class=\"page\" title=\"Page 604\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Noncartilaginous connective tissues, including bone, tendon, skin</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n<td>Osteogenesis imperfecta</td>\n</tr>\n<tr>\n<td>Type II</td>\n<td>\n<div class=\"page\" title=\"Page 604\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Cartilage, vitreous humor</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n<td>Stickler syndrome</td>\n</tr>\n<tr>\n<td>Type III</td>\n<td>\n<div class=\"page\" title=\"Page 604\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Extensible connective tissues, including skin, lung, and vascular system</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n<td>\n<p>Ehler Danos syndrome (Vascular sub-type)</p>\n</td>\n</tr>\n<tr>\n<td>Type IV</td>\n<td> \n<div class=\"page\" title=\"Page 604\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Basement membranes</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n<td>Alport syndrome</td>\n</tr>\n<tr>\n<td>Type VII</td>\n<td> \n<div class=\"page\" title=\"Page 604\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Dermal-epidermal junction</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n<td>Epidermolysis bullosa aquisita</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<div class=\"page\" title=\"Page 3016\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p> </p>\n<p>In <strong>osteogenesis imperfecta</strong>, there is a severe decrease in bone mass that makes bones brittle, associated with blue sclerae, dental abnormalities, progressive hearing loss, and positive family history.</p>\n<p><strong>Stickler syndrome</strong> is characterized by skeletal changes, orofacial abnormalities, and auditory abnormalities.</p>\n<p>In <strong>Ehler Danlos syndrome</strong> ( vascular subtype ) there are features of classic EDS ( skin and joint involvement ) as well as severe muscular hypotonia after birth, progressive kyphoscoliosis, osteopenia, occasional rupture of the eye globe, and great arteries.</p>\n<div class=\"page\" title=\"Page 3019\"><strong>Alport syndrome</strong> is characterized by the presence of a genetically abnormal basement membrane giving rise to proteinuria and hematuria.</div>\n</div>\n</div>\n</div>\n</div><hr><h3>Related Pearl: Types of Collagen</h3><table>\n<tbody>\n<tr>\n<td><strong>Collagen subtypes&nbsp; &nbsp;</strong></td>\n<td><strong>Location</strong>&nbsp;</td>\n<td>&nbsp;\n<p><strong>Associated disease&nbsp;</strong></p>\n</td>\n</tr>\n<tr>\n<td><strong>Type 1</strong></td>\n<td>\n<p>Dermis&nbsp;</p>\n<p>Bone&nbsp;</p>\n<p>Tendons&nbsp;</p>\n<p>Ligaments</p>\n<p>Dentin</p>\n<p>Cornea</p>\n<p>Blood Vessels&nbsp;</p>\n<p>Scar tissue</p>\n</td>\n<td>\n<p>Osteogenesis Imperfecta</p>\n&nbsp;</td>\n</tr>\n<tr>\n<td><strong>Type 2</strong></td>\n<td>\n<p>Cartilage&nbsp;</p>\n<p>Vitreous humor&nbsp;</p>\n<p>Nucleus pulposus</p>\n</td>\n<td>&nbsp;Stickler syndrome</td>\n</tr>\n<tr>\n<td><strong>Type 3</strong></td>\n<td>\n<p>Skin&nbsp;</p>\n<p>Lung&nbsp;</p>\n<p>Intestines&nbsp;</p>\n<p>Blood Vessels&nbsp;</p>\n<p>Bone marrow&nbsp;</p>\n<p>Lymphatics&nbsp;</p>\n<p>Granulation tissue</p>\n</td>\n<td>\n<p>Ehler-Danlos syndrome&nbsp;&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td><strong>Type 4</strong></td>\n<td>\n<p>Basement membrane&nbsp;</p>\n&nbsp;</td>\n<td>Alport syndrome&nbsp;</td>\n</tr>\n<tr>\n<td><strong>Type 7</strong></td>\n<td>\n<p>Dermo-epidermal junction</p>\n</td>\n<td>Epidermolysis bullosa acquisita</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Synthesis of collagen and its disorders</h3><table>\n<tbody>\n<tr>\n<td>1. Collagen backbone</td>\n<td>Preprocollagen - Glycin-proline-lysine</td>\n</tr>\n<tr>\n<td>2. Hydroxylation</td>\n<td>\n<p>Of proline and lysine in the presence of Vit C.</p>\n<p>Deficiency of Vit C causes <strong>Scurvy.</strong></p>\n</td>\n</tr>\n<tr>\n<td>3. Glycosylation</td>\n<td>Formation of procollagen and resulting triple helix</td>\n</tr>\n<tr>\n<td>4. Cleavage of terminals of procollagen</td>\n<td>Resulting in the formation of tropocollagen</td>\n</tr>\n<tr>\n<td>5. Cross-linking by lysyl oxidase (copper-containing enzyme)</td>\n<td>\n<p>Formation of mature collagen.</p>\n<p>Defect causes <strong>Menkes disease</strong> and <strong>Ehlers-Danlos syndrome</strong>)</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD8810",
      "difficulty": "easy"
    },
    {
      "text": "A patient comes to you with vitamin D deficiency. You advise the patient to take a walk under sufficient sunlight everyday. What is the correct sequence of products formed during vitamin D synthesis?<div class='question-desc-html'><ol>\n<li>7-dehydrocholesterol</li>\n<li>Cholecalciferol</li>\n<li>25-hydroxycholecalciferol</li>\n<li>1,25-dihydroxycholecalciferol</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "4-3-2-1"
        },
        {
          "id": 2,
          "text": "1-2-3-4"
        },
        {
          "id": 3,
          "text": "1-3-2-4"
        },
        {
          "id": 4,
          "text": "1-4-3-2"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The correct sequence of products formed during vitamin D synthesis is <strong>1-2-3-4</strong>.</p>\n<p>Vitamin D is obtained by synthesis in the skin with adequate sunlight exposure or dietary supplementation. It helps in regulating calcium absorption and homeostasis. Deficiency results in rickets in children and osteomalacia in adults and is a common problem in areas with inadequate sunlight.</p>\n<p>The sequence of vitamin D synthesis is:</p>\n<ol>\n<li><strong>Skin</strong>:&nbsp;<strong>7-dehydrocholesterol</strong>&nbsp;is nonenzymatically converted to <strong>previtamin D</strong> on exposure to ultraviolet light. It is converted to&nbsp;<strong>cholecalciferol</strong>, which then enters the bloodstream.</li>\n<li><strong>Liver</strong>:&nbsp;Cholecalciferol is hydroxylated to form&nbsp;<strong>25-hydroxyvitamin D&nbsp;</strong>(calcidiol), which is bound to a vitamin D-binding globulin and released into the bloodstream. This is the <strong>main storage form</strong> of vitamin D.&nbsp;</li>\n<li><strong>Kidney</strong>:<strong>&nbsp;</strong><strong>25-hydroxyvitamin D&nbsp;</strong>is further hydroxylated to form&nbsp;<strong>1,25 dihydroxyvitamin D</strong> (calcitriol). This is the <strong>biologically active form</strong> of vitamin D. In some cases, it can also undergo 24-hydroxylation to form an inactive metabolite called 24,25-dihydroxyvitamin D.</li>\n</ol>\n<p>The steps of vitamin D synthesis are summarized below.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/fde3485fa4914eaeae335f36ce978ac3x1280x1630.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Fat-soluble vitamins</h3><table>\n<tbody>\n<tr>\n<td rowspan=\"2\"><strong>Vitamin</strong></td>\n<td rowspan=\"2\"><strong>Active form</strong></td>\n<td rowspan=\"2\"><strong>Deficiency</strong></td>\n<td rowspan=\"2\"><strong>Toxicity</strong></td>\n<td colspan=\"3\"><strong>Required dietary allowance</strong></td>\n</tr>\n<tr>\n<td>Children</td>\n<td>Male</td>\n<td>Female</td>\n</tr>\n<tr>\n<td>Vitamin A</td>\n<td>\n<p>Retinol</p>\n<p>Retinal</p>\n<p>Retinoic acid</p>\n</td>\n<td>\n<p>Night blindness, xerophthalmia,</p>\n<p>Acne, psoriasis,</p>\n<p>Impaired immunity</p>\n</td>\n<td>\n<p>Affects lysosomes</p>\n<p>Acute- pseudotumor cerebrii, exfoliative dermatitis</p>\n<p>Chronic-fractures</p>\n</td>\n<td>\n<p>390-630mcg (1-9 years)</p>\n<p>770-1000mcg (10-18 years)</p>\n</td>\n<td>1000mcg&nbsp;</td>\n<td>&nbsp;\n<p>Adult - 840mcg</p>\n<p>Pregnancy - 900mcg</p>\n<p>Lactation - 950 mcg</p>\n</td>\n</tr>\n<tr>\n<td>Vitamin D</td>\n<td>1,25-Dihydro-cholecalciferol</td>\n<td>\n<p>Children- Rickets</p>\n<p>Adults-osteomalacia</p>\n</td>\n<td>Calcinosis</td>\n<td>&nbsp;\n<p>400 IU (&lt;1 year)</p>\n<p>600 IU (&gt;1 year)</p>\n</td>\n<td>&nbsp;600 IU</td>\n<td>\n<p>Adult - 600 IU</p>\n<p>Pregnancy - 600 IU</p>\n<p>Lactation - 600 IU</p>\n</td>\n</tr>\n<tr>\n<td>Vitamin E</td>\n<td>&alpha;-tocopherol</td>\n<td>\n<p>Hemolytic anemia,</p>\n<p>axonal degeneration,</p>\n<p>spinocerebellar ataxia</p>\n</td>\n<td>\n<p>Reduced platelet aggregation,&nbsp;</p>\n<p>Interferes with vitamin K</p>\n</td>\n<td>&nbsp;5-8 mg</td>\n<td>&nbsp;10 mg</td>\n<td>\n<p>Adult - 8 mg</p>\n<p>Pregnancy - 10 mg</p>\n<p>Lactation - 12 mg</p>\n</td>\n</tr>\n<tr>\n<td>Vitamin K</td>\n<td>\n<p>Menedione</p>\n<p>Menoquinone</p>\n<p>Phyloquinone</p>\n</td>\n<td>\n<p>Elevated prothrombin time and bleeding</p>\n<p>Haemorrhagic disease of newborn</p>\n</td>\n<td>\n<p>Hemolysis</p>\n<p>Hyperbilirubinemia</p>\n<p>Kernicterus</p>\n</td>\n<td>\n<p>&lt;1 year - 2-3&nbsp;&micro;g</p>\n<p>Children - 30-50&nbsp;&micro;g</p>\n&nbsp;</td>\n<td>55 &micro;g&nbsp;</td>\n<td>55 &micro;g&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Note:The <strong>RDA</strong> for <strong>Vitamin D</strong> in the <strong>elderly</strong> (&gt;60 years) is <strong>800 IU</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF0719",
      "difficulty": "easy"
    },
    {
      "text": "A father reports to a pediatrician that his daughter has episodes of lethargy, irritability, and vomiting right after she drinks any fruit juice. Urinalysis after such an episode was positive for Benedict's test. Which of the following enzyme deficiencies is likely in this girl?",
      "choices": [
        {
          "id": 1,
          "text": "Aldolase B"
        },
        {
          "id": 2,
          "text": "Fructokinase"
        },
        {
          "id": 3,
          "text": "Glucose 6-phosphatase"
        },
        {
          "id": 4,
          "text": "Hexokinase"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The given case scenario with symptoms occurring after ingesting fruit juices (containing fructose) points to the diagnosis of <strong>hereditary fructose intolerance</strong>, and<strong> aldolase B </strong>enzyme deficiency seen here.</p>\n<div class=\"page\" title=\"Page 1228\"><strong>Fructose-1,6- bisphosphate aldolase/ aldolase B</strong> is present in the liver, kidney, and intestine. It catalyzes the hydrolysis of fructose-1,6-bisphosphate into triose phosphate and glyceraldehyde phosphate. It also hydrolyzes <strong>fructose-1-phosphate.</strong></div>\n<div class=\"page\" title=\"Page 1228\"> </div>\n<div class=\"page\" title=\"Page 1228\">Hereditary fructose intolerance is an <strong>autosomal recessive</strong> condition, caused by pathogenic variations in the <strong>ALDOB</strong> gene which causes aldolase deficiency.</div>\n<div class=\"page\" title=\"Page 1228\"> </div>\n<div class=\"page\" title=\"Page 1228\">Patients are <strong>asymptomatic until fructose or sucrose </strong>is<strong> ingested</strong> (usually from fruit, fruit juice, sweetened cereal, or table sugar). It usually presents during <strong>infancy</strong> when sugar-containing feeds are introduced, but some patients (who are less sensitive) can present at older ages as well. Clinical features include <strong>jaundice, hepatomegaly, vomiting, lethargy, irritability, </strong>and<strong> convulsions. Acute</strong> ingestion causes <strong>symptomatic hypoglycemia</strong>. <strong>Chronic</strong> intake results in <strong>failure to thrive, hepatic disease, kidney failure, </strong>and<strong> death.</strong></div>\n<div class=\"page\" title=\"Page 1228\"><strong> </strong></div>\n<div class=\"page\" title=\"Page 1228\"><strong>Reducing substances</strong> are seen in the urine during an episode (<strong>Benedict's test positive</strong>) as fructose is a reducing sugar. <strong>Reduced </strong>levels<strong> </strong>of <strong>aldolase B activity</strong> in the <strong>liver</strong> and demonstration of<strong> two pathogenic variants in ALDOB</strong> on molecular genetic testing give a <strong>definitive diagnosis</strong>.</div>\n<div class=\"page\" title=\"Page 1228\"> </div>\n<div class=\"page\" title=\"Page 1228\">Treatment involves <strong>complete cessation</strong> of all sources of sucrose, fructose, and sorbitol from the diet.</div>\n<div class=\"page\" title=\"Page 1228\"> </div>\n<div class=\"page\" title=\"Page 1228\">The image summarizes the metabolic pathways involved in the metabolism of fructose.</div><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/2a4d4759616f486d89e5abd10d6436dbx1280x1831.JPEG\" alt=\"Explanation Image\"><p><br />Other options:<br /><br />Option B: <strong>Fructokinase</strong> converts fructose to fructose-1-phosphate, the deficiency of which can give rise to essential fructosuria. <strong><span class=\"mim-highlighted mim-highlight\">Essential fructosuria</span></strong> is a benign, asymptomatic defect of intermediary metabolism characterized by the intermittent appearance of fructose in the urine.</p>\n<p>Option C: <strong>Glucose-6-phosphatase</strong> is located in the endoplasmic reticulum (ER) and catalyzes the hydrolysis of glucose-6-phosphate to <span class=\"mim-highlighted mim-highlight\">glucose</span> and phosphate. The deficiency of this enzyme leads to von Gierke disease characterised by hypoglycemia, growth retardation, and hepatomegaly.</p>\n<p>Option D: <strong>Hexokinases</strong> catalyse the first step in glucose metabolism, i.e, phosphorylation of intracellular glucose.</p><hr><h3>Related Pearl: Important Disaccharides and Their Compositions</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Disaccharides</strong></p>\n</td>\n<td>\n<p><strong>Monosaccharide units</strong></p>\n</td>\n<td>\n<p><strong>Linkage</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Maltose</p>\n</td>\n<td>\n<p>glucose + glucose</p>\n</td>\n<td>\n<p>α-1,4</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Isomaltose</p>\n</td>\n<td>\n<p>glucose + glucose</p>\n</td>\n<td>\n<p>α-1,6</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Lactose</p>\n</td>\n<td>\n<p>galactose + glucose </p>\n</td>\n<td>\n<p>β-1,4</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Lactulose</p>\n</td>\n<td>\n<p>galactose + fructose</p>\n</td>\n<td>\n<p>β-1,4</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Sucrose</p>\n</td>\n<td>\n<p>glucose+fructose</p>\n</td>\n<td>\n<p>α-1,ß-2</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Trehalose</p>\n</td>\n<td>\n<p>glucose+glucose</p>\n</td>\n<td>\n<p>α-1,1</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Glycogen Storage Diseases</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/782e85c36f0648698a222dca988adfabx1280x1863.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Disease</strong></p>\n</td>\n<td>\n<p><strong>Enzyme deficiency</strong></p>\n</td>\n<td>\n<p><strong>Symptoms</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type 0</p>\n</td>\n<td>\n<p>Glycogen synthase</p>\n</td>\n<td>\n<p>Hypoglycemia</p>\n<p>Early death</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type Ia</p>\n<p><strong>Von Gierke's disease</strong></p>\n</td>\n<td>\n<p>Glucose-6- phosphatase</p>\n</td>\n<td>\n<p>Hepatomegaly and renomegaly&nbsp;due to glycogen accumulation</p>\n<p>Severe fasting hypoglycemia</p>\n<p>Growth failure</p>\n<p>Lactic acidosis</p>\n<p>Hyperuricemia</p>\n<p>Hyperlipidemia</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type Ib</p>\n</td>\n<td>\n<p>Endoplasmic reticulum glucose-6- phosphate transporter</p>\n</td>\n<td>\n<p>Same as Von Gierke's disease</p>\n<p>Recurrent infections due to impaired neutrophil function</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type II</p>\n<p><strong>Pompe's disease</strong></p>\n</td>\n<td>\n<p>Lysosomal &alpha;1,4:1,6 glucosidase</p>\n<p>(Acid maltase)</p>\n</td>\n<td>\n<p>Muscle weakness</p>\n<p>Death by age ~ 2 years (infantile variant)</p>\n<p>Cardiomegaly and heart failure</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type III</p>\n<p><strong>Cori's/Forbes disease</strong></p>\n<p>(Limit dextrinosis)</p>\n</td>\n<td>\n<p>Glycogen debranching enzyme</p>\n</td>\n<td>\n<p>Muscle weakness</p>\n<p>Fasting hypoglycemia</p>\n<p>Hepatomegaly due to accumulation of branched-chain polysaccharide (limit dextrins)</p>\n<p>Growth retardation</p>\n<p>Normal lactate and uric acid levels</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type IV</p>\n<p><strong>Andersen disease</strong></p>\n</td>\n<td>\n<p>Glycogen branching enzyme</p>\n</td>\n<td>\n<p>Failure to thrive</p>\n<p>Hepatomegaly due to accumulation of polysaccharides with few branch points</p>\n<p>Death at age ~ 5 years</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type V</p>\n<p><strong>McArdle disease</strong></p>\n</td>\n<td>\n<p>Muscle glycogen phosphorylase</p>\n</td>\n<td>\n<p>Exercise-induced cramps</p>\n<p>Renal failure due to rhabdomyolysis and myoglobinuria</p>\n<p>Second wind phenomenon</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type VI</p>\n<p><strong>Her's disease</strong></p>\n</td>\n<td>\n<p>Liver glycogen phosphorylase</p>\n</td>\n<td>\n<p>Generally benign</p>\n<p>Mild hypoglycemia</p>\n<p>Hepatomegaly</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type VII</p>\n<p><strong>Tarui's disease</strong></p>\n</td>\n<td>\n<p>Muscle phosphofructokinase</p>\n</td>\n<td>\n<p>Exercise-induced muscle cramps and weakness</p>\n<p>Growth retardation</p>\n<p>Hemolytic anemia</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF2950",
      "difficulty": "medium"
    },
    {
      "text": "A patient died due to poisoning with a substance that inhibits the complex of the electron transport chain that is marked in the image below. Which of the following is likely to be the substance?",
      "choices": [
        {
          "id": 1,
          "text": "Rotenone"
        },
        {
          "id": 2,
          "text": "Oligomycin"
        },
        {
          "id": 3,
          "text": "Carbon monoxide"
        },
        {
          "id": 4,
          "text": "Antimycin A"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>In the given image, the complex of the electron transport chain shown is<strong> complex IV</strong>&nbsp;and<strong> carbon monoxide</strong> <strong>inhibits complex IV</strong>.</p>\n<div class=\"page\" title=\"Page 74\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Molecules like glucose undergo a series of oxidation reactions to produce CO<sub>2</sub> and water. The metabolic intermediates of these reactions donate electrons to NAD and FAD to form NADH and FADH2. They, in turn, donate a pair of electrons to a specialized set of electron carriers called the electron transport chain.&nbsp;</p>\n<p>The electron chain is present in the inner mitochondrial membrane. It has are 4 protein complexes, named complex-I, II, III, and IV. These complexes are connected by two carriers- co-enzyme Q and cytochrome C. The complexes and their inhibitors are summarized below.</p>\n</div>\n</div>\n</div>\n<table>\n<tbody>\n<tr>\n<td><strong>Complexes of ETC</strong></td>\n<td>&nbsp; <strong>Inhibitors</strong></td>\n</tr>\n<tr>\n<td><strong>Complex I</strong>: NADH-Q oxidoreductase</td>\n<td>Piericidin, amobarbital, <strong>rotenone</strong></td>\n</tr>\n<tr>\n<td>Complex II: Succinate-Q reductase</td>\n<td>Carboxin, malonate</td>\n</tr>\n<tr>\n<td><strong>Complex III</strong>: Q- cyt c oxidoreductase</td>\n<td>BAL(British anti-lewisite), <strong>antimycin A</strong></td>\n</tr>\n<tr>\n<td><strong>Complex IV</strong>:&nbsp; cytochrome c oxidase</td>\n<td>Hydrogen sulfide, <strong>carbon monoxide,</strong> <strong>cyanide</strong></td>\n</tr>\n<tr>\n<td>&nbsp;ATP synthase</td>\n<td>Oligomycin</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<p>The following image shows different compounds inhibiting the different components in an electron transport chain.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/1e6d472e821e46bd8c023a35fa29cba8x1279x969.JPEG\" alt=\"Explanation Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/2f4b1ba01a024ffb882213ce4728cc3b.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0512",
      "difficulty": "easy"
    },
    {
      "text": "You are conducting a study on bactericidal activity of immune cells. You find that defects in the metabolism of a particular amino acid lead to dysfunction of nitric oxide production. Identify the involved amino acid.",
      "choices": [
        {
          "id": 1,
          "text": "Serine"
        },
        {
          "id": 2,
          "text": "Alanine"
        },
        {
          "id": 3,
          "text": "Arginine"
        },
        {
          "id": 4,
          "text": "Glutamine"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The involved amino acid is <strong>arginine</strong>, which is required for the production of<strong>&nbsp;nitric oxide (NO)</strong>.</p>\n<p><strong>NO&nbsp;</strong>is an inflammatory mediator synthesized from<strong> arginine</strong> by a calcium-dependent reaction catalyzed by <strong>NO synthase.</strong></p>\n<p>The given image shows the process of nitric oxide synthesis.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/d4d296afd572416f9035ec3f67645237x435x243.PNG\" alt=\"Explanation Image\"><p><strong>The co-enzymes </strong>of NO synthase are :</p>\n<ul>\n<li><strong>FMN</strong></li>\n<li><strong>FAD</strong></li>\n<li><strong>Heme</strong></li>\n<li><strong>Tetrahydrobiopterin (BH4)</strong></li>\n</ul>\n<p><strong>Three isoenzymes</strong> of NO synthase:</p>\n<ul>\n<li><strong>eNOS</strong> (endothelial nitric oxide synthase): Found in the endothelium and plays a role in vasodilatation. It is calcium-calmodulin dependent.</li>\n<li><strong>nNOS</strong> (neural nitric oxide synthase): Found in the neural tissue and acts as a neurotransmitter.&nbsp;It is calcium-calmodulin dependent.</li>\n<li><strong>iNOS</strong> (inducible nitric oxide synthase): TNF-&alpha;, IFN-&gamma; and bacterial endotoxins induce&nbsp;hepatocytes, macrophages, monocytes, and neutrophils to produce this enzyme. It is inducible and calcium independent.</li>\n</ul>\n<p>Functions of NO:</p>\n<div class=\"page\" title=\"Page 150\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<ul>\n<li><strong>Vasodilator</strong>: NO activates the cytosolic form of guanylate cyclase. This increases cGMP, activates protein kinase G, inactivates myosin light-chain kinase and thereby produces<strong>&nbsp;smooth muscle relaxation.</strong></li>\n<li><strong>Macrophage bactericidal activity</strong>: Production of NO synthase is stimulated by bacterial lipopolysaccharide and&nbsp;IFN-&gamma; released in response to infection. The NO formed combines with superoxide radicals from macrophages to form the&nbsp;<strong>OH radical</strong>&nbsp;which is highly bactericidal.&nbsp;</li>\n<li><strong>Inhibitor of platelet aggre&shy;gation</strong>&nbsp;(by activating the cGMP pathway)</li>\n<li><strong>Neurotransmitter</strong>&nbsp;in the brain.</li>\n</ul>\n</div>\n</div>\n</div><hr><h3>Related Pearl: Amino Acid Derivatives</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/7b53b3afcc1c47e792f684ad0097deeex1280x1310.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA7259",
      "difficulty": "easy"
    },
    {
      "text": "What is the correct sequence of events in Southern blotting?<div class='question-desc-html'><p>1 - Transfer to a membrane<br />2 - Hybridization with a labeled probe sequence<br />3 - Separation of DNA fragments by electrophoresis</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "1, 2, 3"
        },
        {
          "id": 2,
          "text": "2, 1, 3"
        },
        {
          "id": 3,
          "text": "3, 1, 2"
        },
        {
          "id": 4,
          "text": "2, 3, 1"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>In Southern blotting<strong> DNA fragments </strong>are first separated by<strong> electrophoresis.</strong></p>\n<ul>\n<li>The DNA in the gel is then made single-stranded by exposure to dilute alkali, and transferred by capillary action to the nylon membrane, which is laid over it. The relative positions of the different DNA fragments are thus preserved on the membrane.</li>\n<li>The membrane is then soaked in buffer containing the labelled probe, which base pairs with the DNA fragment of interest.</li>\n<li>The position of that fragment is then determined by autoradiographic (exposure of the membrane to X-ray film), or fluorescent detection of the hybridized probe.</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/7a976265f58f462db822daefeb3bf6a9x800x494.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB2810",
      "difficulty": "medium"
    },
    {
      "text": "Match the following urine tests with respective substances they detect.<div class='question-desc-html'><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Test</strong></p>\n</td>\n<td><strong>Substance</strong></td>\n</tr>\n<tr>\n<td>\n<p>1. Rothera test</p>\n</td>\n<td>A. Urobilinogen</td>\n</tr>\n<tr>\n<td>\n<p>2. Benedict's test</p>\n</td>\n<td>B. Bile salts</td>\n</tr>\n<tr>\n<td>\n<p>3. Hay's test</p>\n</td>\n<td>C. Glucose</td>\n</tr>\n<tr>\n<td>\n<p>4. Ehrlich's test</p>\n</td>\n<td>D. Acetoacetate</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div>",
      "choices": [
        {
          "id": 1,
          "text": "1-D, 2-A, 3-B, 4-C"
        },
        {
          "id": 2,
          "text": "1-D, 2-C, 3-B, 4-A"
        },
        {
          "id": 3,
          "text": "1-D, 2-C, 3-A, 4-B"
        },
        {
          "id": 4,
          "text": "1-A, 2-C, 3-B, 4-D"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The correctly matched option is <strong>1-D, 2-C, 3-B,</strong><strong> 4-A.</strong></p>\n<p><strong>Rothera’s test</strong> by <strong>nitroprusside reagent</strong> is a specific test used to detect whether <strong>acetone</strong> or <strong>acetoacetate</strong> is present in the given sample of urine. A <strong>purple ring</strong> at the junction of two liquids indicates a positive test. Rothera's test does <strong>not detect</strong> β-hydroxybutyrate.  </p>\n<p>The other test used for the purpose of detecting <strong>acetoacetate</strong> <strong>only</strong> is the <strong>ferric chloride test</strong>. It shows a burgundy red color that is graded from +1 to +4. False-positive results occur with drugs like salicylates and phenols. </p>\n<p>The image below shows the purple ring formed by a positive Rothera test.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/049db47cd2da4b4a8c7d42d7e9ae4d46x720x540.JPEG\" alt=\"Explanation Image\"><p> </p>\n<p><strong>Benedict's test</strong> is a test commonly used in the follow-up of diabetics for the detection of <strong>glucose</strong> in urine (glucosuria). It uses Benedict's reagent containing sodium carbonate, copper sulfate, and sodium citrate. <strong>Reducing sugars </strong>(containing a free aldehyde/ keto group) will reduce Benedict's reagent. Examples include glucose, fructose, and lactose.</p>\n<div class=\"page\" title=\"Page 333\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>The test is a semi-quantitative test. The blue color indicates no reducing sugar. </p>\n<table>\n<tbody>\n<tr>\n<td><strong>Color</strong></td>\n<td><strong>Concentration</strong></td>\n</tr>\n<tr>\n<td>Green</td>\n<td>0.5 g%</td>\n</tr>\n<tr>\n<td>Yellow</td>\n<td>1 g%</td>\n</tr>\n<tr>\n<td>Orange</td>\n<td>1.5 g%</td>\n</tr>\n<tr>\n<td>Red</td>\n<td>2 g%</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n</div>\n</div><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/95a57e39e46642aa9585b57c2b99553ax720x404.JPEG\" alt=\"Explanation Image\"><p> </p>\n<p><strong>Hay's test </strong>is used for the detection of<strong> bile salts </strong>in<strong> urine. </strong>Normally, bile salts (sodium salts of taurocholic acid and glycocholic acid) are not present in urine. Thus, <strong>positive Hay's test</strong> indicates an <strong>obstructive</strong> pathology in the biliary system, leading to the backflow of bile into the circulation. This obstruction may be associated with either obstructive jaundice or hepatic jaundice.</p>\n<p><strong>Ehrlich's test </strong>is used to determine urinary and fecal<strong> urobilinogen.</strong> </p>\n<p>Porphobilinogens form a <strong>red aldehyde compound</strong> with Ehrlich reagent, which is insoluble in chloroform. A red color remaining after chloroform extraction is indicative of porphobilinogens. This test is positive in acute intermittent porphyria and hemolytic jaundice. It is negative in hepatic jaundice (later stages) and obstructive jaundice. The earliest sign of recovery in obstructive jaundice is the re-appearance of urobilinogen in urine.</p><hr><h3>Related Pearl: Rothera's Test Procedure</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/73b9ba92c9384966a6760940ce51d4fcx287x140.JPEG\" alt=\"Pearl Image\"><p>Rothera's test, positive for ketone bodies.</p><hr><h3>Related Pearl: Color of urine  in different conditions</h3><p>Normal color of urine is <strong>pale straw</strong> due to presence of <strong>urochrome.</strong></p>\n<table>\n<tbody>\n<tr>\n<td><strong>Abnormality</strong></td>\n<td><strong>Cause</strong></td>\n</tr>\n<tr>\n<td>Smokey or cloudy</td>\n<td>\n<ul>\n<li>AGN</li>\n<li>Nephrotic syndrome</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>Gross blood</td>\n<td>\n<ul>\n<li>Urological causes&nbsp; &nbsp; &nbsp;</li>\n<li>Nephro causes</li>\n<li>Hematological causes, e.g. PNH</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>Red without blood [brownish tinge]</td>\n<td>\n<ul>\n<li>Rhabdomyolysis&nbsp; &nbsp;</li>\n<li>Beetroot ingestion&nbsp;</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>Tea- or cola-colored urine</td>\n<td>Hemoglobinuria</td>\n</tr>\n<tr>\n<td>High-colored urine</td>\n<td>Bilirubinuria</td>\n</tr>\n<tr>\n<td>Darkens on standing</td>\n<td>Alkaptonuria</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<p>&nbsp;Due to Drugs:&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Abnormality&nbsp;</strong></td>\n<td><strong>Drugs&nbsp;</strong></td>\n</tr>\n<tr>\n<td>Orange</td>\n<td>\n<ul>\n<li>Rifamycins (rifampicin, rifabutin, rifapentine)</li>\n<li>B-complex&nbsp;</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>Blue</td>\n<td>\n<ul>\n<li>Amitriptyline</li>\n<li>Methylene blue</li>\n<li>Copper poisoning</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>Brown</td>\n<td>\n<ul>\n<li>Chloroquine</li>\n<li>Quinine</li>\n<li>Primaquine</li>\n<li>Nitrofurantoin&nbsp;</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>Yellow</td>\n<td>Tetracycline&nbsp;</td>\n</tr>\n<tr>\n<td>Pinkish</td>\n<td>Deferoxamine</td>\n</tr>\n<tr>\n<td>Green</td>\n<td>Triamterene</td>\n</tr>\n<tr>\n<td>Darkens on standing</td>\n<td>\n<ul>\n<li>Metronidazole</li>\n<li>Methyldopa</li>\n<li>Imipenem-cilastin</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD4012",
      "difficulty": "easy"
    },
    {
      "text": "A person cycles for 4 hours on an empty stomach, causing glycogen to break down and release glucose. After reaching home, he has a full meal, leading to glucose being stored as glycogen. Which of the following enzymes is used in both these processes?",
      "choices": [
        {
          "id": 1,
          "text": "Alpha 1,6 glucosidase"
        },
        {
          "id": 2,
          "text": "Glycogen phosphorylase"
        },
        {
          "id": 3,
          "text": "Phosphoglucomutase"
        },
        {
          "id": 4,
          "text": "Glycogen synthase"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>In the given scenario, the person undergoes <strong>glycogenolysis</strong> to break down glycogen and release glucose and then undergoes <strong>glycogenesis</strong> in which glucose gets stored as glycogen. <strong>Phosphoglucomutase</strong> is involved in both glycogenesis and glycogenolysis.</p>\n<p>The substrate for glycogenolysis is glycogen and during this process, glycogen is first converted into glucose-1-phosphate by the enzyme <strong>glycogen phosphorylase</strong>. This is a <strong>rate-limiting</strong> step in the process. Glucose-1-phosphate is then converted to glucose-6-phosphate by the enzyme <strong>phosphoglucomutase</strong> and eventually, glucose is obtained from glucose-6-phosphate by the enzyme phosphatase.</p>\n<p>During <strong>glycogenesis</strong>, glucose is phosphorylated to glucose-6-phosphate, catalyzed by <strong>hexokinase</strong> in muscle and <strong>glucokinase</strong> in the liver. <strong>Glucose-6-phosphate</strong> is isomerized to <strong>glucose-1-phosphate</strong> by <strong>phosphoglucomutase</strong>. <strong>UDP-glucose</strong> is synthesized from glucose-1-phosphate and UTP by UDP-glucose pyrophosphorylase. A protein named <strong>glycogenin</strong> is the primer acting as an <strong>acceptor</strong> of <strong>glucose residues</strong><strong>. </strong>This is glycosylated further by UDP-glucose. Glycogenin further catalyzes the transfer of seven glucose residues from UDP-Glucose, in 1 → 4 linkages, to form a glycogen primer. This in turn serves as the substrate for the enzyme, <strong>glycogen synthase</strong>, which is the <strong>rate-limiting enzyme</strong> of glycogen synthesis.</p>\n<p>Other options:</p>\n<p>Option A: <strong>Alpha 1,6 glucosidase</strong> is involved in <strong>glycogenolysis alone.</strong></p>\n<p>Option B: <strong>Glycogen Phosphorylase</strong> is involved in <strong>glycogenolysis</strong><strong> alone.</strong></p>\n<p>Option D: <strong>Glycogen synthase </strong>is involved in<strong> glycogenesis alone.</strong></p>\n<p> </p><hr><h3>Related Pearl: Steps in Glycogenesis & Respective Enzymes</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Steps</strong></p>\n</td>\n<td>\n<p><strong>Enzymes</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Glucose Phosphorylation</p>\n</td>\n<td>\n<p>Hexokinase&nbsp;in Muscle</p>\n<p>Glucokinase&nbsp;in Liver</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Glucose-6-PO4 to Glucose-1-PO4 conversion</p>\n</td>\n<td>\n<p>Phosphoglucomutase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Attachment of UTP to Glucose-1-PO4</p>\n</td>\n<td>\n<p>UDP Glucose Pyrophosphorylase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Attachment of UDP-Glucose to Glycogen Primer (Glycogenin)</p>\n</td>\n<td>\n<p>Glycogen initiator synthase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Glycogen synthesis</p>\n</td>\n<td>\n<p>Glycogen synthase</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Glycogen Branches formation</p>\n</td>\n<td>\n<p>Branching enzyme (amylo-[1&mdash;4]&mdash;&gt;[1&mdash;6]-transglucosidase)</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Glycogen Storage Diseases</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/782e85c36f0648698a222dca988adfabx1280x1863.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Disease</strong></p>\n</td>\n<td>\n<p><strong>Enzyme deficiency</strong></p>\n</td>\n<td>\n<p><strong>Symptoms</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type 0</p>\n</td>\n<td>\n<p>Glycogen synthase</p>\n</td>\n<td>\n<p>Hypoglycemia</p>\n<p>Early death</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type Ia</p>\n<p><strong>Von Gierke's disease</strong></p>\n</td>\n<td>\n<p>Glucose-6- phosphatase</p>\n</td>\n<td>\n<p>Hepatomegaly and renomegaly&nbsp;due to glycogen accumulation</p>\n<p>Severe fasting hypoglycemia</p>\n<p>Growth failure</p>\n<p>Lactic acidosis</p>\n<p>Hyperuricemia</p>\n<p>Hyperlipidemia</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type Ib</p>\n</td>\n<td>\n<p>Endoplasmic reticulum glucose-6- phosphate transporter</p>\n</td>\n<td>\n<p>Same as Von Gierke's disease</p>\n<p>Recurrent infections due to impaired neutrophil function</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type II</p>\n<p><strong>Pompe's disease</strong></p>\n</td>\n<td>\n<p>Lysosomal &alpha;1,4:1,6 glucosidase</p>\n<p>(Acid maltase)</p>\n</td>\n<td>\n<p>Muscle weakness</p>\n<p>Death by age ~ 2 years (infantile variant)</p>\n<p>Cardiomegaly and heart failure</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type III</p>\n<p><strong>Cori's/Forbes disease</strong></p>\n<p>(Limit dextrinosis)</p>\n</td>\n<td>\n<p>Glycogen debranching enzyme</p>\n</td>\n<td>\n<p>Muscle weakness</p>\n<p>Fasting hypoglycemia</p>\n<p>Hepatomegaly due to accumulation of branched-chain polysaccharide (limit dextrins)</p>\n<p>Growth retardation</p>\n<p>Normal lactate and uric acid levels</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type IV</p>\n<p><strong>Andersen disease</strong></p>\n</td>\n<td>\n<p>Glycogen branching enzyme</p>\n</td>\n<td>\n<p>Failure to thrive</p>\n<p>Hepatomegaly due to accumulation of polysaccharides with few branch points</p>\n<p>Death at age ~ 5 years</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type V</p>\n<p><strong>McArdle disease</strong></p>\n</td>\n<td>\n<p>Muscle glycogen phosphorylase</p>\n</td>\n<td>\n<p>Exercise-induced cramps</p>\n<p>Renal failure due to rhabdomyolysis and myoglobinuria</p>\n<p>Second wind phenomenon</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type VI</p>\n<p><strong>Her's disease</strong></p>\n</td>\n<td>\n<p>Liver glycogen phosphorylase</p>\n</td>\n<td>\n<p>Generally benign</p>\n<p>Mild hypoglycemia</p>\n<p>Hepatomegaly</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type VII</p>\n<p><strong>Tarui's disease</strong></p>\n</td>\n<td>\n<p>Muscle phosphofructokinase</p>\n</td>\n<td>\n<p>Exercise-induced muscle cramps and weakness</p>\n<p>Growth retardation</p>\n<p>Hemolytic anemia</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC8324",
      "difficulty": "medium"
    }
  ]
}